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En Septiembre de 2011 me incorporé al laboratorio del Dr. Carlos G. Dotti para 
desarrollar parte de su Plan Nacional titulado “Dysfunctional mechanisms in the aged 
brain”. En concreto me propusieron estudiar la regulación epigenética de genes de 
memoria en respuesta a estímulos nerviosos, tanto en el cerebro adulto como en el viejo. 
En este trabajo de Tesis nos propusimos caracterizar los mecanismos epigenéticos que 
controlan la transcripción de Bdnf en respuesta a LTD, y la posible relación de éstos con 
los déficits de aprendizaje y memoria que ocurren en el envejecimiento.   
La regulación transcripcional de los genes de memoria de expresión temprana es un 
proceso esencial para la función cerebral, estando involucrada, entre otros procesos, en 
plasticidad sináptica, particularmente para mantener las fases tardías de la potenciación a 
largo plazo (LTP) y la depresión a largo plazo (LTD) ha sido descrita ampliamente. 
Trabajos realizados en animales sujetos a diferentes paradigmas de memoria han 
mostrado que existen mecanismos epigenéticos involucrados en la regulación de 
genesde memoria. Sin embargo poco se conoce sobre la contribución de los mecanismos 
epigenéticos en la expresión de estos genes en respuesta a estímulos puntuales, tanto 
en el cerebro adulto como en el viejo. En esta tesis describimos cómo la LTD, 
desencadenada por adición de bajas dosis de NMDA, induce la transcripción del gen 
Bdnf a partir de sus promotores I, II, IV y VI, mediante la desmetilación de H3K27Me3 y la 
fosforilación de H3K27Me3 en la Serina 28, que a su vez conlleva al desplazamiento de 
EZH2, la subunidad catalítica del Complejo Represor de Polycomb 2. La LTD no solo 
induce el desplazamiento de EZH2, sino también de otra enzima represora, la histona 
deacetilasa 4 (HDAC4), al tiempo que estimula la acetilación de H3K27 via pCREB/CBP. 
A diferencia de la situación descrita, típica del cerebro adulto, presentamos datos que 
muestran la alteración de la transducción normal de los estímulos neuronales al núcleo 
en el hipocampo envejecido. Esta ateración lleva a un estado basal de la cromatina 
diferente en los promotores de Bdnf del ratón viejo, acompañado de una incapacidad de 
remadelar la cromaitna y la transcripción de Bdnf en respueta a LTD. Una característica 
fisiológica del envejecimiento es la perdida de colesterol de la membrana plasmática 
neuronal. De hecho, la adición de colesterol a rebanadas hipocampales envejecidos 
recupera la regulación epigénetica y la expresión de Bdnf en respuesta a LTD, mientras 
que la reducción de colesterol en rodajas de hipocampo de adultos jóvenes resulta en 
deficits similares a las encontradas en los animales viejos. Apoyando nuestra hipótesis de 
que la desregulación epigéntica observada en animales viejos deriva de la pérdida de 
colesterol, la administración oral de Voricionazol, un inhibidor del enzima responsable de 
la pérdida de colesterol cerebral (Cyp46A1), rescata la pérdida de colesterol en el 
hipocampo y mejora las capacidades cognitivas de animales viejos, restituyendo además 
la regulación epigenetica de Bdnf y su transcripción en respuesta a LTD. Estos resultados 
desvelan uno de los mecanismos involucrados en los déficits cognitivos asociados al 
envejecimiento, y proponen a Cyp46A1 como una posible diana teraputica valiosa.  
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Transcription of immediate early memory genes is an essential process in brain 
function, regulating, among other processes, synaptic plasticity. It is well established the 
necessity of gene transcription in order to maintain the late phases of the long-term 
potentiation (LTP) and the long-term depression (LTD). Several works performed in 
animals subjected to different memory paradigms have shown that there are epigenetic 
mechanisms involved in memory genes regulation. However, little is known about the 
contribution of these epigenetics mechanisms in response to a single stimulus, in the adult 
and in the old brain. The aim of this thesis was to characterise such mechanisms in 
response to LTD, in order to better understand the regulation of Bdnf gene expression, 
and its possible relation with the aged associated learning and memory deficits. In this 
thesis we present that LTD stimulation triggered by low NMDA dose in young adult 
animals, induces the transcription of Bdnf gene from promoters I, II, IV and VI by 
H3K27Me3 demethylation and H3K27Me3 phosphorylation at Serine 28, leading to 
displacement of EZH2, the catalytic subunit of Polycomb Repressor Complex 2. LTD not 
only does induce EZH2 repressor detachment, but also the dissociation of another 
transcriptionally repressive enzyme such as histone deacetylase 4 (HDAC4). We also 
show that LTD enhances acetylation of histone H3K27 via pCREB/CBP. Differently from 
the described situation, typical of the mature brain, we present data showing that the 
normal singling transduction of the young upon LTD is impaired in the aged hippocampus, 
leading to a different basal chromatin state at Bdnf promoters in the old. The 
consequence of this impairment is the loss of Bdnf induction in the old when exposed to 
LTD, as a result of impaired HDAC4 dissociation, CBP recruitment and Histone H3K27 
acetylation at Bdnf promoters. We also have observed that the loss of cholesterol at the 
neuronal plasma membrane, a physiological feature of the old, plays a role in these 
epigenetic deficits. In fact, cholesterol addition to old hippocampal slices rescued Bdnf 
epigenetic regulation and expression in response to LTD. Furthermore, cholesterol 
reduction in young adult hippocampal slices led to similar deficits to the ones found in the 
old animals. In further support of the cholesterol loss-epigenetic dysregulation in the old, 
oral administration of Voriconazole, an inhibitor of the enzyme responsible for cerebral 
cholesterol loss (Cyp46A1), rescued hippocampal cholesterol loss and enhanced 
cognitive abilities in the old animals, improving Bdnf epigenetic regulation and expression 
in response to LTD. These results unveil one of the mechanisms involved in the cognitive 
decline of the old and propose Cyp46A1 as valuable therapeutic possibility. 
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- AMPA: α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid  
- AMPAR: AMPA receptor 
- AP: alkaline phosphatase  
- AP2: clathrin adaptor protein  
- BDNF: Brain derived neurotropic factor 
- CaMKII: Ca2+ /calmodulin-dependent protein kinase II  
- CBP:	  CREB-binding protein 
- CCIIh: CREB /CBP Interaction Inhibitor  
- CDYL: chromodomain Y-like protein  
- Chem-LTD: chemical LTD 
- ChIP: Chromatin immunoprecipitation 
- CNS: Central nervous system 
- COase: cholesterol oxidase enzyme  
- CREB:	  cAMP response element-binding protein 
- Cyp46A1: cholesterol 24 hydroxylase 
- Cyp51: sterol-14a-demethylase 
- DNMT: DNA methyltransferase 
- ERK1/2extra- cellular signal-regulated kinase 1/2 
- EZH1/2: Enhancer of zeste homolog-1/2  
- GluN: NMDA  glutamate subtunit 
- GSK3: glycogen synthase kinase-3  
- HAT: Histone Acetyltransferase 
- HDAC: histone deacetylase 
- HMT: histone methyletransferase  
- H3K4Me3: Histone H3 trimethylated at Lys 4 (K4) 
- H3K27Me3: Histone H3 trimethylated at Lys 27 (K27)  
- H3K27Ac: Histone H3 acetylated at Lys 27 (K27)  
- H3K27Me3S28p Histone H3 trimethylated at Lys 27 (K27) and phosphorylated at 
Ser 28 (S28) 
- IEGs: Immediate early genes  
- JMJ: jumonji C (JmjC)-domain-containgin  
- JMJD3:  JmjC Domain-Containing Protein 3 
- JNK1/2: c-Jun N-terminal kinase 1/2 
- KAR: kainate receptor 
- KDM: Histone methyl-lysines demethylases  
- LFS: low-frequency stimulation 
- LTP: Long Term Potentiation 
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- LTD: Long Term Depression  
- MßCD-Ch: cholesterol complexes with methyl-ß-cyclodextrin  
- MBD: methyl-binding domain 
- MeCP2: methyl-CpG-binding protein 2 
- MECS: maximal electroconvulsive seizure  
- MDBP: methyl-DNA binding proteins 
- mGluR: metabotropic glutamate receptor  
- Msk-1/2: mitogen- and stress-activated kinases 1/2 
- NAD: nicotinamide-adenine-dinucleotide 
- NFkB: Nuclear Factor kappa B  
- NMDA: N-methyl-d-aspartate 
- NMDAR: NMDA receptor 
- NSF: N-ethylmaleimide-sensitive factor 
- p38-MAPK p38: mitogen-activated protein kinase 
- PHD: Plant homeodomain  
- PI3K: phosphatidylinositol 3-kinase  
- PKA: protein kinase A  
- PKB/AKT: Protein Kinase B  
- PKC: protein kinase C 
- PLC-gamma: phospholipase C gamma  
- PP1: protein phosphatase 1 
- PP2A: protein phosphatase 2A  
- PP2B: protein phosphatase 2B  
- PRC: Polycomb repressive complexes 
- RNApolII :RNA polymerase II 
- RTFs: regulatory transcription factors 
- RTT: Rett syndrome 
- SIRT: sirtuin 
- STDP: spike-timing dependent plasticity 
- TEZ: transposon exclusion zones 
- TRD: transcription regulatory domain  
- TrkB: tropomyosin-related kinase B  
- TSS: transcriptional start sites  
- UTR: un-translated regions  
- UTX: Ubiquitously Transcribed X Chromosome Tetratricopeptide Repeat Protein 
- vmPFC: ventromedial prefrontal cortex  
- VPA: valproic acid  
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Activity-regulated gene transcription is an essential process in brain function, 
regulating the strength of brain cells’ connections, survival capacity and plasticity (Ghosh 
et al., 1994; Mao et al., 1999). Among the latter, activity regulates the transcription of, for 
example, genes induced during long-term potentiation (LTP) and long-term depression 
(LTD), the electrical grounds for learning and memory (Ahn et al., 1999; Nguyen et al., 
1994). Although the last few years have highlighted the importance of epigenetics in the 
regulation of gene expression in response to external stimuli, little is known about the 
epigenetic mechanisms regulating learning and memory genes in response to a specific 
stimulus.  During this thesis I have analysed the epigenetic mechanisms regulating the 
expression of the learning and memory gene Bdnf in response to a canonical cognitive 
stimulus: the NMDA-induced long-term depression.  
 
1.-Learning and Memory: synaptic plasticity: 
Learning may be described as the mechanism by which new information about the 
environment is acquired, and memory as the mechanism by which that knowledge is 
retained. It is convenient to categorize memory as being explicit, which is defined as that 
involved in the conscious recall of information about people, places and things, or implicit, 
which is characterized by the non conscious recall of tasks such as motor skills. Explicit 
memory depends on the integrity of temporal lobe structures such as the hippocampus, 
subiculum, and entorhinal cortex. Implicit memory includes simple associative forms of 
memory, such as classical conditioning, and non-associative forms, such as habituation, 
relaying on the integrity of the cerebellum and basal ganglia (Squire, 1992).  
Although several areas of the brain play a part in consolidation of several forms of 
learning/memory, the hippocampus has been recognized to be playing a vital role in the 
formation of declarative memory (Scoville and Milner, 1957). It is widely accepted that 
memory formation is dependent on changes in synaptic efficiency allowing different 
degree of associations between neurons; indeed, activity-dependent synaptic plasticity at 
appropriate synapses during memory formation is believed to be both necessary and 
sufficient for storage of information. Cajal originally hypothesized that information storage 
relies on changes in strength of synaptic connections between neurons that are active 
(Ramón y Cajal, 1909). Hebb supported this hypothesis and proposed that if two neurons 
are active at the same time, the synaptic efficiency of the appropriate synapse will be 
strengthened (Hebb, 1949). Now a day we know that not only synaptic strengthening is a 
form of synaptic plasticity, but also synaptic weakening is. Both processes are thought to 
be involved in information storage, and therefore in learning, memory and other 
physiological processes. The two major forms of long-lasting synaptic plasticity in the 
mammalian brain — long-term potentiation (LTP) and long-term depression (LTD) — are 
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characterized by a long-lasting increase or decrease in synaptic strength, respectively.  
 
1.2.-Long term depression: 
LTD is an activity-dependent reduction in the efficacy of a neuronal synapse, a 
process lasting hours, or longer, after a stimulus. LTD occurs in many areas of the central 
nervous system (CNS) with varying mechanisms depending upon brain region and 
developmental progress (Massey and Bashir, 2007). Typically, LTD has two phases; the 
early-phase in which the depotentiation of the synaptic strength takes place, and the late-
phase, which is the maintenance of the depressed currents. The early-phase of LTD is 
independent of macromolecules synthesis, whereas the late-phase, to be maintained, 
requires RNA transcription and protein synthesis (Goelet et al., 1986; Manahan-Vaughan 
et al., 2000).  LTD can be induced by prolonged periods of low-frequency stimulation 
(LFS), by pairing baseline synaptic stimulation with depolarization (known as pairing), by 
appropriately timed back-propagating action potentials (a form of spike-timing dependent 
plasticity or STDP), or by application of an appropriate receptor agonist (known as 
chemical LTD or chem-LTD). Most synapses that undergo LTD respond to the 
neurotransmitter L-glutamate. L-glutamate acts on N-methyl-d-aspartate (NMDA) 
receptors (NMDARs), α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) 
receptors (AMPARs), kainate receptors (KARs) and metabotropic glutamate receptors 
(mGluRs) (Collingridge et al., 2009, 2010). Here I will focus on the NMDAR-dependent 
LTD. 
 
1.2.1.- NMDA receptors-dependent LTD:  
NMDA receptors are tetramers of various GluN subunits (Collingridge et al., 2009). 
Normally they are composed by two GluN1 and two GluN2 subunits, although sometimes 
GluN3 replaces GluN2. The two GluN2 subunits can be identical (GluN2A, GluN2B, 
GluN2C or GluN2D), forming a diheteromer, or they can be different from each other, 
forming a triheteromer together with two identical GluN1 subunits (Collingridge et al., 
2004). During LTD, the activation of NMDA receptors occurs at many different synapses 
(Fujii et al., 1991). As commented above, NMDA receptor activation leading to LTD can 
be induced by LFS or chemically by the brief application of an agonist, i.e. low dose of 
NMDA (NMDA-LTD). Although in general LFS-induced LTD and NMDA-LTD use common 
mechanisms, some differences between the two have been described (Kameyama et al., 
1998; Morishita et al., 2001). In any event, numerous evidences point out that LTD 
involves AMPA receptor removal from synapses (Collingridge et al., 2004). In the 
canonical view, upon the LTD stimulus Ca2+ enters through the NMDAR and binds 
calmodulin. This binding leads to the activation of protein phosphatase 2B (PP2B), which 
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dephosphorylates inhibitor-1, leading to the activation of the protein phosphatase 1 (PP1). 
When PP1 is activated, it dephosphorylates several substrates, including Ser845 on the 
AMPAR subunit GluA1, leading to AMPAR endocytosis and LTD (Collingridge et al., 
2004). The first clue to understand the molecular mechanism that drives to AMPAR 
endocytosis in NMDAR-LTD was the disruption observed of GluA2- N-ethylmaleimide-
sensitive factor (NSF) interaction, an ATPase involved in membrane fusion events. The 
loss of this interaction causes AMPAR internalization, mimicking the one that takes place 
in NMDAR-LTD (Nishimune et al., 1998). Later on, it was shown that clathrin-mediated 
endocytosis was involved, and that the clathrin adaptor protein AP2 binds GluA2 on the 
same site of NSF. These results suggested that AMPAR are stabilized at the membrane 
by NSF, and upon NMDAR-LTD stimulus AP2 replaces NSF to initiate AMPAR 
endocytosis (Lüscher et al., 1999) (Figure I1). 
Although the above studies give the notion that NMDAR-LTD primarily involves the 
activation of phosphatases, several studies have implicated various serine/ threonine 
(Ser/Thr) protein kinases in this process as well. These include protein kinase A (PKA; 
Brandon et al., 1995), cyclin-dependent kinase 5 (Ohshima et al., 2005), p38 mitogen-
activated protein kinase (p38-MAPK; Zhu et al., 2002), Ca2+ /calmodulin-dependent 
protein kinase II (CaMKII; Mayford et al., 1995; Pi et al., 2010), protein kinase C (PKC; 
Gean et al., 1995) and glycogen synthase kinase-3 (GSK3; Peineau et al., 2007; Fig. I1). 
A consensus now exists that both phosphatases and kinases activity are inter-related and 
important for the rapid, early phase of LTD. The late-phase of LTD requires, in addition, 
Figure I1: Signalling mechanisms involved in NMDAR-dependent LTD.  
A) Calmodulin (CaM) detects Ca2+ that enters via NMDARs, leading to PP1 activation, which 
dephosphorylate various targets. B) GluA2-containing AMPARs are stabilised at synapses by N-
ethylmaleimide-sensitive factor (NSF). When increase Ca2+ is sensed the adaptor protein 2 (AP2) is 
targeted to GluA2, displaceing NFS, and inictiateing the clatrin-mediated endocytosis of AMPARs. C) 
Glycogen synthase kinase-3β (GSK3β) is required for NMDAR-LTD during which it can be activated 
by PP1, and represde by Akt. AKAP, A-kinase anchor protein; ARAP, AMPAR-associated protein; I-1, 
inhibitor 1; PP2B, protein phosphatase 2B; RyR, ryanodine receptor. (Adapted from Collingridge et al. 
2010) 	  
A 
     B        C 
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protein synthesis and mRNA transcription (see below; Goelet et al., 1986; Manahan-
Vaughan et al., 2000). 
 
1.3.- Neuronal activity induces immediate early genes transcription:  
The phrase ‘Immediate early genes’ (IEGs) was first used in virology to describe viral 
regulatory factors transcribed de novo by host cells within 2 minutes after viral integration 
(Jayaraman, 1972). It was shown 15 years later that the mRNAs of most of these genes 
were detected at their peaks between 30 minutes and 1 hour (Curran et al., 1985), setting 
up the general definition for IEGs. As commented above, late phases of LTP and LTD 
require gene transcription. Based on screens in control rats and rats that received 
maximal electroconvulsive seizure  (MECS), the number of neuronal activity-induced IEGs 
was initially estimated to be around 500–1000 (Nedivi et al., 1993). Subsequently 
however, the number of activity-induced IEGs was found to be close to 30–40 (Lanahan 
and Worley, 1998). IEGs may be categorized into two functional classes: regulatory 
transcription factors (RTFs), which control transcription of other downstream genes, and 
effector IEGs, which directly influence cellular functions (Lanahan and Worley, 1998). By 
virtue of their ability to regulate transcription, RTFs are well situated to globally regulate 
cell function (Guzowski, 2002). In contrast, effector IEGs have a wide range of cellular 
functions, including those related to cell remodelling (Bdnf, Narp), intracellular signalling 
(RheB, RGS-2, and Homer1a), synaptic modification (Arc, Homer1a, Narp, tissue 
plasminogen activator or Tpa and Bdnf) and metabolism (Cox-2) (see Guzowski, 2002 
and Lanahan and Worley, 1998 and  references therein). In 2011 Saha et all. (2011) 
established a new categorization; rapid or delayed IEGs, depending on the presence of 
RNA polymerase II (RNApolII) in their chromatin, and therefore a fast triggered RNA 
transcription. They show that RNApolII is stalled just downstream of the transcription start 
site of Arc, allowing its near-instantaneous transcription (Saha et al., 2011).  
 
2.-Epigenetics marks and gene regulation: 
Waddington C. in 1957 was the first to use the term epigenetics to describe a 
mechanism or mechanisms that are ‘on top of’ or  ‘above’ the level of the genes encoded 
by the DNA sequence (Waddington, 1957). These mechanisms, which can be influenced, 
among other stimulus, by environmental factors such as diet (Waterland and Jirtle, 2003) 
and experiential factors such as maternal care (Weaver et al., 2004), can ultimately 
control which or when, some genes will be expressed in cells, and even in whole 
organisms with the same genome, to become phenotypically distinct (Fraga et al., 2005). 
In molecular terms, epigenetics refers to the covalent modifications of chromatin that 
affect gene expression. In turn, these can be transient or long lasting modifications, 
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important to induce or perpetuate, respectively, changes in gene expression. The two 
major molecular epigenetic mechanisms are post-translational histone modifications and 
DNA methylation.  
 
2.1. Histone modifications: 
Histones are highly basic proteins that organize DNA into a chromatin unit, the 
nucleosome; 147 bp of DNA is wrapped tightly around an octamer of histone proteins 
(composed by two molecules of each one of the histones H2A, H2B, H3, and H4), and 
these nucleosomes are linked by histone H1 (Luger et al., 1997). The structure of the 
Histones is composed of a globular domain localized in the centre of the nucleosome and 
a N-terminal tail that contains multiple sites for potential modifications, including 
acetylation, phosphorylation, methylation, ubiquitination and ADP-ribosylation (Jenuwein 
and Allis, 2001; Strahl and Allis, 2000). These post-translational modifications are often 
called histone marks. Each of these marks is introduced or removed by specific enzymes; 
for instance, acetylation is catalysed by histone acetyltransferases and removed by 
histone deacetylases, methylation is catalysed by histone methyltransferases and 
removed by histone demethylases, and finally histone phosphorylation can be achieved 
by different nuclear kinases, such as mitogen- and stress-activated kinases 1 (Msk-1), 
and removed by different protein phosphatases, such as protein phosphatase 1 (PP1). 
 
2.1.1.- Histone acetylation: 
Histone acetylation takes place at lysine residues, specifically on their side chain 
amino group, neutralizing their positive charge, and decreasing the affinity between the 
histone tail and the DNA (Hong et al., 1993). Histone acetylation results in a chromatin 
relaxation, and allows the recruitment of transcription factors or RNA polymerase. 
Acetylated histone tails also serve as platforms for others co-activators to reach the 
chromatin. Histone acetylation is generally associated with transcriptional activation and is 
widely present in the active chromatin, the euchromatin (Tollefsbol, 2011). 
Histone Acetyltransferases (HATs) catalyse the direct transfer of an acetyl group from 
acetylCoA to the NH+ group of the lysine within the histone (Bannister and Kouzarides, 
2011). HATs are evolutionarily conserved from yeast to humans and they are generally 
composed by multiple subunits, with the function of the catalytic subunit depending largely 
on the context of the other subunits in the complex (Lee and Workman, 2007). HATs can 
be grouped on the basis of their catalytic domains, Gcn5 and MYST HATs. Although 
these two families of HATs are the predominant ones, other proteins including p300/CBP 
(cAMP response element-binding protein (CREB)-binding protein), Taf1 and a number of 
nuclear receptor co-activators, have also been shown to possess intrinsic HAT activity. 
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However, they do not contain true consensus HAT domains and therefore represent the 
‘orphan class’ of HAT enzymes (Lee and Workman, 2007).  
As commented above, acetyl groups on histone tails can be removed by histone 
deacetylases (HDACs), therefore preventing the expression-prone status given by 
acetylation. Two categories of HDACs have been identified so far: zinc dependent HDACs 
and nicotinamide-adenine-dinucleotide (NAD)–dependent HDACs or sirtuins (SIRT). 
Depending on sequence similarity, the zinc-dependent HDAC family members are 
composed of class I (HDACs 1, 2, 3, and 8), classes IIa and IIb (HDACs 4, 5, 6, 7, 9, and 
10), or class IV (HDAC 11). It is important to note that class I HDACs are found mostly 
within the nucleus, whereas class II members shuttle between the nucleus and cytoplasm 
(Gibson and Murphy, 2010). An exception is found with HDAC6, which is located only in 
the cytoplasm. The class III of HDACs or sirtuins constitutes a family of proteins highly 
conserved from prokaryotes to eukaryotes called the SIRT family (Grozinger et al., 2001).  
 
2.1.2.- Histone methylation: 
Histone methylation takes place on all basic residues: arginines, lysines and histidines 
(Byvoet et al., 1972; Fischle, 2008; Murray, 1964). Lysines can be mono-, di- or tri-
methylated on their amine group, arginines can be mono-methylated, and symmetrically 
or asymmetrically di-methylated (Borun et al., 1972; Byvoet et al., 1972; Murray, 1964; 
Paik and Kim, 1969). Histidines are reported to be mono-methylated, although this 
methylation appears to be rare and has not been further characterized (Borun et al., 1972; 
Gershey et al., 1969). The more studied lysine and arginine methylations are the ones on 
Histones H3 and H4 (H3K4, H3K9, H3K27, H3K36, H3K79, H4K20, H3R2, H3R8, H3R17, 
H3R26 and H4R8). However, other residues of histones have been identified as 
methylated by proteomic studies (Tan et al., 2011). The effect of methylation on gene 
expression is context dependent; the location of residue methylated on a histone and its 
degree of methylation have been associated to different gene expression status. For 
example, H3K27Me3 is associated with repressed chromatin (Greer and Shi, 2012), while 
H3K4Me3 is generally associated with active transcription and elongation (Santos-Rosa et 
al., 2002). The same methylation status can be also associated with different 
transcriptional activity, for instance, H3K4Me2/Me3 when bound to PHD-domain-
containing co-repressor protein inhibitor of growth factor family member 2 (ING2) is 
associated to transcriptional repression due to the stabilization of the HDAC1 complex 
(Shi et al., 2006). Therefore, histone methylation will lead to a different chromatin 
compaction status depending on which histone residue is methylated and depending on 
which proteins are associated to the methylated histone.  
Histone methylation is carried out by histone methyletransferase (HMT) enzymes, 
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which work by adding methyl groups donated from S-adenosylmethionine to histones. 
Three different families of enzymes with HMT activity have been identified. The SET-
domain containing proteins and DOT1-like proteins have been reported to methylate 
lysines, whereas arginines are methylated by protein arginine N-methyltransferase family 
(Greer and Shi, 2012). HMTs are recruited to specific histone targets by different 
mechanisms, namely: specific DNA sequences (Fritsch et al., 1999; Woo et al., 2010), 
long non-coding RNAs (Gupta et al., 2010a), small non-coding RNAs (Ogawa et al., 2008; 
Zilberman et al., 2003), and also DNA methylation state (Bartke et al., 2010). HMTs are 
usually found in complexes, for example HMTs Enhancer of zeste homolog-1/2 (EZH1/2) 
are the catalytic subunits of the Polycomb repressive complexes (PRC) (Lau and Cheung, 
2011; Mousavi et al., 2012; Simon and Lange, 2008).  
Similarly to acetylation, methyl groups can be removed by demethylases. Two 
families of methyl-lysines demethylases have been identified: the amine oxidases and the 
jumonji C (JmjC)-domain-containing, iron-dependent dioxygenases. Theses enzymes are 
highly conserved from yeast to humans. Histone demethylases recruitment is dependent 
on the stimuli; for example Mad1 recruits the histone demethylase RBP2 to the Myc target 
telomerase reverse transcriptase (hTERT) gene promoter to repress transcription via 
H3K4me3 demethylation (Zheng et al., 2010), or CBP recruits UTX to chromatin in order 
to demethylate H3K27Me3 and increase H3K27Ac in stage 4 embryos, not long after 
global transcriptional activation of the zygotic genome (Tie et al., 2012).	   
 
2.1.3.- Histone phosphorylation: 
Histone phosphorylation takes place at serine, threonine and tyrosine residues of 
histone (Rossetto et al., 2012). Different histone phosphorylations are associated to a 
large range of functions, for example Histone H2A phosphorylation at residue T120 and 
S139 or Y142, from H2AX isoform, are associated to DNA repair (Cook et al., 2009; 
Rossetto et al., 2012) or phosphorylation of Histone H3 residues T6, S10 or S28 are 
associated to increased transcription (Clayton et al., 2000; Lau and Cheung, 2011; Lo et 
al., 2000; Metzger et al., 2010). While histone 3 phosphorylation is involved in chromatin 
relaxation and regulation of gene transcription, these modifications were originally 
identified to be associated with chromosome compaction during mitosis and meiosis. It 
has been shown that phosphorylation of the N-terminal tail of histone H2B is essential for 
apoptosis induced chromatin condensation (de la Barre et al., 2001). Kinases such 
ERK1/2, MSK1, p38, JNK1/2 and many others can phosphorylate histone residues in 
response to different stimuli (Choi et al., 2005; Gehani et al., 2010; Zhong et al., 2000). As 
commented above for Histone acetylation and methylation, Histone phosphorylation is a 
dynamic process since the phosphate groups from Histones can be removed by different 
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phosphatases that are in the nucleus, such as PP1 or PP2A (Koshibu et al., 2009; Nowak 
et al., 2003). 
 
2.1.4.- Histone marks in neuroepigenetics: 
A number of behavioural paradigms revealed changes in histone marks in several 
regions/genes, demonstrating that histone modifications are components of memory 
formation and/or consolidation. Thus, for example, it was shown that contextual fear 
conditioning enhances acetylation at several sites of histone H3 and H4 tails in the 
hippocampus, including H3K9, H3K14, H4K5, H4K8 and H4K12 (Peleg et al., 2010). This 
paradigm of associative learning also induces the increase of other activator marks such 
as H3K4 trimethylation or H3S10 phsphorylation, and modulates repressive marks, such 
as H3K9 dimethylation (Chwang et al., 2007; Gupta et al., 2010b). In agreement with 
these results, it was shown that interfering with the molecular machinery responsible for 
histone acetylation, phosphorylation or methylation impairs associative learning and LTP. 
Among the more notable experiments, it is worth mentioning that administration of HDACs 
inhibitors in mice resulted increased histone acetylation and enhanced LTP (Levenson et 
al., 2004) and that impaired memory formation was observed in cbp+/- mice (Alarcón et al., 
2004). The central role of acetylation in memory was also proved genetically in mice 
lacking HDAC2, which displayed enhanced fear conditioning and hippocampal LTP while 
the overexpression of HDAC2 led to impaired memories and LTP (Guan et al., 2009).  
 
2.2.- DNA methylation:  
 
2.2.1.- DNA methylation molecular mechanisms: 
DNA methylation is a  direct modification of a cytosine side-chain by the addition of a  
-CH3 group covalently. Methylation cannot take place at all cytosines; these residues have 
to be immediately followed by a guanine to be methylated. These CpG dinucleotides often 
occur in small clusters, known as CpG islands, and are poorly represented in the genome. 
DNA methylation is catalized by the DNA methyltransferases (DNMTs), which transfer the 
methyl group to cytosine residues, specifically at the 5th position of the pyrimidine ring 
(Bird, 2002; Miranda and Jones, 2007). Two different variants of DNMTs are identified: 
maintenance DNMTs and de novo DNMTs. DNMT1, the maintenance DNMT, methylates 
hemi-methylated DNA, whereas de novo DNMTs (DNMT3a and DNMT3b) methylate 
previously un-methylated CpG sites. Maintenance DNMT1 perpetuates methylation marks 
after cell division, regenerating methylation in the newly synthetized complementary DNA 
strand (Bestor et al., 1992; Hsieh, 1999; Okano et al., 1999). DNA methylation is stable, 
offering an ideal mechanism for the long-term cellular changes necessary to persist and 
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maintenance of memory, but it would also have to be dynamic (i.e. on/off) in order to 
enable neurons to respond to different stimulus. The DNA methylation off rate is controlled 
by DNA demethylation, a process seen for a long time as a passive and not exempt of 
controversy, especially for non-mitotic cells like neurons, mainly because the identity of 
DNA demethylases has remained elusive. However, there are increasing evidences that 
active methylation and dementylation are taking place in mature cells (Roth et al., 2009). 
The predominant view in the literature is that DNA methylation is associated with gene 
repression, and in the majority of the cases large DNA methylation completely silences 
the associated genes. This type of gene silencing mechanism is achieved by recruiting 
methyl-DNA binding proteins (MDBP) at specifics sites of the genome. These proteins 
have the methyl-binding domain (MBD) and a transcription regulatory domain (TRD), 
which in turn recruits HDACs via adaptors/scaffold proteins (Clouaire and Stancheva, 
2008). The HDACs remove acetyl groups form core histones, altering the chromatin 
structure locally, and leading to a more compact chromatin state and transcriptional 
suppression  (see paragraph 2.1.1). Although DNA methylation is traditionally associated 
with gene repression, recent studies have identified other proteins recruited by MDBPs, 
which can also associate with transcriptional activation (Chahrour et al., 2008). 
 
2.2.2.- DNA methylation in neuroepigenetics: 
Several studies have investigated the capacity of DNA methylation to regulate 
synaptic plasticity and memory. It has been shown that DNMTs inhibitors affect DNA 
methylation in adult CNS, blocking LTP (Levenson and Sweatt, 2006; Miller et al., 2008) 
and hippocampal dependent memory formation in a contextual fear-conditioning paradigm 
(Lubin et al., 2008). Furthermore, it was shown that fear-conditioning can induce DNA 
methylation and transcriptional repression of Protein Phosphatase 1 (PP1) and, at the 
same time,  demethylation and gene transcription of the synaptic plasticity gene Reelin 
(Miller and Sweatt, 2007), highlighting the complex interplay of DNA methylation marks 
during cognition. In concordance with this complexity, Miller et al showed that DNA 
methylation has circuit-specific importance, since DNMTs inhibition in prefrontal cortex 
impairs the recall of existing memories but not the formation of new ones (Miller et al., 
2010). The genetic confirmation of the role of DNMTs in cognition was shown in 
conditional forebrain- and neuron-specific deflection of DNMT1 and DNMT3a. These mice 
had impaired performance on the Morris water-maze and the fear learning (Feng et al., 
2010), implying that for this particular mnemonic paradigm, DNA methylation plays a pro-
active role (see however Bdnf regulation by methylation, below).  
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2.3.-Bivalent genes: 
Recent studies have shown that proteins of the Polycomb Repressive Complexes are 
required to silence an important subset of developmental regulator genes in both human 
and mouse embryonic stem (ES) cells, to ensure that expression occurs only at later 
stages, upon ES cell differentiation (Boyer et al., 2006; Lee et al., 2006). Genome-wide 
(Bernstein et al., 2006) and candidate-based chromatin studies (Azuara et al., 2006) 
indicate that the transcriptional start sites (TSSs) of these genes are frequently present in 
a bivalent state: i.e. the presence of histone modifications associated with gene activation 
(such as acetylated histone H3 and tri-methylated H3K4) and with PRC2- mediated gene 
repression (methylated H3K27). A characteristic observed for bivalent promoters in ES 
cells is that the presence of H3K4 methylation shows a strong positive correlation with the 
presence of CpG islands in the underlying DNA sequence, whereas the presence of 
H3K27-methylated regions showed a strikingly low density of transposon-derived 
sequences (transposon exclusion zones or TEZs) (Bernstein et al., 2006).  
 
3.- Epigenetic regulation of learning/memory genes:  
It is well established that learning and memory require immediate early genes 
transcription, and that their transcription is regulated epigenetically (see above). To 
achieve the transcriptional regulation, via chromatin remodelling, different pathways will 
operate after neuronal stimulation (Figure I2). From all IEGs reported, in this thesis I will 
focus on the Bdnf regulation. 
 
 
Figure I2: Hypothetic signal transduction mechanism operating to regulate chromatin 
structure in the hippocampus. 
Different cell surface receptors signal to a complex intracellular downstream cascade, which leads to 
alterations in both transcription factors and chromatin structure. (From Levenson and Sweatt, 2006) 
 
volve epigenetic mechanisms such as those involved in
long-term memory.
Initial studies of the role epigenetics might play in
synaptic plasticity utilized the sensorimotor synapse of
the marine mollusk Aplysia californica. The sensorimo-
tor synapse displays at least two forms of plasticity.
Application of serotonin (5-HT) to the sensorimotor
synapse results in induction of long-term facilitation
(LTF), a persistent form of plasticity that results in en-
hancement of synaptic transmission [41]. Conversely,
exposure to the neuropeptide FMRFamide results in
long-term depression (LTD), which is a lasting decrease
in synaptic transmission [42]. Using these neuromodula-
tory substances, Guan et al. discovered that acetylation
of histone H4 around the promoter of the immediate
early gene ApC/EBP [43] was transiently increased by 5-
HT, and transiently decreased after exposure to FMR-
Famide [20]. T us, two opposing forms of plasticity in
Aplysia, LTF and LTD, induced opposing changes in the
epigenome, suggesting that the epigenome of Aplysia
could be used as a molecular read-out of the functional
state of neurons.
Several studies indicate that regulation of the epigenome
occurs during induction of synaptic plasticity in mam-
malian systems. Long-term potentiation (LTP) is a form
of synaptic plasticity whereby synaptic strength is en-
hanced in response to high-frequency synaptic activity.
First discovered by Bliss and colleagues [44], induction
of LTP requires the activation of NMDA-Rs and engage-
ment of the MEK-ERK MAPK signaling cascade [13,
45, 46]. Direct activati n of NMDA-Rs in the hippocam-
pus resulted in an ERK-dependent increase in acetyla-
tion of histone H3 [23]. Additionally, phosphorylation
of histone H3 is increased in response to activation of
various neurotransmitter pathways in the hippocam-
pus, including dopaminergic, cholinergic and glut-
amatergic [47]. Thus, induction of synaptic plasticity in
the mammalian hippocampus leads to ERK-dependent
increases in histone acetylation and phosphorylation
(see Fig. 2).
Regulation of the epigenome occurs in response to in-
duction of synaptic plasticity in the hippocampus. Sev-
eral recent studies have investigated whether changes in
the epigenome could affect the induction of synaptic
plasticity. In Aplysia, elevation of basal levels of histone
acetylation with the HDAC inhibitor trichostatin A trans-
forms short-term facilitation, which does not require
transcription for its induction, into LTF [20]. Induction of
late-phase LTP, which requires transcriptio , was signif-
icantly impaired in CBP+/– animals [32]. Treatment of
hippocampal slices from CBP+/– animals with the HDAC
inhibitor suberoylanilide hydroxamic acid significantly
improved L-LTP induction [32]. In other studies using
hippocampal slices, induction of LTP using high-fre-
quency stimulation was significantly enhanced by two
HDAC inhibitors, trichostatin A and sodium butyrate
[23]. In addition, LTP in the amygdala that was induced
by forskolin was also enhanced by the HDAC inhibitor
trichostatin A [48]. These studies indicate that the epige-
netic state f the g nome, from invertebrates t  mam-
mals, affects the induction of long-term forms of mam-
malian synaptic plasticity.
1012 J. M. Levenson and J. D. Sweatt Epigenetics in memory
Figure 2. Signal transduction mechanism operating to regulate chromatin structure in the hippocampus. A wide variety of cell surface re-
ceptors are coupled to complex intracellular signal transduction processes in hippocampal neurons, ultimately leading to alterations in both
transcription factors and chromatin structure. One hypothetical set of pathways leading to epigenetic regulation in hippocampal pyramidal
neurons is illustrated in t is figure. Please see the text for additional details a d relevant r ferences.
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3.1. BDNF as model gene: 
The Brain-Derived Neurotrophic Factor (BDNF) is one of the earliest identified 
neurotrophins (Barde et al., 1982). BDNF was demonstrated to play several important 
roles in different biological processes, both during development and in the adult.  In the 
nervous system, BDNF plays important roles in neuronal differentiation, survival, and 
synaptic plasticity (Dincheva et al., 2012; Ding et al., 2006; Ghosh et al., 1994; Lu et al., 
2014). BNDF gene possesses a structural and functional complexity resulting from 
multiple promoters, leading to the expression of multiple transcripts, in turn susceptible of 
alternative splicing, and two different polyadenilation patterns, resulting in different 
precursors isoforms synthesis but only one mature BDNF. 
 
3.2.-BDNF protein: 
 
3.2.1.- BDNF structure and processing: 
BDNF is encoded by the BDNF gene, which produces four different pre-pro-BDNFs 
depending on the TSS used and its translation start codon (Pruunsild et al., 2007). It has 
been proposed that different pre-domains will affect the intracellular BDNF trafficking, 
promoting the segregation of BDNF longer pre forms (Aid et al., 2007). Pro-BDNF is a 32 
kDa precursor that undergoes glycosylation and glycosylsulfonation within the pro-
domain. The precursor can undergo N-terminal cleavage to generate a mature BDNF of 
14 kDa. In the brain it can experience three different paths; 1) it can be edited in the Golgi 
to be secreted as a mature form; 2) it can be secreted as a pro-BDNF which is then 
processed at the synaptic space to mature BDNF; or 3) it can be secreted as a pro-BDNF 
without further processing (Lu et al., 2005). 
 
3.2.2.- BDNF Signal transduction:  
Almost all roles of BDNF in the CNS depend on the interaction with two different 
receptors: p75 and the tropomyosin-related kinase B (TrkB) receptors. p75 is a member of 
the tumor necrosis factor receptor family and it has been postulated that pro-BDNF is the 
activating ligand. While the pro-BDNF/p75 association has been associated to LTD (Woo 
et al., 2005) and neuronal pruning (Deinhardt and Chao, 2014), the best characterized 
role is its involvement in the initiation of apoptosis (Kenchappa et al., 2010). Thus, it has 
been shown that proBDNF/p75 interaction induces the Jun kinase pathway, leading to 
apoptosis through p53 and caspases activation (Reichardt, 2006). This interaction also 
activates the small GTPase RhoA and its downstream Rho Kinases, which have been 
associated with neurite outgrowth inhibition (Sun et al., 2012). Different from pre-BDNF, 
mature BDNF binds to TrkB with high affinity, and this binding has been associated with 
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increased synaptic transmission and plasticity, neuronal proliferation and survival, and 
axonal sprouting (Deinhardt and Chao, 2014; Lu et al., 2005). If TrkB is not present, 
mature BDNF also can bind p75 (Deinhardt and Chao, 2014; Lu et al., 2005). BDNF/TrkB 
interaction leads to the activation of one or more of three major signalling pathways, 
involving phosphatidylinositol 3-kinase (PI3K), phospholipase C gamma (PLC-gamma) 
and extra- cellular signal-regulated kinase 1/2 (ERK1/2) (Huang and Reichardt, 2003). 
These mechanisms promote calcium entrance into the cell, leading to protein synthesis by 
transcriptional and translational mechanisms. This interaction also promotes neuronal 
survival via Protein Kinase B (PKB/AKT) signalling pathway, through PI3K (Koshimizu et 
al., 2010; Sossin and Barker, 2007). 
 
3.3.- BDNF gene: 
 
3.3.1.-Human BDNF gene 
The human BDNF gene is located at chromosome 11, region p13-14: it consists of 11 
exons, nine of which have their own regulatory promoter region, and it has the coding 
sequence residing in the last exon (Pruunsild et al., 2007, 2011)(Figure I3). Exon I also 
contains an in-frame ATG that can be translated alternatively to the one present in Exon 
IX, extending the pre-pro- region of BDNF by eight amino acids (Timmusk et al., 1993).   
This region has the archetypical GU-AG consensus signal intron-exon boundaries for 
alternative splicing (Modarresi et al., 2012; Pruunsild et al., 2007). Exon IX also has two 
different alternative spliced 3’ un-translated regions (UTRs; Aid et al., 2007). Additionally, 
an interesting feature of the structure of the BDNF gene is the existence of a 200Kb 
antisense region that includes 10 exons transcribed from the same promoter with the 
induce abnormal functioning of some brain areas.17,18
Recent interest has been directed to the epigenetic
regulation of BDNF that mediates the effects of
environmental factors on the BDNF gene resulting
in enduring c a ges of its expression.19 Epigene-
tics refers to processes, such as DNA methylation,
histone acetylation or nucleosome sliding, which
are dynamic events controlling the expression of
genes without affect g the DNA sequence (for
reviews, see (refs. 20 and 21).
This review gives an overview of recent findings on
epigenetic mechanisms associated with BDNF gene
regulation in psychiatric disorders and animal mod-
els. The origin of such modifications, that is, risk
factors such as neurodevelopmental stress exposure,
in these pathologies is not under focus here because it
has already been the matter of an extensive recent
review elsewhere.19 Our objective here is to provide
an overview of new insights into the potential role of
the epigenetic regulation of BDNF in the pathophy-
siology of these disorders. Further, we will discuss
some pharmacological perspectives, focusing on
drugs that can modify BDNF gene expression by
affecting epigenetic regulation.
Regulation of BDNF gene expression
The BDNF gene. BDNF has a complex gene
structure, which has been documented and revisited
extensively.22–28 A number of studies have presented
substantial similarities in rodents and humans
(Figure 1). Briefly, the human BDNF gene consists of
several untranslated 50 exons with independent
promoters. These can be connected to a 30 coding
exon to form a bipartite or tripartite transcript
providing different splice variants of BDNF mRNA.24
The 30 coding exon (exon IX) contains the sequence
that codes for the pro-BDNF protein. In addition, the
30 untranslated region of exon IX is composed of two
alternative polyadenylation (polyA) sites, so as to
generate one short splice variant and one long splice
variant.22 The use of distinct BDNF mRNA splice
variants differing either by the 50 or 30 extremity
allows for temporal and spatial regulation of
BDNF expression, which appears to be critical in
the modulation of synaptic plas icity and spine
development in dendrites.29–31 This temporo-spatial
regulation depends largely on the various promoters
of the BDNF gene, which are differentially targeted in
response to diverse stimuli and signaling events.32–34
In addition to regulation at the promoter level,
BDNF gene expression is also controlled at the post-
transcriptional level. In particular, all Bdnf mRNAs
are translated into pro-BDNF and are further
cleaved into mature BDNF by several mechanisms.35
The balance between pro-BDNF and mature BDNF
levels in the synaptic cleft is controlled by tissue
plasminogen activator and is essential for neuronal
plasticity.36 Although pro-BDNF binds specifically
to p75 and primarily promotes cell death and long-
term depression, mature BDNF binds more readily
to TrkB, particularly enabling long-term potentia-
tion and cell survival.37,38 Therefore, the balance
between pro- and mature BDNF on the one hand,
and between the p75 and TrkB receptors on the other,
is of critical importance in determining the functional
characteristics of the BDNF signal.39 Moreover, a
common single-nucleotide polymorphism within the
BDNF gene causes a valin (Val) to methionine (Met)
substitution at codon 66 of the prodomain. This single-
nucleotide polymorphism is thought t alter BDNF
mRNA and protein trafficking, and has been widely
implicated in psychiatric disorders.40–43
Epigenetic control of BDNF gene expression. Various
epigenetic mechanisms have been associated with
repression or activation of the rodent Bdnf gene
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Figure I3: Struc ure of the h an a  rodent BDNF gene.  
Exons are represented a  boxes, nd introns as the lines betw en boxes. Roman numerals indicate 
the number of the exons; Arabic numerals indicate the size of exons and introns. Red boxes represent 
the ATG codon, the initiation transcription marks; the green box at exon IX represents the pro-BDNF 
coding region, including the genetic variant implicated in Val66Met polymorphism and the two 
polyadenilation sites (PolyA). Yellow lines represent de CpG islands. Some exons, like exon II and IX, 
contain different transcript variants with alternative splice-donor sites (A, B, C, D). (From Boulle et al. 
2012) 	  
INTRODUCTION 
	   35 
ability to synthesize a wide variety of anti-BDNF small non-coding RNAs (Kimura et al., 
2006; Pruunsild et al., 2007, 2011). In silico analysis of the gene sequence revealed 
possible CpG islands at promoter I, II and IV of the human gene (Boulle et al., 2012; 
Figure I3). 
 
3.3.2.-Structure of the rodent Bdnf gene: 
The Bdnf gene is located at chromosome 2, region q3, and chromosome 3, region 
q35, in moues and rat respectively. The rodent Bdnf has 9 exons, eight of them have their 
own promoter region and are directly spliced to exon IX, which has the coding sequence 
(Aid et al., 2007).  As it happens with human BDNF, Exon I of rodent gene has the ATG 
that can be alternatively translated (Timmusk et al., 1993). Exon II has three different 
isoforms due to its alternative splicing. Exon IX also has two different alternatively spliced 
3’ UTRs, as it happens in the human BDNF gene (Aid et al., 2007). Taking into account 
the gene architecture, there are, at least, 22 different Bdnf mRNAs isoforms. Antisense-
BDNF transcripts are not expressed in rat and mouse (Aid et al., 2007). Five different CpG 
islands have been described at the rodent Bdnf gene, located around the transcription 
start sites of exons I, II, IV, V and VI (Lubin et al., 2008; Figure I3). Interestingly, 
transposon exclusion zones were found overlapping this four is promoters suggesting a 
possible bivalency of the these Bdnf promoters (Bernstein et al., 2006). Different DNA 
binding sites for distinct transcription factors have been characterized in different 
promoters (Marmigère et al., 2001; West et al., 2001).  
 
 
3.3.3- Bdnf epigenetic regulation: 
 
3.3.3.1.- Bdnf regulation by DNA methylation: 
Several studies have focused on DNA methylation at Bdnf CpG islands. Experiments 
performed in cell lines treated with 5-azacitidyne, a DNMT inhibitor, revealed increased 
expression of exons I, IV, V, VIII and IX in C6 rat glioma cells, and exons I, III and IV in 
mouse neuroblastoma, Neuro2A, cells (Aid et al., 2007; Ishimaru et al., 2010). A similar 
regulation seems to occur in vivo; it was shown that zebularine, a DNMT inhibitor, infused 
to CA1 increases transcription of Bdnf exons I, IV, VI, and that increased mRNA levels 
correlate with decreased DNA methylation at the respective CpG islands (Lubin et al., 
2008). Furthermore, it was reported that fear-conditioning induces demethylation of the 
CpG islands present at exons IV but no VI, resulting in increased transcription from exon 
IV. The behaviour-induced changes in DNA methylation at Bdnf CpG islands require 
NMDAR activation, since the pharmacological inhibition of the receptor by MK801 impairs 
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DNA demethylation and RNA transcription from promoter IV after fear conditioning (Lubin 
et al., 2008). In addition to these, physiological, Bdnf epigenetic regulatory processes, 
several groups have shown that aberrant regulation of Bdnf gene can play a role in the 
neural phenotype of Rett syndrome (RTT) mouse model, a severe progressive 
neurological disorder characterized by autistic behaviour, mental retardation and motor 
dysfunction.  RTT is associated with mutations in methyl-CpG-binding protein 2 (MeCP2), 
which has been shown to selectively regulate Bdnf in response to neuronal activity (Chen 
et al., 2003; Martinowich et al., 2003; Zhou et al., 2006). In fact, it has been shown that 
membrane depolarization induces calcium-mediated MeCP2 phosphorylation, which in 
turn decreases MeCP2 binding to methylated CpGs, facilitating Bdnf transcription (Chen 
et al., 2003; Martinowich et al., 2003). In contraposition, more recent data presented by Li 
et al. showed that impairing MeCP2 activity-induced phosphorylation enhances 
synaptogenesis, LTP and spatial memory (Li et al., 2011). All in all, the studies on DNA 
methylation suggest that this epigenetic mechanism plays a role on Bdnf gene 
expression.  
 
3.3.3.2.- Bdnf regulation by Histone acetylation: 
There are emerging evidences that histone acetylation is a key event controlling Bdnf 
transcription upon neuronal stimulus. Proper histone acetylation levels have been shown 
to affect LTP and long-term memories (Alarcón et al., 2004). It has been reported that 
increased acetylation of histone H4 at Bdnf promoters I and IV in prefrontal cortex 
contributes to improve the extinction of conditioned fear in mice (Bredy et al., 2007). 
Moreover, the HDAC inhibitor valproic acid (VPA) enhanced not only the extinction of 
cued fear memory but also its acquisition and consolidation (Bredy and Barad, 2008). 
Interestingly, a single exposure to prolonged stress before fear conditioning in rats 
increased acetylation of histones H3 and H4 at the Bdnf promoters I and IV and 
heightened the hippocampal levels of Bdnf transcription, thus strengthening the 
subsequent consolidation of fear memories (Takei et al., 2011). In further agreement, it 
was shown that contextual fear conditioning in mice results in increased H3 acetylation at 
the Bdnf promoter IV (Lubin et al., 2008). Several other studies have reported the positive 
correlation between histone acetylation with Bdnf expression through the use of 
mood/cognitive-enhancer or anti-depressants drugs used in the clinics. Thus, chronic 
treatment with imipramine, an antidepressant drug, restored hippocampal Bdnf expression 
through hyper-acetylation of promoters IV and VI and selective downregulation of HDAC5 
in chronic social defeat stress mice, which normally present lower Bdnf expression 
(Tsankova et al., 2006). The administration of fluoxetine, another antidepressant that 
specifically inhibits serotonin reuptake, promoted acetylation at Bdnf promoter IV and 
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reversed depression-like behaviour in depressive-induced mice model (Onishchenko et 
al., 2008). Interestingly, neither imipramine nor fluoxetine did alter the repressive histone 
methylation marks in these two studies. Trichostatin A, an HDAC inhibitor, but also 
fluoxetine, have been shown to reactivate visual cortical plasticity in adult rats, inducing a 
transient increased transcription of Bdnf through histone hyperacetylation at its promoters 
(Maya Vetencourt et al., 2011). The impact of acetylation on Bdnf has been also shown in 
studies focusing on the mechanisms of action of drugs of social abuse. Cocaine-induced 
neuronal plasticity has been implicated in the activation of Bdnf promoter IV by increased 
acetylation and phosphor-CREB recruitment in rat prefrontal cortex. In contrast, cocaine 
abstinence increases histone H3 acetylation and induces Bdnf exon I transcription in 
ventral tegmental area (Schmidt et al., 2012). Epigenetic activation of Bdnf promoter I in 
the ventromedial prefrontal cortex (vmPFC) through acetylation of histone H3 has been 
associated with the successful extinction of aversive memories of morphine withdrawal 
(Wang et al., 2012).  
 
3.3.3.3.- Bdnf and Histone methylation: 
Several groups reported changes in histone methylation and therefore changes in 
Bdnf transcription in vivo. Onishchenko and colleagues showed that the induction of a 
depression-like behaviour in mice, by perinatal exposure to methylmercury, decreases 
Bdnf total mRNA in dentate gyrus, and that this reduction was due to increased histone 
H3 Lys 27 trimethylation at Bdnf promoter IV (Onishchenko et al., 2008). Other groups 
also showed similar effects on Bdnf transcription by other adverse environmental 
conditions, such as defeat stress or light deprivation. For instance, defeat stress induces 
the downregulation of Bdnf transcripts IV and VI accompanied by increased H3K27 
dimethylation at these promoters (Tsankova et al., 2006) and one week of light 
deprivation in male rats decreases Bdnf transcripts of exons I, II, IV and VI in visual cortex 
by increasing H3K27 trimethylation (Karpova et al., 2010). On the contrary, positive 
environmental conditions, such as environmental enrichment, increase Bdnf total mRNA 
expression, which is accompanied by decreased repressive methylations (H3K9Me3 and 
H3K27Me3) and increased levels of the activating methyl mark H3K4Me3 (Kuzumaki et 
al., 2011). 
 
3.3.4.-Post-transcriptional regulation of Bdnf mRNAs trafficking: 
Localized delivery of mRNAs to dendrites in response to a cognitive stimulus is 
thought to be a critical event in synaptic plasticity, assuring the rapid synthesis, through 
the dendritic translation machinery, of the essential factors required in the cognitive 
process; dendritic transport of Bdnf mRNAs fits into this premise (Bramham and Wells, 
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2007; Tongiorgi et al., 1997). In fact, the Bdnf gene complex structure allows diversity in 
expression, not only for the temporal neuronal response to different stimulus, but also for 
the differential spatial distribution of Bdnf transcripts (Aid et al., 2007; An et al., 2008; 
Chiaruttini et al., 2008, 2009; Pruunsild et al., 2007). Studies in neuronal cultures show 
that Bdnf transcripts targeting to dendrites might be promoted by a constitutively active 
element in the protein-coding region, while multiple 5’ or 3’ UTRs, with either inhibitory or 
permissive signals for dendritic targeting, control the transcript selective trafficking 
(Chiaruttini et al., 2009). The dendritic targeting of Bdnf mRNAs is driven by the protein-
coding sequence and is mediated by the RNA-binding protein Tarnslin. This interaction is 
blocked by the C196A (or Val66Met) mutation, compromising mRNA trafficking to distal 
dendrites, and therefore the correct spatial segregation of Bdnf mRNA variants (Chiaruttini 
et al., 2009).  
Different groups have shown that Bdnf splice variants containing the 5´exons II and VI 
are transported to distal dendrites whereas the transcripts containing 5´exons I and IV are 
required in the soma or in proximal dendrites. (Baj et al., 2011; Chiaruttini et al., 2008, 
2009). By use of overexpression and silencing of specific Bdnf mRNA isoforms, Baj and 
colleagues found that dendritic BDNF (from exons II and VI) plays a role in secondary 
dendrites’ plasticity in response to external stimuli. Furthermore, the expression of 
individual Bdnf splice variants was shown to be relevant for the spatially restricted 
activation of TrkB receptors: i.e. overexpression of exon I or IV transcripts led to 
phosphorylation of 80–100% of TrkB receptors within the first 45 µm from the soma 
whereas overexpressing exon II or VI Bdnf variants led to 80%TrkB phosphorylation at 80 
µm from the soma and beyond. Thus, the spatial segregation of Bdnf transcripts enables 
this neurotrophic factor to differentially shape distinct dendritic compartments (Baj et al., 
2011). 
Bdnf mRNAs trafficking is further regulated by the two different 3’ UTR, the short or 
long one. Bdnf mRNAs containing the short 3’ UTR have been shown to be located 
somatically, where they are constitutively translated in order to maintain the basal levels of 
BDNF protein. In contrary, the long 3’ UTR containing transcripts are targeted to distal 
dendrites and they are translated upon neuronal stimulus (An et al., 2008; Lau et al., 
2010). Moreover, different neuronal stimuli, such as KCl-induced depolarization in rat 
hippocampal neurons, change the somatic targeting of the short 3’UTR targeting to distal 
dendrites (Oe and Yoneda, 2010). 
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4.- Physiological relevance: Learning, memory and neuroepigenetics in ageing: 
Ageing is characterized by a progressive decline in cognitive capacities that can, in 
part, be explained by changes in neuronal plasticity or cellular alterations that directly 
affect plasticity mechanisms (Burke and Barnes, 2006). 
 
4.1.- Learning and memory in ageing: 
At the beginning of the second half of 20th century, several studies attributed cognitive 
impairments in the aged brain to neuronal loss, reaching up to 60% loss in cortical 
neurons, and also in the hippocampus (Ball, 1977; Brody, 1955; Coleman et al., 1987).  It 
was not until late 80´s, when new stereological principle were developed, that it was 
shown that in normal ageing there is no significant cell death in the hippocampus or 
neocortex (Pakkenberg and Gundersen, 1997; Rasmussen et al., 1996; West et al., 
1994). Different studies in dendritic extent have confirmed that, in general, there is no 
regression of dendrites with age in the hippocampus (Flood et al., 1987; Hanks and Flood, 
1991). Pyramidal neurons, on the other hand, show decreased dendritic branching with 
age, both in apical and basal dendrites, in superficial cortical layers (Grill and Riddle, 
2002). Spine density age-associated alterations are also region-specific. For instance, no 
differences in spine density was found at the CA1 or dentate gyrus while significant 
reduction of spine density is found in the subiculum (Curcio and Hinds, 1983; Uemura, 
1985). Apparently there are no major changes in brain anatomy in the old, but several 
studies show that spatial memory, which is essential for most episodic memories, declines 
with ageing in humans, monkeys, dogs, rats and mice (Bach et al., 1999; Head et al., 
1995; Newman and Kaszniak, 2000; Rapp et al., 1997; Rosenzweig and Barnes, 2003). 
Because the hippocampus is particularly susceptible to ageing, it is not surprising that 
task performances that require information processing are declined with ageing.  
 
4.2.- Neuroepigenetics in ageing: 
Several recent reports indicate that epigenetic mechanisms are affected in the aged 
brain and contribute to the aged brain phenotype (Morse et al., 2015; Penner et al., 2010, 
2011).  Thus, RNA microarray-based screening revealed the significant down-regulation 
of zif268/early growth response 1 (Egr1), Arc, Narp and Homer1 in the hippocampus of 
old rats (Blalock et al., 2003; Rowe et al., 2007). Also, Hattiangady and colleagues found 
that Bdnf is also downregulated in the hippocampus of middle-aged and aged rats 
(Hattiangady et al., 2005). We now know that the reduced IEG transcription can occur by 
an increase in repressive marks (H3K9Me2-Me3 or H3K27Me3), a decrease in activator 
marks (H3K9Ac, H3K14Ac, H4K12Ac or H4K20Me1), and/or decreased marks linked to 
transcriptional elongation processes (H3K36Me3) (Peleg et al., 2010; Tang et al., 2011; 
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Walker et al., 2013; Wang et al., 2010). Furthermore, it has been shown that not only 
histone marks are differently present in the chromatin of the old brain, but also HDACs 
undergo age-associated changes (Baltan, 2012; Chouliaras et al., 2013). On the other 
hand, a number of studies suggest that the state of chromatin of the old can still be 
modulated by different paradigms, turning a repressed transcriptional state into a more 
active state and facilitating IEG transcription (Morse et al., 2015; Peleg et al., 2010; 
Reolon et al., 2011). In this regard, Morse and colleagues have recently published that 
environmental enrichment enhances memory in old mice by increasing H3K4Me3 at Bdnf 
promoter IV and the subsequent increased transcription of total Bdnf (Morse et al., 2015). 
Furthermore, Peleg and colleagues showed that H4K12Ac increase was a key difference 
between young and old animals in response to fear conditioning, and that by treating old 
mice with SAHA, an HDAC inhibitor, they could enhance memory in the old mice. These 
authors attributed the improved memory effect to an increase in H3K12Ac after fear-
conditioning resulting in increased IEG transcription (Peleg et al., 2010).  
 
4.3.- LTD in ageing: the role of cholesterol: 
In all sub-regions of the hippocampus, most electrical properties remain constant over 
lifespan (Barnes, 1994). However CA1 pyramidal neurons show an increased Ca2+ 
conductance, possibly due to increased density of L-type Ca2+ channels that might 
contribute to plasticity deficits associated with ageing (Foster and Norris, 1997; Thibault 
and Landfield, 1996).  While increased Ca2+ could lead to facilitated LTD in the aged 
(Norris et al., 1996), several works reported deficits of NMDA-LTD in ageing (Billard and 
Rouaud, 2007; Martin et al., 2014a; Yang et al., 2013; Figure I4). Furthermore, 
hippocampal neurons maintained for long period in culture, until showing aging signs, 
present reduced AMPA mobility and endocytosis, and a poor LTD response to the 
addition of NMDA (Martin et al., 2014a). In this study it was shown that reduced AMPA 
mobility, endocytosis and LTD could be rescued by the addition of cholesterol, both in 
vitro and in vivo (Martin et al., 2014a; Figure I4). 
 
 
Figure I4: Impaired LTD in the old can be 
rescued by the addition of cholesterol. 
Intraventricular infusion of cholesterol in old mice 
restored NMDA-LTD. Field excitatory postsynaptic 
potentials (fEPSPs) were recorded from 
hippocampal slices of 24- month-old mice infused 
with cholesterol (♢) or vehicle (♦) in the lateral 
ventricle for 14 days. A significant NMDA-LTD was 
obtained in slices prepared from cholesterol-infused 
mice, but no LTD was observed in the vehicle-
treated group. (From Martín et al. 2014a) 
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The important role of cholesterol in the cognitive deficits of the old was also 
suggested by other lines of work. Thus, it was shown that synaptic plasticity of CNS is 
limited by the reduced availability of cholesterol provided by glial cells in mature brains 
(Goritz et al., 2005; Mauch et al., 2001). Also, age-dependent loss of cholesterol was 
reported in the human brain (Söderberg et al., 1990; Svennerholm et al., 1991, 1994, 
1997) and in the rodent hippocampus, in vivo and in vitro (Martin et al., 2008, 2014a; 
Sodero et al., 2011). At present, the precise causes for the age-associated cholesterol 
loss are not known. However, this may be the consequence of the cooperation between 
three different mechanisms: increased catabolism, reduced synthesis and reduced 
transference from astrocytes (Martin et al., 2014b). Increased catabolism is the 
consequence of the transcriptional activation of the brain-specific cholesterol-
hydroxylating enzyme Cyp46A1 (Ohyama et al., 2006; Sodero et al., 2012), increasing 
cholesterol solubility and removal from membranes for its subsequent extrusion from the 
brain. This possibility is supported by the observations that Cyp46A1 transcription in vitro 
is induced by oxidative stress by-products but not by sterol levels (Ohyama et al., 2006) 
and also by the observation that enzyme’s activity increases in high stress situations, such 
as during cortical injury, induced autoimmune encephalomyelitis and in Alzheimer’s 
disease (Bogdanovic et al., 2001; Cartagena et al., 2008; Teunissen et al., 2007).  Age-
dependent reduced synthesis was observed in neurons together with impaired delivery of 
newly synthesized cholesterol from glial cells (Thelen et al., 2006). Irrespective of the real 
contribution of each of these processes, the final outcome is that old neuronal cells 
contain reduced cholesterol levels and that this is in part responsible for impaired LTD.  
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The general Objectives planned for this Thesis were: 
 
1.- To determine the epigenetic mechanisms involved in Bdnf expression after NMDA 
receptor stimulation by chemical LTD.  
2.- To determine the relationship between cholesterol reduction and immediate early 
genes transcription associated to the cognitive deficits in the old.   
 
The work performed to reach the above objectives consisted in the following two phases.   
 
Phase 1: 
 
1.1.- Analysis of the transcriptional response of Bdnf transcripts containing exons I, 
II, IV, or VI to a pure cognition-related chemical stimulus as NMDA induced LTD. 
1.2.- Analysis of different activation and repressive histone marks and associated 
chromatin remodelling enzymes at Bdnf promoters I, II, IV and VI in basal 
conditions and after NMDA-LTD stimulation. 
1.3.- Dissection of the biochemical pathway connecting NMDA receptor stimulation 
(NMDA-LTD) to the epigenetic remodelling  involved in Bdnf expression. 
 
Phase 2: 
 
2.1.- Analysis of the basal state of the different epigenetic marks on Bdnf 
promoters in the aged hippocampus. 
2.2.- Analysis of Bdnf epigenetic regulation and transcription in the old in response 
to NMDA-LTD. 
2.3.- Analysis of the relationship between cholesterol reduction with age and Bdnf 
expression by NMDA-LTD.  
2.4.- Test a pharmacological approach to increase cholesterol levels in the old in 
order to enhance memory and rescue epigenetic regulation and IEGs transcription.
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1.- Primary hippocampal neurons: 
Primary cultures of hippocampal neurons were prepared from embryonic day 18 (E18) 
Wistar rats as described in Kaech et al. (Kaech and Banker, 2006). For our experiments 
hippocampal neurons were kept in culture for 15 days in vitro (15 DIV), when they have 
reached full maturation.  
Hippocampi were dissected and placed into ice-cold Hank’s solution with 7 mM 
HEPES and 0,45% glucose. The tissue was then treated with 0,005% trypsin (trypsin 
0,05% EDTA; (Invitrogen; Life Technologies Co.) and incubated at 37º C for 16 min and 
then treated with DNase (72 µg mL-1; Sigma-Aldrich) for 1 min at 37º C. Hippocampi were 
washed three times with Hank’s solution. Cells were dissociated in 5 mL of plating 
medium (Minimum Essential Medium (MEM) supplemented with 10% horse serum and 
20% glucose) and cells were counted in a Neubauer Chamber. Cells were plated into pre-
coated dishes with poly D-lysine (Sigma-Aldrich) (750.000 cells in a 10 cm dish and 
270.000 in a 6 cm dish) and placed into a humidified incubator containing 95% air and 5% 
CO2. The plating medium was replaced with equilibrated neurobasal media supplemented 
with B27 and GlutaMAX (Gibco; Life Technologies Co.). On DIV 7 the culture medium was 
replaced with medium without GlutaMAX. Cultures were used at 15 DIV.  
 
2.- Hippocampal Slices: 
Hippocampal slices were prepared from C57BL/J mouse (8 month the adult mice and 
20 month old the old mice). Hippocampi were extracted in dissection solution (10 mM D-
glucose, 4 mM KCl, 26 mM NaHCO3, 233.7 mM sucrose, 5mM MgCl2, 1:1000 Phenol 
Red), oxygen saturated with carbogen (95 % O2 / 5% CO2), and sliced in an automatic 
tissue chopper (McIlwain Tissue Chopper, Standard Table, 220V, Ted Pella Inc.) to obtain 
400µm hippocampal slices. Then, slices were kept in artificial cerebrospinal fluid (ACSF; 
119 mM NaCl, 2.5 mM KCl, 1 mM NaH2PO4, 11 mM glucose, 1.2 mM MgCl2, 2.5 mM 
CaCl2; osmolarity was adjusted to 290 Osm; ACSF was oxygen saturated with carbogen) 
for 1 hour. Finally the experiments were performed in ACSF. 
 
3.- Cell Cultures:  
HEK293T cells (ATCC) and Mouse Embrionic Fibroblasts (MEFs) WT and p38 KO 
(Porras et al., 2004) (kindly provided by Dr. A. R. Nebreda; Institute for Research in 
Biomedicine (IRB Barcelona), Barcelona, Spain) were grown with Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% FBS and antibiotics (100 units/mL 
penicillin and 100 mg/mL streptomycin). DMEM was supplemented with 2 mM L-glutamine 
for MEFs culture. Cells were incubated at 37ºC in a humidified atmosphere of 5% CO2.  
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4.- Drug treatments: 
Stock solutions of CBP-CREB Interaction Inhibitor (250 mM (CCIIh); Millipore ref. 
217505), KDM6A/B inhibitor (GSK-J4; 100 mM; Tocris Bioscience ref. 4594), p-38 MAK 
inhibitor (SB203580; 100mM; Axon Medchem ref. Axon 1363), Forskolin (50 mM, Tocris 
Bioscience ref. 1099) and Rolipram (100µM, Tocris Bioscience ref. 0905) were prepared 
in dimethyl sulfoxide (Sigma). Stock solutions of CaMKII inhibitor (KN93 phosphate; 20 
mM; Tocris ref. 5215), mitogen- and stress-activated kinases 1/2 (Msk1/2) inhibitor (H89 
dihydrochloride; 25 mM; Tocris ref. 2910), Portein Kinase C (PKC) inhibitor (Chelerytrine 
chloride; 10 mM; Tocris ref. 1330) and NMDA (20mM; Sigma-Aldrich ref. M3262) was 
prepared in Milli-Q water. Hippocampal neurons were treated with 5 µM CCIIh (1 hour), 10 
µM GSK-J4 (1 hour), 10µM SB203580 (1 hour), 30 µM KN93 (20 min), 50 µM H89 (20 
min) or 10 µM Chelerytrine (20 min) prior to NMDA-LTD induction. Stock solution of 
Cholesterol Oxidase (COase; 500 U/mL; Millipore ref. 228250) was prepared in water. 
MßCD-Ch solution was prepared freshly at use concentration, containing 30 µM of 
Cholesterol Water soluble (Sigma-Aldrich ref. C4951) with 5 µM Cholesterol (Sigma-
Aldrich ref. C3045). Hippocampal slices were treated with COase 10 U/mL for 30 min or 
with MßCD-Ch for 1 hour prior to NMDA-LTD induction. For all biochemical experiments 
LTD was induced by 20 µM NMDA (Sigma-Aldrich ref. M3262) for 5 minutes, medium was 
then replaced and samples collected 5 or 25 minutes after LTD induction. Samples 
without LTD induction were used as a control. The experiments conducted in primary 
hippocampal neurons were performed at 37ºC, the ones conducted in hippocampal slices 
were performed at 25ºC. For Voriconazole treatments see below (Animals oral treatment 
paragraph 17.1). 
 
5.- Relative RT-PCR:  
Hippocampal slices on primary neurons were homogenized with Trizol Reagent 
(Ambion / RNA Life Technologies Co.) and the RNA was extracted with Direct-zolTM RNA 
minipreps (Zimo research ref. R2052) following manufactures instructions. RNA was 
quantified by absorbance at 260 nm using a Nanodrop ND-100 (Thermoscientific; Themo 
Fisher Scientific Inc.). Retrotranscription to first strand cDNA was performed using 
RevertAid H Minus First Strand cDNA Synthesis kit (Thermoscientific; Themo Fisher 
Scientific Inc.). Briefly, 5 ng of synthesized cDNA was used to perform the qPCR using 
GoTaq® qPCR Master Mix (Promega Co., Madison, WI, USA) in ABI PRISM 7900HT 
SDS (Applied Biosystems; Life Technologies Co.). The primers purchased to Sigma-
Aldrich (Supplementary Table 1) were used at 0.5µM final concentration. Three 
housekeeping genes Gapdh, GusB and Pgk1 were used as endogenous controls. 
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6.- Chromatin immunoprecipitation (ChIP): 
ChIP experiments were performed as described by Millanes-Romero et al. (Millanes-
Romero et al., 2013). Briefly hippocampal slices were crosslinked with 1% formaldehyde 
for 15 min at RT. Primary hippocampal neurons were crosslinked with 1% formaldehyde 
for 10 min at 30ºC. Crosslinking was stopped by adding glycine to a final concentration of 
0.125 M for 2 min at RT. Samples were washed three times with cold PBS and 
homogenized in cold Soft Lysis Buffer (50 mM Tris [pH 8.0], 10 mM EDTA, 0.1% NP-40 
and 10% glycerol) plus inhibitors (protease inhibitor (cOmplete, EDTA-free; Roche), 
phosphatase inhibitor cocktail 2 (Sigma-Aldrich) and NaBut [5mM] (Sigma-Aldrich)). 
Finally, lysates were centrifuged at 3.000 rpm at 4 ºC for 15 minutes. Nuclei enriched 
pellets were lysed with SDS Lysis Buffer (1% SDS, 10mM EDTA and 50mM Tris [pH 8.0]) 
plus inhibitors and extracts were sonicated with Bioruptor® Plus 300 to generate 400 to 
700 bp DNA fragments. Samples were centrifuged at 13.000 rpm, 4ºC, 10 min to remove 
insoluble material, and the supernatant containing DNA–protein complexes was collected. 
Additionally, protein quantification from sonicated chromatin was performed using Pierce® 
BCA protein assay kit (Thermoscientific; Themo Fisher Scientific Inc.). The chromatin was 
diluted 1/10 with Dilution Buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA pH8, 16.7 
mM Tris pH 8 and 167 mM NaCl) and pre-cleared with 50 µL protein A/G agarose beads 
(Santa Cruz Biotechnology, Inc.) and 40 µg of normal IgG (Santa Cruz Biotechnology, 
Inc.) for each 500 µg of protein. Samples were placed in a rotor for 1–3 h at 4ºC. The 
mixture was centrifuged and the supernatant was collected. 100 µg of protein were used 
for each ChIP assay, reserving 10µg as the input. The antibodies (Supplementary Table 
2) were added to the chromatin lysate, incubated on a rotor O/N at 4ºC. Immune 
complexes were precipitated by the addition protein A/G agarose beads. As a negative 
control, non-immune rabbit IgG (Santa Cruz Biotechnology, Inc.) was used in place of 
specific antibodies. Immuneprecipitated complexes were washed three times with the 
following buffers: Low-Salt Wash Buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA pH8, 
20 mM Tris pH 8 and 150 mM NaCl), High-Salt Wash Buffer (0.1% SDS, 1% Triton X-100, 
2 mM EDTA pH8, 20 mM Tris pH 8 and 500 mM NaCl), and LiCl Wash Buffer (250 mM 
LiCl, 1% NP-40, 1% NaDOC, 1mM EDTA and 10 mM Tris pH8). Immune complexes were 
eluted in 100 µL 1% SDS and 100 mM NaHCO3 at 37ºC for 30 min. DNA-protein cross-
links were reversed by adding NaCl to a final concentration of 200mM O/N at 60ºC. 
Protein digestion was preformed 1h at 37ºC by adding Proteinase K 0.04 mg/mL 
(Promega ref. MC5005), 50 mM EDTA pH8 and 500 mM Tris pH6.5 at final concentration. 
Finally, DNA was purified with QIAquick Gel Extraction Kit following the manufacturer 
procedures (Qiagen, Hilden, Germany) and eluted in 140 µL DNA/RNAse free MilliQ 
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water. 4µL of purified DNA was used to perform a qPCR, using the listed primers on 
Supplementary Table 1.    
 
7.- Protein identification by Western Blot: 
Hippocampal slices or primary hippocampal neurons were lysed on ice with a solution 
containing 1M Tris-HCl, 1% Nonidet P-40, 150 mM NaCl, 5 mM EDTA, 1 mM sodium 
orthovanadate, 1 mM dithiotreitol, pH 7.4, protease inhibitor cocktail (Roche) and 
phosphatase inhibitor cocktail 2 (Sigma-Aldrich). Protein concentration was determined by 
Pierce® BCA protein assay kit (Thermoscientific). Protein samples were 
electrophoretically resolved within reduced and denaturing gels: 8% for CREB, 10% for 
CaMKIIα and 15%  for Histones, and afterwards transferred to nitrocellulose membranes 
using iBlot Gel Transfer System (Invitrogen). Membranes were blocked for 1 hour in 
Tween 20-Tris buffer solution (TTBS: 0.1% v/v Tween 20, 100 mM Tris-HCl, 150 mM 
NaCl, pH 7.5), containing 5% BSA (Sigma-Aldrich), and incubated overnight at 4°C with 
the antibodies (Supplementary Table 2), diluted in 5% BSA in TTBS. Peroxidase-
conjugated polyclonal goat anti-rabbit (Dako ref. P0448) or peroxidase-conjugated 
polyclonal rabbit anti-mouse (Dako ref. P0260) were used as secondary antibodies at 
1:5000 for 1 h at RT in TTBS containing 5% BSA. Bands were visualized with Super 
Signal (Thermoscientific) in an ImageQuant LAS 4000 Mini (GE Healtcare Life Sciences). 
Bands were quantified with ImageJ. 
 
8.- p38 antobody validation for ChIP: 
Wild type and p38 KO MEFs were traded with 100 mM NaCl for 45 minutes in order to 
induce hyperosmotic stress, a treatment known to activate p38 and promote its 
recruitment to different genes promoters (Ferreiro et al., 2010). In Figure R7 (see pag. 66) 
we show p38 is recruited to Cox2 promoter upon hyperosmotic stimulation in WT MEFs 
and that this recruitment does not take place in p38 KO MEFs. These results suggest that 
the antibody used is ChIP grade for p38 (Supplementary Table 2). 
 
9.- H3K27Me3S28p antibody crossreactivity: 
Inreasing amounts of Histone H3 peptides containing different marks (Diagenode: 
H3K9Me3S28p ref. C16000128, H3K27 unmodified ref.C16000998, H3K27Me3 ref. 
C16000069, H3K27Me3S28p ref. C16000091) mixtures were loaded onto a nitrocellulose 
membrane using a dot-blot (Bio-Rad, ref. 1706545). Membrane were blocked 1h with 5% 
BSA in TTBS and incubated O/N with H3K27Me3S28p antibody (Supplementary Table 2). 
Peroxidase-conjugated polyclonal goat anti-rabbit (Dako ref. P0448) was used as 
secondary antibody at 1:5000 for 1 h at RT in TTBS containing 5% BSA. Dots were 
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visualized with Super Signal (Thermoscientific) in an ImageQuant LAS 4000 Mini (GE 
Healtcare Life Sciences). 
 
10.- Histone H3 peptides dephosphorylation: 
20 µL of Histone H3 peptides H3K27Me3 and H3K27Me3S28p 10 µM (Diagenode, 
H3K27Me3 ref. C16000069, H3K27Me3S28p ref. C16000091) were incubated for 1hour 
at 37ºC with 4 units of Alkaline Phosphatase (CIP; New England BioLabs ref. M0290S) 
and in a buffer containing 50 mM HEPES (pH 7.9) and MgCl 10 mM. 20 µL of Histone H3 
peptides H3K27Me3 and H3K27Me3S28p 10 µM control non dephosphorylated peptides 
were incubated in a buffer containing 50 mM HEPES (pH 7.9) and MgCl 10 mM plus 
phosphatase inhibitors. After treatment mixtures were loaded onto a nitrocellulose 
membrane using a dot-blot (Bio-Rad, ref. 1706545). Membrane were blocked 1h with 5% 
BSA in TTBS and incubated O/N with H3K27Me  or H3K27Me3S28p antibodies 
(Supplementary Table 2). Peroxidase-conjugated polyclonal goat anti-rabbit (Dako ref. 
P0448) was used as secondary antibody at 1:5000 for 1 h at RT in TTBS containing 5% 
BSA. Dots were visualized with Super Signal (Thermoscientific) in an ImageQuant LAS 
4000 Mini (GE Healtcare Life Sciences). 
 
11.- Chromatin dephosphorylation: 
Samples were collected and sonicated in Sof Lysis Buffer and SDS Lysis buffer with 
protease inhibitors and without EDTA, and finally chromatin was adjusted at 1µg/µL with 
SDS Lysis Buffer without EDTA. Samples were incubated for 1hour at 37ºC with 4 units of 
Alkaline Phosphatase per µg of chromatin (CIP; New England BioLabs ref. M0290S) and 
MgCl 10 mM. After 1 hour phosphatase inhibitor was added. Control non-de-
phosphorylated samples were incubated 1 hour at 37ºC with MgCl 10 mM and 
phosphatase inhibitors. After de-phosphorylation treatment we followed ChIP protocol by 
diluting samples 1/10 with Dilution Buffer. 
 
12.- Lentiviral production and neuronal infection: 
Packaging plamids and Sh-RNA plamid against JMJD3 or srcamble were purchased 
from Origene. Lentiviral particles were produced in HEK293T according to Origene 
instructions. Neurons were infected at 11 DIV and medium was fully changed with 
neuronal conditioned medium at 12 DIV. Experiments were performed at 15 DIV. 
 
13- JMJD3 antibody validation for ChIP: 
In the Figure R9 we show the experiments designed to assess the specificity of the 
antibody used. In the panel A we show that treatment of hippocampal neurons in culture 
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with a lentivirus expressing a shRNA to knock down JMJD3 leads to a 50% reduction in 
the amount of the specific mRNA compared to cultures infected with leniviral particles 
expressing a scrambled shRNA. In the panel B, the Western blot show that JMJD3 knock 
down resulted in a 75% reduction of JMJD3 compared to scrambled-shRNA treated 
controls. The ChIP experiments performed with the Abcam, ab38113 antibody 
(Supplementary Table 2) show that the enrichment of JMJD3 at the Bdnf promoters is lost 
in cultures where JMJD3 was knocked down. These results suggest that the antibody 
used is ChIP grade for JMJD3.  
 
14.- In vitro JMJD3 demethylase activity assay: 
Histone demethylase assay was performed as described by Hong et al. (Hong et al., 
2007) with minor modifications. Briefly, 10 µM of H3K27Me3 (Diagenode) peptide were 
incubated with 0 or 14 pmol of the active human recombinant JMJD3 (Sigma-Aldrich, ref. 
SRP0162) in the demethylase assay buffer [50 mM HEPES (pH 7.9), 50 mM KCl, 50 mM 
(NH4)2Fe(SO4)2 · 6(H2O), 1 mM α-ketoglutarate, and 2 mM ascorbic acid]. 10 µM 
H3K27Me3S28p peptide (Diganeode) were incubated with increasing concentrations (0, 
3.5, 7 and 14 pmol) of the active human recombinant JMJD3 in the demethylase assay 
buffer. Demethylation assay mixtures were kept for 5 h at 37°C with soft agitation (400 
rpms).   Assay mixtures were loaded onto a nitrocellulose membrane using a dot-blot (Bio-
Rad, ref. 1706545). Membrane were blocked 1h with 5% BSA in TTBS and incubated O/N 
with specific antibodies (Supplementary Table 2). Peroxidase-conjugated polyclonal goat 
anti-rabbit (Dako ref. P0448) was used as secondary antibody at 1:5000 for 1 h at RT in 
TTBS containing 5% BSA. Dots were visualized with Super Signal (Thermoscientific) in an 
ImageQuant LAS 4000 Mini (GE Healtcare Life Sciences). Dots were quantified with 
ImageJ. 
 
15.- Immunoprecipitation: 
HEK293T cells were transfected with Lipofectamine 2000 according to the 
manufacturer instructions (Life technologies, ref. 11668) using a plasmid that drive the 
expression of 6xMyc-JMJD3-FLAG (Addgene, ref. 17440; Hong et al., 2007) and a 
plasmid that drive the expression of CBP when co-transfectred with a Tet-Off containing 
plasmid (kindly provided by Dr A. Barco; Instituto de Neurociencias, Universidad Miguel 
Hernández-Consejo Superior de Investigaciones Científicas, Alicante, Spain; Valor et al., 
2011). HEK293T were treated with Forskolin (50µM) and Rolipram (0.1 µM) for 15 min 
and crosslinked with dithiobis(succinimidyl-propionate) (DSP) 5 mM (Life technologies ref. 
22585) for 30 min at RT, and reaction was stopped by adding Tris pH7.5 at final 
concentration 20 mM for 15 min. Cells were washed two times with cold PBS and 
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homogenized in STEN plus inhibitors and sonicated until clarification. Samples were pre-
cleared with 40 µL protein A/G agarose beads and 10 µg of normal IgG for each 200 µg of 
protein. Samples were placed in a rotor for 1–3 h at 4ºC. The mixture was centrifuged and 
the supernatant was collected. 200 µg of protein were used for each IP assay. The 
antibodies (Supplementary Table 2) were added to the lysate, incubated on a rotor O/N at 
4ºC. Immune complexes were precipitated by the addition protein A/G agarose beads. As 
a negative control, non-immune mouse IgG was used in place of specific antibodies. 
Immuneprecipitated complexes were washed five times with STEN Buffer and one time 
with PBS. Complexes were eluted with Laemmli Buffer 2X (120 mM Tris pH 6.8, 4% SDS, 
20% glycerol, 2% ß-mercaptoethanol and 0,02% bromophenol blue) for 10 min at 95ºC 
and proteins were identified by Western Blot. 
 
16.- Cholesterol quantification: 
Hippocampal slices were washed in cold PBS and then homogenized in a lysis buffer 
containing 25 mM MES, 2 mM EDTA and cocktails of protease and phosphatase inhibitors 
from Roche. The protein amount was quantified by Pierce® BCA Assay Kit (Thermo 
Scientific) and the cholesterol content measured per µg of protein using the Amplex® Red 
Cholesterol Assay Kit (Invitrogen). 
 
17.- Animal treatment and behaviour experiments: 
17.1.- Oral Treatment with Voriconazole: 
Voriconazole (from HangZhou Dayangchem Co., CAS No:137234-62-9) was 
solubilized using hydroxyl propyl-b-cyclodextrin (Sigma): 15g of hydroxyl propyl-b-
cyclodextrin were dissolved in 100ml of saline solution (0.9% NaCl) and heated to 80°C in 
a water bath with stirring. Then, 1.5g Voriconazole was slowly added to the cyclodextrin 
solution with stirring at 80°C until complete dissolution. This stock solution (15 mg 
voriconazole/ml cyclodextrin/saline) was conserved at 4°C protected from the light. On the 
first day of experimentation, an aliquot of this solution was diluted in drinking water to a 
final concentration of 0.68 mg/ml Voriconazole.  Considering that a mouse drinks 3 ml 
water per day, the dose corresponds to 2.04 mg/day. The average weight of a mouse is 
34 g, resulting therefore in a dose 60 mg/kg b.w.  Water with this concentration of 
Voriconazole was used as the hydration source in 19 month-old mice during 45 days. 
Vehicle, 19 month-old mice received the same amount of hydroxyl propyl-b-cyclodextrin 
than Voriconazoles during 45 days. Bottles containing the Voriconazole or Vehicle water 
were changed weekly.  
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17.2.- Water Maze Learning: Spatial training 
The water maze was a white circular pool (1.5 m diameter, 45 cm high) filled with 
water diameter containing water made opaque with white non-toxic paint, at 24 ± 1 ºC. An 
invisible escape platform (10 cm diameter) was placed at a fixed location equidistant from 
the sidewall and middle of the pool, and submerged 1 cm below the water surface. The 
behaviour of the animal (latency, distance, swim speed, and navigation path) was 
monitored by a video camera, mounted in the ceiling above the centre of the pool, and a 
computerized tracking system (Ethovision 1.90, Noldus IT, The Netherlands). Mice 
received four trials of 90 s maximum, separated by a 45- to 60-min inter-trial interval every 
day for four consecutive days. If the animal failed to escape within 90 s, it was gently 
guided to the platform by the experimenter and allowed to remain on it for 30 s. During the 
training procedure, the location of the platform remained constant in one virtual quadrant 
of the maze, and the starting position for each trial was varied among four equally spaced 
positions around the perimeter of the maze. On day 5, we conducted a probe trial in which 
the escape platform was removed from the pool and the mouse was allowed to swim for 
60 sec. The trial began with the mouse in the quadrant opposite to the trained platform 
location. The time spent in each quadrant was recorded. During the visible platform task, 
the platform was cued with a black flag.  
 
17.3.- Novel-Object Location 
Mice were first habituated individually to an empty open-field box (35 x 35 x 15 high 
cm) for 30 min, during 2 consecutive days. A sample trial (object exposure) consisted of 
placing a mouse into the test box, which contained 2 identical objects, small plastic toys 
(10 x15 high cm) that were placed in a symmetrical position about 5 cm away from walls, 
and the animal was allowed to explore them for 5 min. The objects were always 
thoroughly cleaned between sessions using a 0.1% acetic acid solution. Spatial memory 
was evaluated after a 30 min delay during a 3 min test. A preference index, a ratio of the 
amount of time spent exploring the novel object over the total time spent exploring both 
objects, was used to measure recognition memory. Exploration was defined as follows: 
directing the nose to the object at a distance of no more than 2 cm and/or touching the 
object with the nose. Novel and familiar object location was counterbalanced across 
animals. This task depends on the hippocampal function (Galani et al., 1998). 
 
17.4.- Fear conditioning 
Training and testing took place in a rodent observation cage (30 × 37 × 25 cm) that 
was placed in a sound-attenuating chamber. In the training (conditioning), the mouse was 
exposed to the conditioning context (180 sec) followed by a tone (CS, 20 sec, 2 kHz, 85 
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dB).  After termination of the tone, a footshock (US, 0.75 mA, 2 sec) was delivered 
through a stainless steel grid floor. Mice received three footshocks with an inter-trial 
interval of 60 s. Mice were removed from the fear conditioning box 30 sec after shock 
termination and returned to their home cages. Testing: In the contextual fear conditioning 
version, mice were placed back into the original training context for 8 min, during which no 
footshock was delivered. In the auditory-cued fear conditioning version, animals were 
placed into a novel context (same cages, but with different walls, floor, and background 
odour), and, after a 3 min baseline period, they were continuously reexposed to the tone 
(same characteristics as at conditioning) for 5 min, but in the absence of shocks. The 
animals' behaviour was video recorded and later scored by an observer blind to the 
treatment condition. Using a time-sampling procedure every 2 s, each mouse was scored 
blindly as either freezing or active at the instant the sample was taken. Freezing was 
defined as behavioural immobility except for movement needed for respiration. 
 
18.- Animal handling:  
All the experiments were performed in accordance with European Union guidelines 
(2010/63/UE) regarding the use of laboratory animals.  
 
19.- Statistical analysis:  
All values are presented as mean	 ± SEM. In Chapter 1, Mann-Whitney U test or 
Kruskal-Wallis followed by Mann-Whitney U test multiple comparisons with Bonferroni 
adjustment were used for statistical analysis. In Chapter 2, data normality and variances 
were tested by Shapiro–Wilk test and Levene test respectively. Mann–Whitney U-test, 
Kruskal-Wallis or Friedman were used for nonparametric data, and one-sample t-test, 
Student's t-test or ANOVA for parametric data, assuming or not equal variances. All the 
analysis was performed using SPSS6 (SPSS6 Statistics, IBM.). For values and statistical 
analysis see Supplementary tables 3-32. In the figures asterisks indicate P values as 
follows: *< 0.05; **< 0.01; ***< 0.001.  
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CHAPTER I: Epigenetic regulation of Bdnf transcription upon LTD.  
 
1.1.- Transcriptional analysis of Bdnf promoters. 
We first determined whether or not the mild synaptic stimulation triggered by low 
doses of N-methyl-D-aspartate (NMDA) is able to induce expression changes of Bdnf 
promoters. Hippocampal neurons maintained in culture for 2 weeks were exposed during 
5 min to 20µM NMDA, a stimulus known to lead to LTD (Ehlers, 2000; Fernández-Monreal 
et al., 2012; Lee et al., 1998; Lin et al., 2000). The expression levels of exons I, II, IV and 
VI were then determined by qPCR at different time points after stimulation. Fig. R1 A-B 
shows that a significant increase was observed for transcripts II and VI at 10min after 
NMDA addition. The amount of these mRNAs reached a peak at 30 min after stimulation 
and returned to basal levels at later time-points: 60 min for mRNA VI and 180 min for 
mRNA II. The expression of exons I and IV however, presented a different behavior since 
a significant increase of these mRNAs was observed only after 30 min upon stimulation. 
The levels of mRNA I remained at maximum along the entire length of time analyzed 
(180min) while the levels of mRNA IV returned to basal at 180min after NMDA application.  
These results reveal that chemically induced LTD (NMDA-LTD) triggers two different 
responses of these Bdnf promoters, a fast response of promoters II and VI driving a 
transient expression of Bdnf exons II and VI and a slower response of promoters I and IV, 
leading to a more stable expression of exons I and IV. 
 
1.2.- Epigenetic marks found at Bdnf promoters in mature neurons. 
As commented in the Introduction, the structure and genetic environment of Bdnf 
promoters I, II, IV and VI suggest that Bdnf could be a bivalent gene, and that its 
promoters are potential sites to be controlled by repressive (PRC) and activating 
(H3K4Me3) marks. Hence we next assessed if activator trimethyl-H3K4 (H3K4Me3) and 
repressor trimethyl-H3K27 (H3K27Me3) are present at Bdnf promoters under non-
stimulated conditions. In addition, we also searched for the presence of acetyl-H3K27 
(H3K27Ac) as an activation form of the H3K27. Chromatin immunoprecipitation (ChIP) 
assays followed by promoter-specific qPCR performed in non-stimulated hippocampal 
neurons revealed that these three histone marks are present in all the four Bdnf promoters 
(Figure R2 A-C). 
The amount of each histone mark at Bdnf promoters was compared to the amount 
bound to the promoters of two control genes, ßActin and hoxA1. In fact, the constitutively 
active ßActin presents high levels of activator marks H3K27Ac and H3K4Me3 (Fig. R2 A, 
B) and low levels of the repressive H3K27Me3 mark (Fig. R2C). In contraposition, the 
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constitutively repressed hoxA1 showed high levels of the repressive H3K27Me3, low 
amounts of H3K4Me3 and undetectable H3K27Ac (Fig. R2 A-C).  
To further substantiate that Bdnf promoters I, II, IV and VI are repressed by PRC in 
non stimulated neurons, we determined the level of association to Enhancer of zeste 
homologue 2 (EZH2), the catalytic subunit of the Polycomb Repressive Complex 2 
(PRC2), to these promoters. ChIP experiments revealed the presence of EZH2 associated 
to the four Bdnf promoters (Fig. R2D) at levels that are comparable to the levels bound to 
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Figure R2: Epigenetic marks found at Bdnf promoters in mature neurons 
A-E) ChIP-qPCR analysis of epigenetic marks and regulatory proteins bound at Bdnf promoters in basal 
conditions: (A) H3K27Ac, (B) H3K4Me3, (C) H3K27Me3, (D) EZH2 and (E) JMJD3. The plots also show 
the levels of the respective marks found at the promoter region of two control genes: a constitutively 
transcribed ßActin and a repressed gene hoxA1. For values see Supp. Table 4. 
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Figure R1: Response of Bdnf promoters to NMDA stimulation in mature hippocampal 
neurons. 
A) RT-qPCR analysis of the levels of Bdnf mRNAs transcribed from promoters I, II, IV and VI after NMDA 
stimulation. B) The bar plot shows the relative amount of each transcript compared to non stimulated 
controls at 10 or 30 min after NMDA addition. Data are represented as mean ± SEM (*p<0.05; **p<0.01, 
***p<0.001). For statistical analysis see Supp. Table 3. 
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the PRC2 repressed gene hoxA1. Strikingly, a similar ChIP experiment revealed that, 
different from hoxA1, high levels of the H3K27Me3-demethylase Jumonji domain 
containing-3 (JMJD3) were present at these Bdnf promoters suggesting that these 
promoters are ready to be de-repressed by H3K27Me3 demethylation (Fig. R2E).  
 
1.3.- NMDA leads to epigenetic remodeling at Bdnf promoters. 
To test if NMDA-LTD induces quantitative changes in the different histone marks at 
our target promoters, similar ChIP experiments were performed in 2 week-old 
hippocampal neurons in culture 10 minutes after NMDA stimulation. Figure R3A shows 
the result of this study: the activation marks H3K4Me3 and H3K27Ac, as well as the 
JMJD3 demethylase, all increased by the LTD stimulus at promoters II and VI. 
Furthermore, NMDA treatment resulted in lower levels of the repressor EZH2 at promoters 
II and VI and reduction of the repressive H3K27Me3 mark at promoter VI. These results 
may explain the enhanced expression of these transcripts after NMDA stimulation. On the 
other hand, no change in the levels of these marks were detected at promoter I after 
stimulation, according to the later expression time of this transcript (30 min, see Fig. R1A). 
However, in promoter IV, which also undergoes a delayed increased expression (see Fig. 
R1A), significant decreased levels of repressor EZH2 were accompanied by recruitment of 
the H3K27Me3 demethylase JMJD3 and decreased amount of H3K27Me3, which would 
imply derepression at this early time. However, different from promoters II and VI, no 
increase of the activator marks H3K4Me3 and H3K27Ac was observed at this promoter 
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Figure R3: NMDA stimulation induces 
epigenetic remodeling of Bdnf 
promoters. 
A) ChIP-qPCR analysis showing the changes in 
the levels of these proteins at the Bdnf 
promoters measured 10 min after NMDA 
stimulation. The phosphorylation of H3K27Me3 
at Serine 28, which is reported to displace the 
repressor EZH2, is also analyzed. B) ChIP-
qPCR analysis shows that the levels of these 
proteins do not change 10 min after NMDA 
………. 
 
stimulation at control ßActin and hoxA1 promoters. Data are represented as mean ± SEM (*p<0.05; 
**p<0.01, ***p<0.001). For statistical analysis see Supp. Table 5. 
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implying that both, increase of activation marks and decreased repressive marks, are 
required for fast transcriptional induction.   
As expected, we did not observe changes in the levels of these epigenetic marks in 
the promoter regions of the control genes ßActin and hoxA1, which are not regulated by 
NMDA (Fig. R3B). 
ChIP experiments performed 30 min after NMDA stimulation showed that the levels of 
all histone marks and their upstream regulators were restored to basal conditions. 
Significantly, lower levels of H3K27Ac, compared to non-stimulated controls, were 
observed at promoters II, IV and VI (Fig. R4A), suggesting that H3K27Ac deacetylation is 
involved in the silencing of these promoters after stimulus. However, the possibility of a 
general effect triggered after NMDA-LTD could not be discarded since reduced levels of 
H3K27Ac were also observed at the control genes 30 min after NMDA application (Fig. 
R4B).  
 
1.4.- Derepression of Bdnf requires H3K27Me3S28 phosphorylation. 
It has been reported that p38 MAPK and mainly its downstream kinases, mitogen- 
and stress-activated kinases (Msk1 and Msk2), lead to gene activation through 
H3K27Me3 phosphorylation at Serine 28, and the consequent displacement of the EZH2 
and promoter derepression (Gehani et al., 2010). That was proposed as a mechanism 
required to activate a subset of Polycomb group of proteins (PcG) target genes by 
biological stimuli in developing cells (Gehani et al., 2010). ChIP experiments revealed that 
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Figure R4: Basal epigenetic status is 
restored 30 min after stimulation. 
A) ChIP-PCR analysis showing that the 
levels of most of the histone marks and 
regulatory proteins found at Bdnf promoters 
I, II, IV and VI return to basal levels at 30 
min after NMDA stimulation. Differences 
with controls are still observed for 
H3K4Me3 at promoter II and H3K27Me3 at 
promoter IV.  B) ChIP-qPCR analysis of 
these proteins 30 min after NMDA 
stimulation at ßActin and hoxA1 control 
promoters. Levels of H3K27Ac that are 
  
promoters. Levels of H3K27Ac that are lower than in non stimulated cells were ound at all promote s
suggesting a that H3K27 deacetylation could be a general effect observed at 30 min after NMDA 
addition. Data are represented as mean ± SEM (*p<0.05; **p<0.01). For statistical analysis see Supp. 
Table 6. 
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H3K27Me3S28 phosphorylation occurs at Bdnf promoters II and VI after 10 min of NMDA 
stimulation (Figure R3A), suggesting that a mechanism similar to the one reported in 
developing cells may participate during NMDA-induced Bdnf expression in mature 
neurons. In the Figure R5 we show that the antibody used in our experiments does not 
cross react with H3K9Me3S10p as previously reported for other rabbit polyclonal 
antibodies for H3K27Me3S28p (Gehani et al., 2010; Rothbart et al., 2015). 
To assess if the p38 MAPK pathway may be involved in H3K27Me3S28 
phosphorylation in mature neurons, we treated NMDA-stimulated hippocampal neurons 
with the p38 specific inhibitor SB-203580 (Kramer et al., 1996; Powell et al., 2003; 
Saklatvala et al., 1996). The qPCR analysis revealed that this treatment prevented 
NMDA-induced increase of transcripts II and VI (Fig. R6A). Moreover, ChIP experiments 
showed that p38 MAPK inhibition abolished NMDA-induced H3K27Me3S28 
phosphorylation at promoters II and VI (Fig. R6B). According to these results, ChIP 
assays performed using a ChIP tested antibody against p38 (Fig R7A) showed that LTD-
induced recruitment of p38 to promoters II and VI at 10 min after stimulation (Fig. R7B-C).  
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Figure R5: H3K27Me3S28p 
antibody corsreactivity. 
H3K27Me3S28p Rabbit antibody 
cross reactivity: Increasing concen- 
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Figure R6: LTD induced derepression and transcription of Bdnf promoters II and VI requires 
EZH2 displacement via p38 pathway activation. 
A) RT-qPCR analysis of the Bdnf transcripts shows that treatment with the p38 inhibitor SB-203580 blocks 
the increase of mRNAs transcribed from promoters II and VI at 30 min after NMDA stimulation. B-C) ChIP-
qPCR analysis performed 10 min after stimulation shows that SB-203580 impairs H3K27Me3S28 
phosphorylation at promoters II and VI (B). Interestingly, SB-203580 blocked EZH2 displacement from the 
four promoters studied suggesting a role for EZH2 in the transcriptional control of these regions (C). Data are 
represented as mean ± SEM (*p<0.05; **p<0.01; ***p<0.001). For statistical analysis see Supp. Table 7. 
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In further support that phosphorylation of H3K27Me3S28 is required for Polycomb 
removal, p38 inhibition precluded EZH2 displacement from Bdnf promoters II and VI after 
NMDA stimulation (Fig R6C). Differently from these promoters, the expression of exons I 
and IV was not affected by the treatment with the inhibitor (Figs. R6A and R6B), further 
strengthening our early assumption that promoters I and IV are controlled by mechanisms 
different from the ones controlling promoters II and VI. Although the SB-203580 also 
blocked the release of EZH2 from promoters I and IV (change not significant in the case of 
promoter I), increases in H3K27Me3S28p were not observed in these two promoters after 
NMDA stimulation, further strengthening the notion that both derepression and activation 
are required for NMDA-induced Bdnf expression.  
Altogether, these data show that the p38 pathway is involved in H3K27Me3S28 
phosphorylation and required for the displacement of EZH2 from promoters II and VI after 
NMDA treatment. Gehani et al. (2010) (Gehani et al., 2010) have demonstrated that 
Msk1/2 kinases are required for H3K27Me3S28 phosphorylation in human developing 
fibroblasts. Furthermore, by in vitro experiments these authors have shown that Msk2 
kinase phosphorylates H3K27Me3S28 more efficiently than p38. Hence, it appears 
reasonable to conclude that p38 could lead to H3K27Me3S28 phosphorylation by a dual, 
direct and indirect (via its downstream kinases Msk2) mechanism. Moreover, the results 
presented here also suggest that the EZH2 displacement could be involved, but is not 
sufficient, to induce the derepression of promoters I and IV.  
 
Figure R7: p38 is recruited to Bdnf promoters II and VI after LTD. 
A) p38 antibody validation for ChIP : WT or p38-KO MEFs were treated with 100 mM NaCl for 45 min 
in order to induce p38 recruitment to Cox2 promoter. The ChIP experiments show that p38 is detected, 
above of non specific signal, only in the WT cells. B) ChIP assays performed in neuronal cultures 
show that LTD induction triggers the recruitment of p38 to promoters II and VI at 10 min after 
stimulation. C) p38 is not recruited to the promoter region of control genes ßactin and hoxA1 after LTD 
induction. Data are represented as mean ± SEM. (*p<0.05). For statistical analysis see Supp. Table 8. 
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1.5.- JMJD3 recruitment to Bdnf is required for activation by LTD. 
Our previous ChIP experiments showed that JMJD3 demethylase is recruited to 
promoters II, IV and VI after LTD induction (Fig. R3A). To test if JMJD3 demethylase 
activity is in fact playing a role for the transcriptional induction of these Bdnf promoters by 
LTD, ChIP and qPCR were performed in hippocampal neurons treated with the Jumonji 
H3K27Me3 demethylase inhibitor GSK-J4 (Kruidenier et al., 2012) at the time of 
stimulation. The qPCR experiment revealed that GSK-J4 inhibited the transcriptional 
activation of promoters II and VI but had no effect on promoters I and IV (Fig. R8A). The 
ChIP experiments confirmed that GSK-J4 treatment impaired the decrease of H3K27Me3 
observed after NMDA on promoters IV and VI (Fig. R8B). The absence of changes in the 
levels of H3K27Me3 at promoter II at 10 min after stimulation suggests either that 
H3K27Me3 demethylation at this promoter occurs at a lower extent than at promoter VI or 
that it is not detected at 10 min after stimulation. Again, the increase of mRNAs containing 
exons I and IV was unaffected by the treatment, further supporting the notion that these 
promoters are controlled by a different regulatory mechanisms. As a matter of fact, even if 
the GSK-J4 prevented H3K27Me3 demethylation at promoter IV (Fig. R8B), it did not 
block its activation (Fig. R8A). 
The GSK-J4 inhibitor is able to block the catalytic activity of the KDM6 demethylase 
proteins but also blocks the activity of demethylases from the KDM2, KDM3, KDM4 and 
KDM5 subfamilies (Heinemann et al., 2014). KDM3 and KDM4 proteins demethylate the 
repressor mark H3K9Me3, meaning that inhibition of these proteins by GSK-J4 could 
block induction of the Bdnf promoters after LTD, however by ChIP experiments we found 
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Figure R8: JMJD3 is involved in H3K27Me3 demethylation and Bdnf induction after LTD. 
A) The RT-qPCR analysis show that the H3K27Me3 demethylases inhibitor GSK-J4 impairs the NMDA-
triggered increase of Bdnf mRNAs II and VI observed 30 min after stimulation. B) ChIP-qPCR studies 
confirm that H3K27Me3 demethylation observed at Bdnf promoters IV and VI is blocked by GSK-J4. C) 
ChIP experiments showing that demethylation of the repressive mark H3K9Me3 is not involved in the 
transcriptional induction of Bdnf promoters I, II, IV and VI by NMDA-LTD. According to this conclusion, the 
treatment with the KDM inhibitor GSK-J4 has no effect on the levels of H3K9Me3 bound to these 
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For statistical analysis see Supp. Table 9. 
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that no H3K9Me3 demethylation is observed at any of the four Bdnf promoters at 10 min 
after NMDA application (Fig R8C) 
To further prove that JMJD3 is involved in H3K27Me3 demethylation and Bdnf 
induction after NMDA-LTD, hippocampal neurons were infected with lentiviral particles 
expressing an shRNA to knock down JMJD3, validating JMJD3 antibody for CIP (Fig. 
R9A-C). In agreement with the pharmacological results, the qPCR analysis show that 
JMJD3 knock down blocked the NMDA-mediated Bdnf induction of transcripts II and VI 
(Fig. R9D). The ChIP results have shown that the H3K27Me3 demetylation was also 
blocked by JMJD3 knock down (Fig. R9E). All together these results confirm that JMJD3 
is involved in H3K27Me3 demethylation after NMDA-LTD.  
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Figure R9: Genetic validation of JMJD3 involvment in H3K27Me3 demethylation and Bdnf 
induction after LTD. 
A) Quantification by qPCR show that the treatment of hippocampal neurons in culture with a lentivirus 
expressing a shRNA to knock down JMJD3 (Sh) led to a 50% reduction in the amount of the specific mRNA 
compared to cultures infected with leniviral particles expressing a scrambled shRNA (Scr). B) Western blot 
showing that JMJD3 knock down resulted in a 75% reduction of JMJD3 compared to scrambled-shRNA 
treated controls. C) The ChIP experiments performed with the Abcam, ab38113 antibody show that the 
enrichment of JMJD3 at the Bdnf promoters is lost in cultures where JMJD3 was knocked down. D) The 
qPCR analysis show that JMJD3 knock down blocked the increase of the Bdnf transcripts II and VI triggered 
30 minutes after LTD. E) The ChIP results show that the H3K27Me3 demethylation observed at promoters 
IV and VI in control neuronal cultures (Scr) at 10 min after NMDA addition was blocked by JMJD3 knock 
down (Sh). Data are represented as mean ± SEM (*p<0.05; **p<0.01). For statistical analysis see Supp. 
Table 10. 
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 It has been described that H3K27Me3 phosphorylation at Serine 28 masks the 
recognition of H3K27Me3 by different specific antibodies (Gehani et al., 2010; Rothbart et 
al., 2015), an event also observed by us (Fig. R10A). It means that the decreases 
observed in the levels of H3K27Me3 at Bdnf promoters after stimulation could be 
attributed to epitope masking rather than true demethylation. However, experiments 
Figure R11: JMJD3 is able to demethylate H3K27Me3S28p in vitro. 
A) Dot blot revealed for H3K27Me3S28p indicate that the recombinant JMJD3 catalytic domain is able 
to demethylate the phosphorylated peptide H3K27Me3S28p in vitro. B) Control demethylation 
recombinant JMJD3 catalytic domain assay on H3K27Me3 peptide. C) Quantification of dot blots as 
shown in A and B. For statistical analysis see Supp. Table 12. 
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Figure R10: H3K27Me3 demethylation in the 
absence of epitope masking. 
A) Dot blot showing that the antibody anti H3K27Me3 does 
not recognize the epitope in the presence of H3S28 
phosphorylation. The peptides H3K27Me3 and 
H3K27Me3S28p were treated with alkaline phosphatase 
(AP) and then loaded onto a membrane. The dot blots 
were revealed with the specific antibodies. AP treatment to 
dephosphorylate H3S2p8 rescued de epitope recognition 
by the anti H3K27Me3 antibody. B) ChIP experiments 
showing that the treatment of the chromatin extracts with 
AP completely removed the phosphate groups from 
H3K27Me3S28p since only background levels (similar to 
….	   levels obtained with IgG) of this mark were identified at the four Bdnf promoters treated. C) The ChIP 
experiments show that the levels of H3K27Me3 bound to promoters IV and VI decrease at 10 min 
after LTD induction in AP treated samples. Data are represented as mean ± SEM (*p<0.05). For 
statistical analysis see Supp. Table 11. 
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based on extracts obtained from neuronal cultures treated with alkaline phosphatase to 
remove the phosphate group from H3K27Me3S28p (Fig. R10B) followed by ChIP with 
H3K27Me3 antibodies, still revealed demethylation. This ChIP shows a significant 
decrease of H3K27Me3 at promoters IV and VI in phosphatase-treated samples indicating 
that H3K27Me3 demethylation does occur in an epitope unmasked situation (Fig. R10C). 
Moreover, in vitro assays using the human recombinant catalytic domain of JMJD3, 
suggest that JMJD3 is able to demethylate the phosphorylated peptide H3K27Me3S28p 
(Fig. R11A-C). If this is the case in vivo, epitope masking would have the opposite effect 
because H3K27Me3S28p demethylation will not be detected, and demethylation may be 
underestimated. 
Thus, in this likely three-way scenario where H3K27Me3S28 phosphorylation, 
H3K27Me3S28p demethylation and H3K27Me3 demethylation occur it becomes difficult 
to assess the contribution of epitope masking to H3K27Me3 demethylation. However, our 
observations indicate that epitope masking would not be a major determinant of 
decreased methylation under LTD because demethylation is prevented by inhibiting 
demethylase activity with GSK-J4 or by JMJD3 knock-down (Fig. R8 and Fig. R9). 
Consistently, in the absence of epitope masking LTD still induces demethylation (Fig. 
R10). In further support that epitope masking is not the main cause of reduced 
methylation in LTD, we did not observe a decrease of H3K27Me3 at Bdnf promoter II in 
neuronal cells in which this promoter presented increased H3K27Me3S28p (Fig. R3A).  
1.6.- Bdnf induction requires CREB-p/CBP/ JMJD3.  
Several signaling pathways lead to the activation of cAMP response element-binding 
protein (CREB) kinases, which phosphorylate CREB on the transcriptional regulatory 
residue Ser133 (Gonzalez and Montminy, 1989; Sheng et al., 1990, 1991). Upon 
phosphorylation at Ser133, CREB translocates to the nucleus and recruits the 
transcriptional co-activator CREB-binding protein (CBP), a histone acetyl transferase that 
promotes histone acetylation and assembly of transcriptional complexes (Vo and 
Goodman, 2001). We speculated that a similar mechanism could explain the H3K27 
acetylation induced by NMDA stimulation (Fig. R3A). Consistent with this possibility, 
NMDA-LTD triggers a transient CREB phosphorylation at Serine 133 (CREB-pS133) 10 
min after stimulation (Fig. R11A). To determine the pathway by which NMDA stimulation, 
i.e. Ca2+/calmodulin-dependent protein kinase II (CamKII) or Protein Kinase C (PKC), 
leads to CREB phopsphorylation, hippocampal neurons were treated with the CamKII 
inhibitor KN93 or the PKC inhibitor Chelerytrine before NMDA stimulation. The levels of 
pS133-CREB were then determined by Western blot at 10 min after LTD induction. Both 
KN93 and Chelerytrine blocked CREB phosphorylation at 10 min after NMDA stimulation 
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(Fig. R11B-C), suggesting that the NMDA-LTD paradigm used in our study may require 
synergic activities between PKC and CamKII, like previously reported during LTP. In fact, 
it was shown that PKC potentiates NMDA receptor gating in turn enhancing Ca2+ influx 
and intracellular Ca2+/camodulin, which could trigger CaMKII autophosphorylation 
(Gardoni et al., 1999; Strack and Colbran, 1998; Yan et al., 2011). To further dissect the 
pathway leading to S133-CREB phosphorylation, we analyzed the contribution of Msk1, a 
downstream kinase common to PKC and CamKII pathways. To address this possibility, 
hippocampal neurons were incubated with the Msk1 inhibitor H89 before NMDA 
stimulation. As shown in Figure R11D, the treatment with H89 blocked CREB 
phosphorylation at 10 min after NMDA stimulation indicating that Msk1 triggers CREB 
phosphorylation at Ser 133. We can conclude that our NMDA-dependent paradigm of LTD 
Figure R12: NMDA stimulation triggers CREB phosphorylation at Ser133 in mature 
hippocampal neurons via CamKII-PKC/MSK1 kinases. 
A) Western blot studies show the CREB phosphorylation at its Ser133 in basal control conditions 
(CNT), at 10 min (LTD 10) and at 30 min (LTD 30) after NMDA stimulation. B-D) Western blots and it 
quantification showing that the S133-CREB phosphorylation observed in neuronal cultures at 10 min 
after LTD induction (LTD10) is blocked by treatment with the CamKII inhibitor KN93 (B), the PKC 
inhibitor Chelerytrine (C) and the Msk1 inhibitor H89 (D). Data are represented as mean ± SEM. 
(*p<0.05; **p<0.01). For statistical analysis see Supp. Table 13. 
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leads to S133-CREB phosphorylation via CamKII-PKC/Msk1 kinases. However, since 
H89 also inhibits PKA with a similar potency (Lochner and Moolman, 2006), we could not 
exclude a role of PKA in the phosphorylation of CREB by NMDA. 
Coherent with the CREB activation, NMDA triggers a transient and a significant 
increase in the acetylation of H3K27 10 min after treatment (Fig. R13A). Such increased 
acetylation of H3 was not observed at other lysine residues, H3K9, H3K14 or H3K18, after 
NMDA addition (Fig. R13B-D).  To directly assess the functional association with CREB 
activation, we treated hippocampal neurons with CREB-pS133/CBP Interaction Inhibitor 
(CCIIh) to impair CREB-pS133/CBP binding (Best et al., 2004; Li and Xiao, 2009). This 
treatment blocked the transcriptional activation of promoters II and VI and impaired H3K27 
acetylation at these promoters (Fig. R14A and R14B). These results confirm that CREB-
p/CBP is required for H3K27 acetylation at promoters II and VI and for the activation of 
these promoters after NMDA-LTD. The activation of promoters I and IV was unaffected by 
the inhibitor. In fact, no changes of H3K27Ac were observed at promoters I and IV at 10 
Figure R13: NMDA stimulation triggers Histone H3 acetylation at Lysine 27, but not at 
Lysines 9, 14 or 18 in mature hippocampal neurons. 
A-D) Western blots analysis of histone H3 acetylation at different Lysine residues in basal conditions, at 
10 min and at 30 min after NMDA stimulation; H3K27Ac (A), H3K9Ac (B), H3K14Ac (C) and H3K18Ac 
(D). The bar plots show the quantification of the western blots. Each acetylated form was corrected for 
total levels of H3 histone. Data are represented as mean ± SEM (*p<0.05; **p<0.01). For statistical 
analysis see Supp. Table 14. 
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min after induction (Fig. R3A). ChIP experiments also revealed that active CREB is bound 
to the Bdnf promoters either in the presence or absence of the inhibitor in NMDA 
stimulated neurons. However, treatment with the CREB/CBP inhibitor CCIIh blocked the 
recruitment of CBP to these promoters (Fig. R14C and R14D). 
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Figure R15: p65-Serine 276 is not phospho-
rylated at 10 min after NMDA-LTD. 
Western blot and its quantification show that 
stimulation of hippocampal neurons in culture with 
20µM NMDA is not able to trigger phosphorylation of 
p65Ser273 at 10 min after stimulation (LTD10). 
CNT: control non-stimulated neurons. Data are 
represented as mean ± SEM. For statistical analysis 
see Supp. Table 16. 
  
  
 
Figure R14: CREB-CBP/JMJD3 interaction is required to fully activate and transcribe Bdnf 
promoters II and VI. 
A) RT-qPCR showing that the increased expression of Bdnf mRNAs II and VI observed 30 min after NMDA 
stimulation is impaired when CREB-CBP interaction is blocked by CCIIh. B-F) ChIP-qPCR analysis show that 
treatment with CCIIh: blocked H3K27 acetylation at promoters II and VI (B), it does not block CREB binding 
to Bdnf promoters (C), it prevents CBP recruitment to promoters I, II, IV and VI (D) it prevents JMJD3 
recruitment at promoters II, IV and VI (E) and H3K27Me3 demethylation at promoters IV and VI (F). Data are 
represented as mean ± SEM SEM (*p<0.05; **p<0.01; ***p<0.001). For statistical analysis see Supp. Table 
15. 
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The CCIIh inhibitor blocks the interaction between the KID domain of CREB and the 
KIX domain of CBP. This KIX domain in CBP also interacts with the p65 subunit of the 
transcriptional activator Nuclear Factor kappa B (NFkB), implying that the interaction CBP-
p65 is also disrupted by CCIIh (Best et al., 2004). Although a role of NFkB has been 
described in the activation of Bdnf promoters I and IV but not in the activation of 
promoters II and VI (Lipsky et al., 2001; Lubin and Sweatt, 2007; Tian et al., 2010a), the 
possibility exists that the observed effect of CCIIh could be due to inhibition of the 
recruitment of CBP by NFkB to promoters II and VI.  
Zhong et al. (Zhong et al., 1998) have shown that the activation of p65 by 
phosphorylation at its Serine 276 is strictly required for the interaction with CBP: in Figure 
R15 we show that application of 20µM NMDA to hippocampal neurons in culture was not 
able to trigger phosphorylation of p65-Ser273 at 10 min after stimulation, indicating that 
p65 is not involved in the recruitment of CBP to Bdnf promoters at least at this time point 
after NMDA stimulation.  
The interaction of CBP with the demethylase UTX from the Lysine-specific 
demethylase 6 (KDM6) family has been described (Tie et al., 2012), opening the 
possibility that CREB-p/CBP complex would be also involved in the recruitment of the 
demethylase JMJD3 (also a member of the KDM6 family) to the Bdnf promoters after 
stimulation. The ChIP experiments confirmed that the recruitment of JMJD3 to promoters 
II, IV and VI is impaired by CCIIh (Fig. R14E). In addition, CCIIh blocked the H3K27Me3 
demethylation induced by NMDA at promoters IV and VI (Fig. R14F). Note that CCIIh 
treatment also resulted in significantly higher levels of H3K27Me3 at promoter II after 
stimulation (Fig. R14F). These results support our previous conclusion that H3K27Me3 
demethylation is required for induction of promoter II (Fig. R3A), but it occurs at lower 
levels than at promoters IV and VI. The direct interaction CBP-JMJD3 was further 
confirmed by coimmunoprecipitation (Fig. R16). 
From these results we conclude that the mechanism of Bdnf induction triggered by 
NMDA involves CREB-p mediated recruitment of CBP and JMJD3 to all Bdnf promoters, 
yet rapid transcription from promoters II and VI requires H3K27Me3 demethylation 
followed by H3K27 acetylation. 
 
IP:$$$$$$$$$$$$$IgG$ IP$FLAG$ Input$
250$KDa$4$
WB:$CBP$
Figure R16: CBP coimmunoprecipitates with 
JMJD3. 
Detection of CBP by Western blot in samples where 
JMJD3-FLAG or IgG (negative control) were 
immunoprecipitated from total protein extracts prepared 
from HEK transfected cells expressing both proteins and 
treated with Forskolin and Rolipram in order to induce 
CREB activation. The coimmunoprecipitation of CBP and 
JMJD3 confirms the interaction of these proteins. 
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1.7.- Validation in acute hippocampal slices.  
 Our results indicate that Bdnf promoters II and VI are subjected to EZH2 repression 
and that, after specific neuronal stimuli, the increased transcriptional activity is due to the 
release of the repressor EZH2 as a consequence of H3K27Me3Ser28 phosphorylation, 
H3K27Me3 demethylation and H3K27 acetylation. Because our data were obtained in 
neurons grown in vitro, we decided to test our model in neurons that had developed and 
matured in a physiological environment. To explore whether our conclusions obtained in 
vitro also occur in vivo, we analyzed the effect of NMDA-LTD on the expression levels and 
epigenetic marks found at Bdnf promoters in hippocampal slices prepared from adult 
mice. Similar to what occurs in vitro, NMDA addition to hippocampal slices resulted in 
increased levels of mRNA species II and VI at 10 min, and in increased levels of the four 
species at 30 min after stimulation (Fig. R17). The data shown in the Figure R17 
represent the mRNA levels relative to unstimulated controls. Likewise in vitro, higher 
increases were observed for mRNAs transcribed from promoters II and VI (Fig. R17). Also 
paralleling the data in cultures, the repressive H3K27Me3 and EZH2 marks were detected 
at these four Bdnf promoters in adult mice hippocampus (Figs. R18A and R18B). High 
amounts of JMJD3 demethylase were also found at these promoters (Fig. R18C), 
suggesting that transcriptional activity requires H3K27Me3 demethylation. As expected, 
the presence of activation marks H3K4Me3 and H3K27Ac were also observed at 
promoters I, II, IV and VI at the same  proportions than in neuronal cultures (Figs. R18D 
and R18E). However in hippocampal slices, the amount of H3K27Ac found at promoter II 
was comparable to the levels found at the repressed gene hoxA1, suggesting a low basal 
transcriptional activity for this promoter.  
The ChIP experiments performed in hippocampal slices revealed that LTD induces 
phosphorylation of H3K27Me3S28p and displacement of EZH2 not only at promoters II 
and VI but also at promoters I and IV (Fig. R19A). These results strengthen the conclusion 
previously obtained from in vitro data that phosphorylation of H3K27Me3S28 displaces 
EZH2 repressor from all the four promoters (see Fig. R6C). In hippocampal slices, 
H3K27Me3 demethylation was also evident at promoter II (Fig. R19A), explaining the 
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Figure R17: Response of Bdnf promoters to 
NMDA stimulation in hippocampal slices. 
According to the data in vitro, RT-qPCR analysis 
performed in acute hippocampal slices from adult mice 
show that NMDA stimulation triggers the increase of the 
Bdnf mRNAs transcribed from promoters II and VI 10 min 
after LTD, and from promoters I, II IV and VI at 30 min 
after stimulation. Data are represented as mean ± SEM. 
For statistical analysis see Supp. Table 17. 
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Figure R18: Epigenetic marks found at Bdnf promoters in adult hippocampus. 
ChIP-qPCR analysis performed in adult mice hippocampus. The presence of activator and repressor 
histone marks and chromatin remodeling enzymes, indicate that Bdnf promoters I, II, IV and VI are bivalent 
in adult mice: (A) H3K27Me3, (B) EZH2, (C) JMJD3, (D) H3K4Me3 and (E) H3K27Ac. The levels of these 
proteins at promoter regions of the control genes ßActin and hoxA1 are also shown in the plots. Data are 
represented as mean ± SEM. For values see Supp. Table 18. 
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Figure R19: NMDA stimulation in adult 
hippocampal slices induces epige-
netic remodeling of Bdnf promoters.  
A) ChIP-qPCR analyses show that NMDA 
stimulation leads to H3K27Me3S28 
phosphorylation and displacement of the 
polycomb protein EZH2, JMJD3 demethylase 
recruitment, H3K27Me3 demethylation and 
increased levels of the activator H3K4Me3 at 
the four Bdnf promoters I, II, IV and VI. 
H3K27 acetylation was observed only at 
promoters II and VI suggesting that this mark 
is responsible for the fast induction of these 
two promoters. H) ChIP-qPCR analyses at 
promoter regions of the control genes ßActin 
and hoxA1 after NMDA stimulation. The data 
show that, except for the increased levels of 
   
promoters II and VI suggesting that this mark is responsible for the fast induction of thes  two promoters. B) 
ChIP-qPCR analyses at promoter regions of the control genes ßActin and hoxA1 after NMDA stimulation. Th  
data show that, except for the increased levels of JMJD3 observed at the ßActin promoter, none of the other 
marks present changes after NMDA stimulation. Data are represented as mean ± SEM (*p<0.05; **p<0.01, 
***p<0.001). For statistical analysis see Supp. Table 19. 
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effect of GSK-J4 on this promoter in vitro (see Fig. R8B). Interestingly, increases of the 
activation mark H3K4Me3 was observed for all the four promoters in hippocampal slices 
(Fig. R19A). Similar to in vitro grown hippocampal neurons, H3K27 acetylation in 
hippocampal slices was only evident at promoters II and VI (Fig. R19A), suggesting that 
H3K27 acetylation may be the relevant modulator for the fast induction of these two 
promoters after stimulation. Except for an increase in JMJD3 interaction with ßActin 
promoter, for which we do not have an explanation, no other changes in the levels of 
these marks were observed at the promoters of the control genes (Fig. R19B).  
All in all, the results obtained in hippocampal slices reinforce the notion that these four 
promoters of Bdnf are controlled by PRC2 repressor and suggest that fast (10min) 
response of promoters II and VI would be due to H3K27 acetylation. 
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CHAPTER II: Cholesterol role in aged-associated cognitive decline and synaptic 
plasticity. 
 
2.1.- Epigenetic marks at Bdnf promoters in aged hippocampus. 
Of the four Bdnf promoters studied in the first chapter, we focused on the regulation of 
promoters II and VI, as the mRNA species transcribed from these promoters are 
transported to distal dendrites and are thought to play a role in TrkB/BDNF-mediated 
dendritic architectural and functional plasticity in response to external stimuli (Baj et al., 
2011; Chiaruttini et al., 2008; Pattabiraman et al., 2005), a process known to decline with 
ageing. 
 Firstly we analysed the relative amount of Bdnf mRNAs containing exons II and VI in 
the hippocampus of old mice, compared to adult hippocampus. In agreement with 
previous reports (Perovic et al., 2013), we also found reduced Bdnf expression of 
transcripts II and VI in the old hippocampus   (Fig. R20).  In order to determine if age-
associated reduced expression of Bdnf was due to increased repression or decreased 
activation of its promoters, we analysed the basal levels of histone H3 marks. We found 
that the old hippocampus present higher H3K27Me3 and also higher H3K27Me3S28p 
marks (Fig. R21A-B).  The existence of increased levels of H3K27ME3S28p implies 
reduced EZH2 binding to these promoters, suggesting therefore that age-associated 
reduced Bdnf expression levels are not due to increased repression but to a decreased 
activation of Bdnf promoters.  
We next analysed the levels of histone H3 Lys 27 acetylation and CBP at Bdnf 
promoters II and VI. This study revealed decreased levels of both in the old hippocampus 
(Fig. R21C-D), reinforcing our previous assumption that reduced Bdnf expression in the 
old is predominantly due to an activation deficit. As a matter of fact, reduced CBP implies 
reduced levels of JMJD3 bound to Bdnf promoters, and therefore increased H3K27Me3 
mark at its promoters.  
In view that the hippocampus of old mice presents lower levels of the acetylated mark, 
we next wondered if it presents also higher levels of deacetylases bound to its promoters. 
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Figure R20: Bdnf transcripts containing 
exons II and VI are reduced in ageing. 
RT-qPCR analysis of the levels of Bdnf mRNAs 
transcribed from promoters II and VI in adult (8 
month) and old (20 month) hippocampus of mice. 
Data are represented as mean ± SEM (*p<0.05; 
**p<0.01). For statistical analysis see Supp. Table 
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Among all the histone deacetylases (HDACs), we focused on the HDAC class IIb, more 
specifically on HDAC4 since it is known that its activity is regulated by Ca2+ and it has 
been implicated in Bdnf regulation (Backs et al., 2006; Koppel and Timmusk, 2013; 
McKinsey et al., 2000). As expected, we found higher levels of HDAC4 bound to Bdnf 
promoters II and VI (Fig. R21E).  
All in all, the above series of experiments suggest the existence of reduced 
expression of Bdnf in the old could be due to decreased transduction of the transcriptional 
activation signalling to the nucleus.  
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Figure R22: Impaired Bdnf 
transcription after LTD in 
hippocampal slices from old mice. 
RT-qPCR analysis of the levels of Bdnf 
mRNAs transcribed from promoters II and 
VI after NMDA stimulation in adult and old 
hippocampal slices. Data are represented 
as mean ± SEM (*p<0.05; **p<0.01). For 
statistical analysis see Supp. Table 22.	  	  
Figure R21: Epigenetic marks found at Bdnf promoters in the old hippocampus 
ChIP-qPCR analysis of the differential epigenetic marks and regulatory proteins bound at Bdnf 
promoters in basal conditions during ageing: (A) H3K27Me3, (B) H3K27Me3S28p, (C) H3K27Ac, (D) 
CBP and (E) HDAC4. Data are represented as mean ± SEM (*p<0.05; **p<0.01, ***p<0.001). For 
statistical analysis see Supp. Table 21.	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2.2.- Aged-impaired Bdnf transcription in response to LTD. 
As commented in the introduction, ageing is characterized by a progressive cognitive 
decline and synaptic plasticity impairment, and it is accompanied by reduced transcription 
of IEGs (see Introduction paragraph 4). Thus we studied the ability of NMDA-LTD stimulus 
to induce Bdnf transcription in old hippocampal slices; Figure R22 shows that LTD fails to 
induce Bdnf transcription in the old. Taking into account that the old presents lower levels 
of CBP and higher levels of HDAC4 bound to Bdnf promoters at basal state (Fig. R22), 
and also previous data showing LTD membrane signalling defects in old mice hippocampi 
(Martin et al., 2014a), we proceeded with the analysis of CREB and CaMKII activation. 
Figure R23A shows that induction of LTD in hippocampal slices from old mice does not 
result in CREB phosphorylation, an event required for CBP binding and histone 
acetylation (Hu et al., 1999; Vo and Goodman, 2001). A similar reduced activation in 
response to LTD was observed for CaMKII (Fig. R23B), the activity of which is required for 
Figure R23: Impaired nuclear activating signal and chromatin remodelling upon LTD in 
hippocampal slices from old mice. 
A-B) Western blot analysis of (A) CREB and (B) αCaMKII activation 10 minutes after LTD in 
hippocampal slices of adult and old mice. C-E) ChIP-qPCR analysis of H3K27Ac and regulatory 
proteins bound at Bdnf promoters 10 minutes after LTD induction in hippocampal slices from adult and 
old mice: (C) CBP, (D) H3K27Ac and (E) HDAC4. Data are represented as mean ± SEM (*p<0.05; 
**p<0.01, ***p<0.001). For statistical analysis see Supp. Table 23.	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the functional repressive phosphorylation and nuclear export of HDAC4 (Backs et al., 
2006; McKinsey et al., 2000). In order to determine whether reduced LTD activation of 
kinases in old hippocampi had an effect on chromatin remodelling, therefore resulting in 
impaired Bdnf transcription, we performed ChIP experiments. According to the 
transcriptional and kinase activation results, ChIP performed in extracts obtained 10 min 
after NMDA stimulation showed impaired recruitment of the histone acetyl transferase 
CBP and preventing the H3K27 acetylation at these Bdnf promoters in the slices from old 
mice compared to slices from adult, middle age, mice (Fig. R23C-D). Furthermore, ChIP 
experiment revealed that NMDA stimulation failed to trigger a significant displacement of 
the histone deacetylase HDAC4 from the Bdnf promoters in hippocampal slices from old 
mice compared to the effect in slices from middle age mice (Fig. R23E). Altogether, the 
above data are consistent with the view that LTD is ineffective to trigger the transcriptional 
induction from Bdnf promoters II and VI in the hippocampus of old mice. These data 
suggest that defects exist in the signalling pathways linking the activation of NMDA 
receptors in LTD to the downstream kinases leading to the epigenetic remodelling 
required for Bdnf transcription.  
 
2.3.- Cholesterol is sufficient to rescue LTD-induced Bdnf transcription.  
We then wanted to determine whether the loss of cholesterol that occurs with aging 
(Svennerholm et al., 1991, 1994, 1997, Martín et al 2008, see also Fig. R24A) is involved 
in the membrane signalling defects, preventing the proper transcriptional induction of the 
Bdnf promoters under LTD. Hippocampal slices of old mice were incubated in a 
cholesterol-rich solution, using a protocol known to restore the cholesterol concentration 
on the plasma membrane found in adult animals (Fig. R24B; Martin et al., 2014a).  
Figure R24: Restoring age-associated cholesterol loss is sufficient to rescue Bdnf 
transcription. 
A-B) cholesterol quantification of adult and old mouse hippocampus (A) and of quantification old 
hippocampal slices treated with MßCD-Ch (B). RT-qPCR analysis of the levels of Bdnf mRNAs 
transcribed from promoters II and VI after NMDA stimulation in old hippocampal slices compared to 
old hippocampal slices treated with MßCD-Ch. Data are represented as mean ± SEM (*p<0.05; 
**p<0.01; ***p<0.001). For statistical analysis see Supp. Table 24.	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Consistent with a possible cause-effect association, addition of cholesterol to hippocampal 
slices from old mice rescued Bdnf transcription in response to NMDA stimulus at 10 and 
30 minutes (Fig R24C). To further validate cholesterol sufficiency, we studied kinases 
activation and chromatin remodelling in response to LTD. Figures R25A and R25B shows 
that in cholesterol enriched old hippocampal slices NMDA stimulus triggers CaMKII and 
CREB phosphorylation, as in young adult slices (see Figures R23A and R23B). 
Furthermore, NMDA addition was able to trigger chromatin remodelling 10 minutes after 
LTD in old slices where cholesterol levels were restored; increased levels of histone 
H3K27Ac were accompanied by CBP recruitment and HDAC4 detachment of Bdnf 
promoters in response to LTD (Fig. R25C-E). The above results strongly suggest that 
reduced cholesterol levels impair LTD downstream signalling and Bdnf transcription, and 
reinforce our assumption that the lack of pro-transcriptional signal transduction upon 
NMDA activation in the old brain might reside on the lipidic composition of the membrane. 
 
2.4.- LTD-induced Bdnf transcription requires the appropriate neuronal cholesterol 
content.  
To further test that a low cholesterol environment has negative consequences on the 
expression of the Bdnf gene, the levels of endogenous cholesterol were lowered in 
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Figure R25: Cholesterol restoration 
is sufficient to rescue the nuclear 
signalling and chromatin 
remodelling upon LTD in old 
hippocampal slices. 
A-B) Western blot analysis of (A) αCaMKII 
and (B) CREB activation 10 minutes after 
LTD in hippocampal slices of old mice 
treated with MßCD-Ch. C-E) ChIP-qPCR 
analysis of H3K27Ac and regulatory 
proteins bound at Bdnf promoters 10 
minutes after LTD induction from old 
hippocampal slices treated with MßCD-Ch: 
(C) H3K27Ac, (D) CBP and (E) HDAC4. 
Data are represented as mean ± SEM 
(*p<0.05; **p<0.01). For statistical analysis 
see Supp. Table 25. 
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hippocampal slices of adult middle age animals, by transient application of cholesterol 
oxidase enzyme, which it has been show to reduce cholesterol levels (Fig. R26A; Brachet 
et al., 2015). This treatment impaired Bdnf transcription 10 and 30 minutes after LTD 
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Figure R26: Reduced cholesterol levels impair Bdnf transcription after LTD in adult 
hippocampal slices. 
A) Cholesterol quantification of adult hippocampal slices treated with COase. B) RT-qPCR analysis of 
the levels of Bdnf mRNAs transcribed from promoters II and VI after NMDA stimulation in adult 
hippocampal slices compared to adult hippocampal slices treated with COase. Data are represented 
as mean ± SEM (*p<0.05; **p<0.01; ***p<0.001). For statistical analysis see Supp. Table 26.	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levels impair the nuclear signalling 
and chromatin remodelling upon 
LTD in adult hippocampal slices. 
A-B) Western blot analysis of (A) αCaMKII 
and (B) CREB activation 10 minutes after 
LTD in hippocampal slices of adult mice 
treated with COase. C-E) ChIP-qPCR 
analysis of H3K27Ac and regulatory 
proteins bound at Bdnf promoters 10 
minutes after LTD induction from adult 
hippocampal slices treated with COase: (C) 
CBP, (D) H3K27Ac and (E) HDAC4. Data 
are represented as mean ± SEM (*p<0.05; 
**p<0.01). For statistical analysis see Supp. 
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induction (Fig. R26B). According to our hypothesis, low cholesterol levels also disrupted 
the signalling downstream LTD. Figures R27A and R27B show that in the low cholesterol 
scenario LTD fails to activate CREB and CaMKII. Therefore, the chromatin remodelling 
events that lead to Bdnf transcription were impaired; COase treated hippocampal slices 
presented reduced CBP recruitment and H3K27 histone acetylation and, on the opposite 
side, showed no detachment of HDAC4 from Bdnf promoters 10 minutes after LTD (Fig. 
R27C-E). These results show that appropriate cholesterol levels are required to activate 
the mechanisms leading to Bdnf transcription upon neuronal stimuli, and strengthen the 
idea that low cholesterol content in the aged brain is responsible, at least in part, for the 
decreased IEG transcription, synaptic plasticity impairment  and cognition decline. 
 
2.5.- Oral administration of the Cyp46A1 inhibitor Voriconazole to old mice rescues 
epigenetic control of Bdnf transcription and enhances cognition. 
 We next tested if preventing the loss of cholesterol in the old might be able to rescue 
the transcriptional induction of Bdnf in response to LTD and, more generally, we tested if it 
can result in beneficial effects at the cognitive level in living animals. To restore 
cholesterol levels in the old, we inhibited the main cholesterol catabolic enzyme of the 
brain, cholesterol 24 hydroxylase (or CYP46A1; Russell et al., 2009). This was 
accomplished by administering to old mice Voriconazole, a drug used in the clinics to treat 
resistant fungal infections (Dolton and McLachlan, 2014). Different from fungi where 
Voriconazole inhibits the enzyme sterol-14a-demethylase (Cyp51) involved in the 
synthesis of ergosterol, in mammalian  cells  Voriconazole  binds  and  inhibits  Cyp46A1,  
both  in vitro  and  in vivo. 
Importantly, it was also shown that Voriconazole 
crosses the blood brain barrier when administered 
intraperitoneally and inhibits brain Cyp46A1 (Shafaati 
et al., 2009).  
The Voriconazole treatment consisted in the oral 
administration of a Voriconazole solution (60 mg/kg 
b.w./day) to 19 month-old mice during 45 days. 
Analysis of cholesterol concentration in the 
hippocampus   of   Voriconazole   and   vehicle  treated  
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Figure R28: Oral administration of Voriconazole reduces the age-associated cholesterol 
loss. 
Cholesterol quantification of hippocampus of Voriconazole- (Vori) and vehicle- (Veh) treated old mice for 
45 days. Data are represented as mean ± SEM (*p<0.05; **p<0.01). For statistical analysis see Supp. 
Table 28. 	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animals revealed that the treatment reduced the age-associated cholesterol loss by 51% 
(Fig. R28). We observed that Voriconazole treatment rescued Bdnf transcription 10 and 
30 min after LTD induction, while no transcriptional induction was observed in slices 
prepared from vehicle treated mice (Fig. R29A). The ChIP experiments performed in 
hippocampal slices from Voriconazole treated animas also showed an increase in histone 
H3K27 acetylation at Bdnf promoters II and VI facilitating Bdnf transcription. (Fig. R29B).  
On the contrary, no differences were found in vehicle-treated animals (Fig. R29B). These 
experiments support the notion that appropriate cholesterol levels are necessary to induce 
IEG transcription by a LTD stimulus. In further support, Voriconazole treatment also 
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Figure R29: Oral administration of Voriconazole reduces Bdnf transcription and 
chromatin remodelling. 
Ex vivo analysis of oral administration of Voriconazole (Vori) and Vehicle (Veh): (A) RT-qPCR analysis 
of Bdnf mRNAs levels transcribed from promoters II and VI after LTD and (B) ChIP-qPCR analysis of 
H3K27Ac 10 minutes after NMDA stimulation. Data are represented as mean ± SEM (*p<0.05; 
**p<0.01; ***p<0.001). For statistical analysis see Supp. Table 29. 
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Figure R30: Oral administration of Voriconazole reduces other IEGs transcription. 
 
RT-qPCR analysis of Arc (A) and Ppp1cc (B) mRNAs 10 and 30 minutes after NMDA induction in 
adult, old, Voriconazole- (Vori) and vehicle- (veh) treated mice. Data are represented as mean ± SEM 
(*p<0.05; **p<0.01; ***p<0.001). For statistical analysis see Supp. Table 30. 	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rescued the expression of Arc and Ppp1cc (Fig. R30A-B), two IEG whose transcriptional 
induction is also impaired in the hippocampus of old mice in response to LTD (Fig. R30A-
B). Altogether, these results indicate that hippocampal cholesterol loss with age is, to a 
certain extent, responsible for the reduced transcription of IEG.  
The results showing that IEG induction by LTD can be rescued in old animals by 
treatment with Voriconazole led us to hypothetize that cognition would be improved in old 
mice in vivo. To test this possibility, Voriconazole or vehicle treated mice were subjected 
to three different behavioural tests: novel object location, Morris water maze and 
contextual fear conditioning. In the novel location task, the exploration phase was similar 
in Voriconazole-treated and untreated animals; however, during the retention session, 
animals chronically treated with Voriconazole explored more the object that was placed in 
a novel position indicating a better spatial memory (Fig. R31A).  In the hidden-platform 
version of the Morris water maze test, which evaluates hippocampal function, both groups 
showed improved performance during all successive trials throughout the 4 days of spatial 
Fig. 31: Oral administration of Voriconazole to old mice improves behaviour. 
A-E) behavioural tests of old mice treated for 45 days with Voriconazole (Vori) or Vehicle (Veh): (A) Object 
location memory test, (B) Spatial learning, (C) Spatial memory test, (D) Contextual fear conditioning test 
and (E) Auditory-cued fear conditioning test. Data are represented as mean ± SEM (*p<0.05). For 
statistical analysis see Supp. Table 31. 	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training.  No group effect was found, indicating that controls and Voriconozole-treated 
animals learned the location of the platform at an equivalent rate (Fig.R31B), but in the 
memory probe test, Voriconazole-treated animals spent significantly more time in the 
target quadrant, compared with the control group, indicating that Voriconazole-treated 
showed a better spatial reference memory (Fig. R31C). In the contextual fear-conditioning 
test, which is primarily contingent on hippocampal function, Voriconazole-treated animals 
exhibited improved memory recall compared to controls (Fig. R31D). During the auditory-
cued fear memory test, which depends on amygdala function but not hippocampus, both 
animal groups displayed similar levels of freezing behaviour (Fig. R31E) suggesting that 
Voriconazole increases contextual fear conditioning through an improvement of 
hippocampal function. Both groups presented similar sensitivity to the electric shock. All 
behavioural tests together indicate that the low cholesterol content associated to aged 
brain is in part responsible for the cognition decline observed in ageing, and that 
increasing the cholesterol content in brain is sufficient to enhance memory in the old. 
 
The above series of experiment imply that the age associated cholesterol loss is 
deeply related to the cognitive decline in ageing, and that by restoring cholesterol levels in 
the old brain mnemonic processes at the behavioural level, but also at the molecular level, 
can be enhanced.  
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In this thesis we show that neuronal stimulation with low doses of NMDA, a protocol 
widely used to induce long term depression, triggers the fast transient activation of Bdnf 
promoters II and VI, whereas promoters I and IV present a slower response with a 
transcriptional activation that remains stable for a longer time, and that this differentiated 
pattern can be explained by H3K27 acetylation. Moreover, we show that the fine 
regulation of Bdnf promoters II and VI is disrupted in the aged brain because a low 
cholesterol environment impairs the signal transduction from the NMDA receptors to the 
nucleous, explaining at least in part, the age-associated cognitive deficits through IEGs 
transcription impairment. 
 
1.- LTD induced Bdnf regulation in adult hippocampus: 
The biological significance of this alternative promoter usage could be explained from 
the works developed by Baj et al (Baj et al., 2011). These authors have shown that the 
transcripts containing the 5´exons II and VI are transported to distal dendrites whereas the 
transcripts containing 5´exons I and IV are required in the soma or in proximal dendrites. 
By use of overexpression and silencing of specific Bdnf mRNA isoforms, the authors 
found that dendritic BDNF (from exons II and VI) plays a role in secondary dendrites’ 
plasticity in response to external stimuli. Furthermore, the expression of individual Bdnf 
splice variants was shown to be relevant for the spatially restricted activation of TrkB 
receptors: i.e. overexpression of exon I or IV transcripts led to phosphorylation of 80–
100% of TrkB receptors within the first 45 µm from the soma whereas overexpressing 
exon II or VI Bdnf variants led to 80% TrkB phosphorylation at 80 µm from the soma and 
beyond. Thus, the spatial segregation of Bdnf transcripts enables this neurotrophic factor 
to differentially shape distinct dendritic compartments. 
At first sight it would seem that a fast induction of a promoter localized more than 50 
kb 5´ away from the Bdnf coding exon (exon IX) is not, physiologically speaking, the 
optimal situation. However the fast induction of promoter II in our model would have an 
important biological significance. Because the ultimate destination of Bdnf mRNAs is 
dictated by the presence of different 5´UTR exons, it means that the fast induction of 
promoters II and VI at 10 min after LTD induction would be required to provide the 
stimulated cell with the adequate amounts of 5´exons II and VI-containing transcripts at 
the appropriate timing to be delivered to distal dendrites.  
We have shown that, in adult non-stimulated neurons, Bdnf promoters are present in 
a bivalent state, partially repressed by EZH2. Application of NMDA at doses that produce 
chemical LTD leads to the remodelling of the transcriptional complexes, namely increased 
levels of activator H3K4Me3 and recruitment of H3K27Me3-demethylase JMJD3 and by 
the consequent decrease of the repressive mark H3K27Me3. We also found that LTD 
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stimulus triggers the phosphorylation of the H3K27Me3 at its Ser 28 leading to the 
displacement of the repressor protein EZH2 (Fig. D1). In proof of functional association 
between these changes and activation of Bdnf expression, preventing H3K27Me3S28 
phosphorylation blocks EZH2 release and the transcriptional stimulation of promoters II 
and VI.  
In ES in vitro, PRC2 mediates di- and trimethylation of H3K27 to establish repression 
of specific genes. Stress, mitogenic signaling or retinoic acid induce differentiation via 
histone H3K27Me3S28 phosphorylation, displacement of polycomb proteins and gene 
expression (Gehani et al., 2010). Our data suggest that a similar mechanism may operate 
in fully mature neurons in vitro, in response to a memory-related stimulus. Although 
H3K27Me3S28 phosphorylation, EZH2 derepression and H3K27Me3 demethylation also 
occur after LTD at Bdnf promoters I and IV, blocking these processes with inhibitors does 
not impair the late occurring transcriptional induction of these two promoters, suggesting 
that the Polycomb derepression mechanism is mostly restricted to promoters II and VI.  
The molecular mechanism by which a physiological mnemonic process like LTD 
affects Bdnf expression has not been studied previously. However, it has been shown that 
MeCP2 acts as a repressor mechanism on promoter IV through the association with the 
co-repressor molecule Sin3a and HDAC1 (Chen et al., 2003; Im et al., 2010; Klose and 
Bird, 2003; Martinowich et al., 2003). In these studies, it was shown that membrane 
depolarization by KCl correlated with DNA demethylation and the phosphorylation and 
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Figure D1: Schematic model descri-
bing the proposed mechanism for 
activation of Bdnf promoters.  
In adult non-stimulated neurons, activator 
(H3K4Me3, H3K27Ac) and repressor 
(H3K27Me3) marks coexist. Bdnf promoters 
are present in a partially repressed status 
exerted by EZH2. LTD triggers to the 
remodeling of the transcriptional complexes 
leading to increased levels of activator 
H3K4Me3 and recruitment of p38 MAPK/ 
Msk1/2 that phosphorylate H3K27Me3 at its 
Ser 28 and displaces the repressor protein 
EZH2. LTD induction also leads to activation 
I 
sp rylat  H3K27 e3 at its Ser 28 and displaces the repressor protein EZH2. LTD 
induction also leads to activation of CREB by phosphorylation at its Ser 133 and recruitment of the 
complex Ser133-CREB/CBP/JMJD3 to Bdnf promoters. The LTD stimulus triggers the increase of the 
activator mark H3K27Ac only at promoters II and VI, suggesting that H3K27 acetylation is an important 
factor in the high transient expression of these two promoters. 	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dissociation of MeCP2 from Bdnf promoter IV (Chen et al., 2003; Martinowich et al., 
2003). It has also been shown that NMDA receptor activation de-represses transcription 
from Bdnf promoter I and IV in correlation with reduced occupancy by HDAC1 and MeCP2 
in cultured hippocampal neurons (Tian et al., 2010a, 2010b). Since memory consolidation 
after fear conditioning involves LTD induction, it is possible that DNA demethylation and 
MeCP2 derepression would be involved in the activation of promoters I and IV after LTD.  
It was recently shown that the chromodomain protein and transcription co-repressor 
chromodomain Y-like (CDYL) protein represses Bdnf promoter II in developing neurons by 
a polycomb-mediated mechanism and that derepression can be induced by electrical 
activity through the degradation of CDYL (Qi et al., 2014). We also analysed whether a 
CDYL-dependent mechanism would also contribute to the expression changes of any of 
the Bdnf transcripts triggered by NMDA. While CDYL was enriched at Bdnf promoter II, 
this was not the case for promoters I, IV and VI (Fig. D2A), the levels of CDYL bound to 
promoter II decreased significantly and remained low at 30 min after NMDA stimulation 
(Fig. D2B) in coincidence with protein degradation induced by the stimulus (Fig. D2C). 
However, as it has been shown in Figure R4, the basal levels of EZH2 are restored at 
promoter II, 30 min after induction. These data indicate first, that CDYL would not be 
involved in the de-repression of Bdnf promoter VI and second, that CDYL would not be 
involved in EZH2 recruitment to promoter II at 30 min after stimulation. However it cannot 
be excluded that CDYL degradation would be required also in mature neurons together 
with H3K27Me3S28 phosphorylation for EZH2 displacement from promoter II. 
The regulation of neuronal differentiation by members of the Polycomb group of 
proteins has been widely described. In adult mice, a role for EZH2 in the regulation of 
adult neurogenesis has also been reported. In this work using Ezh2 knockout mice, 
impaired learning and memory was attributed to the decreased proliferation of the 
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Figure D2: NMDA stimulation modulates CDYL attachment at Bdnf promoter II in 
mature hippocampal neurons. 
A) ChIP analysis showing the presence of CDYL only at Bdnf promoter II. B) The ChIPs show that 
CDYL levels decrease at promoter II after NMDA stimulation, opening the possibility that CDYL-
mediated de-repression of promoter II could be also playing a role in mature neurons.  C) Western blot 
analysis and its cuantification show that NMDA stimulation induces CDYL degradation in mature 
neurons. Data are represented as mean ± SEM (*p<0.05; **p<0.01, ***p<0.001). For statistical 
analysis see Supp. Table 32. 
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progenitor cells (Zhang et al., 2014). We here show that EZH2 directly controls memory 
formation by regulating the expression of Bdnf gene in mature neurons. 
After LTD induction, increases in the levels of the activator mark H3K27Ac were only 
observed at promoters II and VI, suggesting that H3K27 acetylation is an important factor 
in the high transient mRNA expression mediated by these two promoters (Fig. D1). A 
series of evidences are in support of the notion that transcripts II and VI rely on H3K27 
acetylation. We have shown that H3K27 acetylation after NMDA stimulation at these 
promoters requires CREB phosphorylation. It is well known that neuronal stimulation by 
NMDA activates a signalling cascade resulting in CREB phosphorylation (Das et al., 1997; 
Nijholt et al., 2002). Phosphorylated CREB moves to the nucleus and interacts with the 
histone acetyl transferase CBP. Our results demonstrate that H3K27 acetylation is 
catalysed by the CREB-p/CBP complex, as inhibition of the CREB-p/CBP interaction 
impairs H3K27 acetylation and transcriptional activation of these two promoters. The 
presence of a CREB binding site has been observed at promoter IV and a possible role 
for CREB in the regulation of this promoter has been proposed but not directly 
demonstrated (Martinowich et al., 2003; West et al., 2001). In our work, we show that 
CREB-p/CBP complex is required for H3K27 acetylation and activation of promoters II and 
VI after LTD induction, but not for the activation of promoters I and IV.  
Our results strengthen the notion that synaptic activity differentially controls the Bdnf 
promoters by use of epigenetic mechanisms that include H3K27 acetylation via 
CREB/CBP and Polycomb derepression in mature neurons. It is tempting to speculate 
that a similar epigenetic mechanism may regulate the expression of other early genes 
involved in learning and memory.  
 
2.- The role of cholesterol in Bdnf regulation in old hippocampus: 
Hippocampal cholesterol loss is a characteristic in the hippocampus of aged rodents 
and humans (Martin et al., 2008, 2014a; Söderberg et al., 1990; Sodero et al., 2011; 
Svennerholm et al., 1991, 1994, 1997). The data presented in the second chapter of this 
thesis suggest that age-associated cholesterol reduction contributes to cognitive decline in 
the aged brain by altering the epigenetic mechanisms involved in IEGs transcription.  As a 
matter of fact, we have shown that hippocampal slices of the old mice fail to activate the 
signalling cascade in response to LTD, which is required for proper chromatin remodelling 
(HDAC4 detachment, CBP recruitment and H3K27 acetylation), resulting in impaired Bdnf 
transcriptional induction (Fig. D3). These results provide an additional mechanism to 
explain the reduced LTD and impaired memory in the brain of the old mouse, together 
with other biochemical deficits previously demonstrated by others ( Billard and Rouaud, 
2007; Lee et al., 2005; Martin et al., 2014a).  
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Early work indicated that LTD and NMDAR-dependent synaptic plasticity impairment 
in old animals are related to changes in the availability of the ligands required to activate 
the proper receptors in the post-synapse (Billard and Rouaud, 2007). Others showed that 
reduced LTD in ageing could be attributed to increased basal levels of phosphorylated 
AKT, probably due to increased levels of stress mediators, like interleukins, preventing 
GSK3ß activation and, as consequence, impairing glutamate receptor internalization and 
therefore reducing LTD (Martin et al., 2014a). Other groups attribute age-associated 
cognitive decline to changes in the composition of the NMDA receptors, and the 
interaction with membrane scaffolding proteins (Zamzow et al., 2013). One possible event 
that could conciliate all these results is the change in the lipidic environment of glutamate 
receptors during ageing; as this “simple” fact would be sufficient to alter not only 
receptors’ ligand affinity but also their mobilization and internalization and the downstream 
signalling. In fact, enhanced learning and memory and improved electrophysiological 
response in the old was obtained by manipulating the ability of NMDAR to operate (Billard 
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Figure D3: Schematic model describing the impaired 
signaling transduction and epigenetic mechanism for 
IEG transcription in the old. 
A) In adult animals, LTD activates the phosphorylation cascade 
required for HDAC4 displacement from the chromatin and 
induction of H3K27 acetylation via CBP. B) In old mice, LTD 
poorly activates the transcription cascade, resulting in the 
preservation of HDAC4 and reduced CREB-mediated CBP 
binding, impairing immediate early memory gene transcription.  C) 
Lipid legend. 
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and Rouaud, 2007; Kumar and Foster, 2013), and also by increasing membrane 
cholesterol levels (Martin et al., 2014).  Moreover, numerous evidences support the view 
that changes in the lipidic composition of the plasma membrane and lipid rafts leads to 
NMDAR malfunction and neuronal excitability (Frank et al., 2004; Hering et al., 2003; 
Schrattenholz and Soskic, 2006).	   
Of the different lipid content changes occurring during aging, the loss of cholesterol is 
the one for which a functional association has been best characterized.  Thus, Martín et al 
2014 showed that adding cholesterol to old neurons is sufficient to rescue LTD in vitro, in 
vivo and in ex vivo paradigms (Martin et al., 2014a). These authors also showed that 
perfusion of cholesterol in the third ventricle of old mice reverts some of the cognitive 
deficits displayed. In concordance with these results, we present data in this thesis that 
point to the fact that cholesterol loss, as it takes place in the aged, impairs the glutamate 
receptor downstream signalling required to induce CREB and CaMKII phosphorylation 
and consequently the chromatin remodelling to facilitate Bdnf transcription (Fig. D3).  That 
this failure is due to the low cholesterol typical of old neurons was demonstrated by 
increasing the cholesterol content in old hippocampal slices. This simple manipulation 
turned out to be sufficient to rescue CREB and CaMKII phosphorylation upon LTD, and 
HDAC4 detachment, CBP recruitment at Bdnf promoters. This manipulation was also 
sufficient for the increase in H3K27Ac, all in all leading to better Bdnf transcription by the 
old neurons. Another demonstration that the reduced expression of Bdnf in old neurons is 
due to the cholesterol loss comes from the opposite experiments, where removing 
cholesterol in hippocampal slices of young mice prevents the proper epigenetic regulatory 
pathway activation. Reduction of cholesterol by COase treatments led to impaired 
activation of the CREB and CaMKII kinases with the subsequent reduced chromatin 
remodelling and Bdnf transcription. Hence, these results reinforce the idea that a major 
and rather biochemical “upstream” problem in old neurons resides in the reduced levels of 
cholesterol in the plasma membrane. Intuitively, the paucity of this sterol would suffice to 
alter most neurotransmitter receptors downstream events required for the proper 
expression of learning and memory genes.  
Supporting the view that disrupting the signalling cascade that leads to the epigenetic 
regulation for gene expression determines poor cognitive abilities, several reports have 
shown the number of genes expressed in young and old in response to cognitive stimuli 
are significantly different, and that modulating chromatin remodelling enzymes facilitates 
gene transcription in the old, in parallel with enhanced memory. Thus, Peleg and colleges 
(Peleg et al., 2010) showed that just 16 transcripts were altered in aged mice 1 hour after 
fear conditioning, while in young more than 2000 had changed. This reduced 
transcriptional plasticity was associated with impaired learning, and it was argued that 
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gene transcription differences were due to changes in H4K12 acetylation after fear 
conditioning. Consistently, plasticity induced gene transcription, H4H12Ac and memory in 
the old were all rescued by treating mice with the HDAC inhibitor SAHA 1 h before fear 
conditioning (Peleg et al., 2010). The association between learning and memory deficits in 
the old and epigenetic-mediated gene expression deficits was also shown by other 
means. Thus, it was shown that treating old rats 1 hour after novel object recognition with 
sodium butyrate, another HDAC inhibitor, improves memory retention 24 hours after 
training (Reolon et al., 2011). In addition to HDACs, deficits in DNA methylation can also 
underlie poor memory of the old. Thus, it was shown that brain ageing is accompanied by 
decreased DNA methylation, mainly due to reduced de novo methylation of the active 
chromatin, or euchromatin (Kang et al., 2001). Furthermore, Oliveira et al showed that the 
old hippocampus presents lower levels of DNMT3a2, which is associated to euchromatin 
(Chen et al., 2002). In this work, it was also shown that Dnmt3a2 transcription depends on 
NMDAR activation, thus behaving like an IEGs. Consistently, increasing DNMT3a2 levels 
in the old hippocampus, by stereotaxically delivered recombinant adeno-associated virus, 
enhanced fear conditioning memories (Oliveira et al., 2012). While not directly 
demonstrated, it appears reasonable to argue that the membrane changes that 
characterize the old may be responsible for the HDAC and methylation deficits described 
above. The lipidic changes may certainly impair neurotransmitter receptor activation 
strength, being not sufficient to reach the threshold needed to activate chromatin 
remodelling and IEGs transcription.   
There are numerous evidences that modulation of plasma membrane lipid 
composition, in ageing and in disease, can enhance memory and learning. Thus, in 
Niemann Pick type A mice, that mimic this rare and severe neurological disease 
characterized by the abnormal accumulation of sphingomyelin, Arroyo et al showed that 
the administration of dexamethasone orally increases the levels and activity of the 
enzyme neutral sphyngomyelinase, resulting in a reduction in sphingomyelin levels and 
enhancing spatial memories (Arroyo et al., 2014). Cholesterol modulation was also shown 
to play a role in the cognitive deficits of old mice and in certain pathological situation of the 
old.  In regard to the latter, a recent study demonstrated that systemic administration of 
cholesterol-filled nanoparticles can cross the blood-brain barrier and increases cholesterol 
content in striatal neurons, rescuing Huntington disease deficits in a mouse model 
(Valenza et al., 2015). Concerning the normal cognitive deficits of the old, previous work 
from this laboratory has shown that intraventricular perfusion of cholesterol in old rats 
improved cognition and cognition-related electrophysiological parameters (Martin et al., 
2014a). While these last results show the importance of cholesterol loss in the cognitive 
deficits of the old, direct brain cholesterol manipulation through replenishment, whether 
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direct brain perfusion or via systemically administered nanoparticles, does not appear a 
most convenient strategy for therapeutic use. A more practical solution would be 
interfering with the mechanism involved in cholesterol loss during aging.  
As commented earlier, brain cholesterol reduction in the aged can be the 
consequence of increased catabolism, reduced synthesis or/and reduced transference 
from astrocytes (Martin et al., 2014b). The degree of participation of any of these 
mechanisms varies in different brain regions. Thus, reduced synthesis and transference 
appears to be the main mechanism operating in the striatum, whereas increased 
catabolism is the main factor in the hippocampus (Martin et al., 2008; Valenza et al., 
2005). In the hippocampus, higher catabolism with age appears to be due to increased 
expression of the brain specific cholesterol hydroxylase Cyp46A1 (Martin et al., 2008). In 
turn, increased expression of Cyp46A1 is due to oxidative stress accumulation (Ohyama 
et al., 2006). In agreement with this possibility, enzyme levels and activity increase in 
models of cortical injury, autoimmune encephalomyelitis and Alzheimer’s disease 
(Bogdanovic et al., 2001; Cartagena et al., 2008; Teunissen et al., 2007). It then appeared 
reasonable to us that the inhibition of Cyp46A1 activity could be a suitable strategy, at 
least in part, to prevent the cholesterol loss that normally occurs with age. In fact, our in 
vivo experiments confirmed this hypothesis; orally administrated Voriconazole, the 
Cyp46A1 inhibitor, rescued chromatin remodelling and Bdnf transcription upon LTD and 
enhanced memory in the old treated mice. Moreover, we showed that the rescued 
transcription by Voriconazole treatment is not restricted to Bdnf, but also to others IEGs 
such as Arc and Ppp1cc, suggesting that increased cholesterol levels would facilitate the 
normal transcription after neuronal stimulation, and therefore enhance learning and 
memory. 
From all the data presented in the second chapter of this thesis, it appears reasonable 
to propose that, apart from non pathological age-associated cognitive decline, also 
pathological conditions such as Alzheimer’s and Huntington’s disease, all characterized 
by significant changes in cholesterol content (Leoni and Caccia, 2014; Molander-Melin et 
al., 2005; Papassotiropoulos et al.; Roher et al., 2002; Valenza et al., 2005, 2010), may 
obtain benefits by strategies that prevent the loss of this sterol: this would in turn facilitate 
the restoration of numerous membrane signalling pathways, among them, those required 
for proper learning and memory gene activation.  
All in all, the work in this thesis has contributed to unveil some of the epigenetic 
mechanisms involved in the expression of a synaptic plasticity gene, Bdnf, in response to 
a chemical paradigm of learning and memory and highlights the importance of brain 
cholesterol homeostasis in gene expression regulation and learning and memory 
processes.
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1.- Bdnf promoters are found in a bivalent epigenetic state in the adult, with the 
coexistence on the same promoters of activating marks such as H3K4Me3 and H3K27Ac 
with the repressive mark H3K27Me3. 
 
2.- NMDA-LTD triggers two different types of transcriptional responses of Bdnf promoters: 
a fast transient induction of promoters II and VI and a slower, more stable response of 
promoters I and IV. 
 
3.- NMDA uses the p38/Msk1/2 pathway for H3K27Me3S28 phosphorylation, which is 
required for EZH2 displacement from Bdnf promoters II and VI after stimulus. 
 
4.- NMDA-LTD leads to CREB activation via CamKII-PKC/MSK1 kinases. Activated CREB 
recruits the histone acetyl transferase CBP to Bdnf promoters. 
 
5. CBP recruits the histone demethylase JMJD3, contributing to de-repress and fully 
activate Bdnf expression by decreasing H3K27Me3 and by acetylating H3K27 at Bdnf 
promoters II and VI upon LTD.  
 
6.- The old hippocampus presents lower Bdnf transcripts II and VI levels, correlating with 
increased H3K27Me3 and H3K27Me3S28p, and decreased H3K27Ac and CBP comared 
to the adult, suggesting impaired activation on the corresponding promoters. 
 
7.- NMDA-LTD in the old fails to induce the normal downstream activation cascade that 
leads to chromatin remodelling at Bdnf promoters, resulting in impaired Bdnf transcription 
after stimulation. 
 
8.- Cholesterol at the plasma membrane is necessary for LTD signal transduction to the 
nucleus, achieving Bdnf chromatin remodelling and transcription. 
 
9.- Cyp46A1 inhibition by orally administrated Voriconazole rescues the age-associated 
cholesterol loss in the old, enhancing learning and memory. 
 
10.- Voriconazole treatment rescues the nuclear signalling transduction upon LTD, 
facilitating H3K27Ac at Bdnf promoters and its transcription. Moreover, this transcriptional 
rescue it is not restricted to Bdnf, but also to other IEGs such as Ppp1cc and Arc. 
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1.- En el adulto, los promotores de Bdnf se encuentran es un estado epigenético 
bivalente, coexistiendo en el mismo promotor marcas activadoras como H3K4Me3 y 
H3K27Ac con la marca represora H3K27Me3. 
 
2.- La NMDA-LTD desencadena dos tipos de respuestas transcripcionales de los 
promotores de Bdnf: una respuesta rápida y transitoria de los promotores II y VI, y una 
respuesta lenta, y más sostenida, de los promotores I y IV. 
 
3.- El NMDA se sirve de la via de p38/Msk1-2 para la fosforilación de H3K27Me3S28, la 
que se requiere para el desplazamiento de EZH2 en los promotores II y VI en respuesta a 
estímulo. 
 
4.- La NMDA-LTD conduce a la activación de CREB mediante las quinasas CaMKII-
PKC/MSK1. Una vez activo, CREB recluta la histona acetyltransferasa CBP a los 
promotores de Bdnf. 
 
5.- CBP recluta a la desmetilasa de histonas JMJD3, contribuyendo a la desrepresión y la 
completa activación de la expresión de Bdnf, reduciendo la metilación de H3K27 e 
incrementando la acetilación de H3K27 en los promotores II y VI de Bdnf tras la LTD. 
 
6.- El hipocampo de ratones viejos presenta niveles bajos de los transcritos II y VI de 
Bdnf, acompañado de un incremento en H3K27Me3 y H3K27Me3S28p, y una reducción 
de H3K27Ac y CBP, sugiriendo déficits en la activación de los correspondientes 
promotores. 
 
7.- La NMDA-LTD en el ratón viejo no es capaz de inducir la cascada de activación que 
lleva al remodelado de la cromatina en los promotores de Bdnf, resultando en una 
incapacidad de transcribir Bdnf después del estímulo. 
 
8.- El colesterol en la membrana plasmática es necesario para la eficiente transducción al 
núcleo de la señal de LTD, facilitando el remodelado de la cromatina y transcripción de 
Bdnf. 
 
9.- La inhibición de Cyp46A1 por la administración oral de Voriconazole, rescata la 
perdida de colesterol asociada al envejecimiento, mejorando el aprendizaje y la memoria. 
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10.- El tratamiento con Voriconazole rescata la transducción de la señal nuclear en 
respuesta a LTD, facilitando la H3K27Ac en los promotores de Bdnf, así como su 
transcripción. Además, este recate de la transcripción no está restringido solamente a 
Bdnf, sino que también otros IEGs como Ppp1cc y Arc. 	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Supp. Table 1: Primer List 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rat
EXPRESSION PRIMERS
Reverse
Bdnf Exon I 5'- TTTCAACATCGATGCCAGT  -3' 5'- ATCCACCTTGGCGATTACAG  -3'
Bdnf Exon II 5'- AGTCCATTCAGCACCTTGGA  -3' 5'- CTACCACCTCGGACAAATCC  -3'
Bdnf Exon IV 5'- AAATGGAGCTTCTCACTGAAGG  -3' 5'- ATTGCATGGCGGAGGTAATA  -3'
Bdnf Exon VI 5'- CAACAATGTGACTCCACTGC  -3' 5'- CAACAATGTGACTCCACTGC  -3'
Jmjd3 5'- CTGAAACTGCCTGCCTTCAT  -3' 5'- CTAAGCATGTTGCCTGTGGA  -3'
Gapdh 5'- ATGACTCTACCCACGGCAAG  -3' 5'- GATCTCGCTCCTGGAAGATG  -3'
GusB 5'- GCCAATGAGCCTGTCTCTTC  -3' 5'- TCCAGTTCTTGGGGAATCTG  -3'
Pgk1 5'- AATGATGCTTTTGGGACTGC  -3' 5'- TCAAAAATCCACCAGCCTTC  -3'
CHIP PRIMERS
Reverse
Bdnf Promoter I 5'- GCCTCTCGCCTAGTCATCAG  -3' 5'- CCCCACAACTTTCCCTTTTC  -3'
Bdnf Promoter II 5'- GGACTGGAGGGGGTTGTTAT  -3' 5'- TCAGACAAGCATCAGCTTTGA  -3'
Bdnf Promoter IV 5'- GTGAGTTCGCTAGGACTGGAA  -3' 5'- GGCATTGCATGCTTTGTAGA  -3'
Bdnf Promoter VI 5'- CTCCCACAGAACTTGGGTGT  -3' 5'- TTTGCAACTCTCCCCATCTT  -3'
βActin 5'- CATCGCCAAACTCTTCATCC  -3' 5'- GAGCGAGAGAGAAAGCGAGA  -3'
hoxA1 5'- TCTTGCGCACTGTACATTCA  -3' 5'- CCTCCATAGGACCAGAGAAGAA  -3'
Mouse
EXPRESSION PRIMERS
Reverse
Bdnf Transcript I 5'- TTTCAACATCGATGCCAGTT  -3' 5'- ATCCACCTTGGCGACTACAG  -3'
Bdnf Transcript II 5'- CCATCCACACGTGACAAAAC  -3' 5'- TGCTCTAGACGGTTTCTTCCA  -3'
Bdnf Transcript IV 5'- AAATGGAGCTTCTCGCTGAA  -3' 5'- ATTGCATGGCGGAGGTAATA  -3'
Bdnf Transcript VI 5'- GAGACCCGGTTCCTTCAACT  -3' 5'- CTTTCTCGTCTGCCCCAAG  -3'
Arc 5'- AGCCAGGAGAATGACACCAG  -3' 5'- GTGATGCCCTTTCCAGACAT  -3'
Ppp1cc 5'- GGCTTGGACCCTCTCACTTC  -3' 5'- AACATCGACAGCATCATCCA  -3'
Gapdh 5'- CTCCCACTCTTCCACCTTCG  -3' 5'- CATACCAGGAAATGAGCTTGACAA  -3'
GusB 5'- AGCCGCTACGGGCGTCG  -3' 5'- GCTGCTTCTTGGGTGATGTCA  -3'
Pgk1 5'- TACCTGCTGGCTGGATGG  -3' 5'- CACAGCCTCGGCATATTTCT  -3'
CHIP PRIMERS
Reverse
Bdnf Promoter I 5'- GCCTCTCGCCTAGTCACAG  -3' 5'- CCCCACAACTTTCCCTTTTC  -3'
Bdnf Promoter II 5'- CTGGCTGTTCAAAGCTGATG  -3' 5'- GGATGGAATACAAGACGGTTG  -3'
Bdnf Promoter IV 5'- AAAAACGGTCCAAAGACCAC  -3' 5'- TCACTAAGCCCCCTTCCTCT  -3'
Bdnf Promoter VI 5'- AAACCAGGGGAGAAAGATTTG  -3' 5'- GGAGGAAGCGAGTGTGAGTC  -3'
βActin 5'- CCTGTACATCTGGGCCTACG  -3' 5'- ATGAAGAGTTTTGGCGATGG  -3'
hoxA1 5'- GCCACAAGAGAGCCAGGA  -3' 5'- TGAACTGGCAAGAGGTGAGA  -3'
Cox1 5'- GAGAGGGGGAAAAGTTGGTG  -3' 5'- TGTCTTTCCGCTTAGGCTTT  -3'
Forward
Forward
Forward
Forward
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Supp. Table  2: Antibodies List 
 
 
 
 
 
 
 
 
 
 
 
 
  
Antibody against Raised in (Isotype) ChIP WB IP DB Origin & Ref.
Hitone H3 Rabbit (IgG) 0.1 µg 1:1000 - - Cell Signaling ref. 4499
Trimethyl-Histone H3 (Lys4) Rabbit (Serum) 4 µL - - - Active Motif ref. 39159
Acetyl-Histone H3 (Lys9) Rabbit (IgG) - 1:1000 - - Cell Signaling ref. 9649
Trimethyl-Histone H3 (Lys9) Rabbit (IgG) 4 µg - - - Abcam ref. ab8898
Acetyl-Histone H3 (Lys14) Rabbit (IgG) - 1:1000 - - Cell Signaling ref. 4318
Acetyl-Histone H3 (Lys18) Rabbit (IgG) - 1:1000 - - Cell Signaling ref. 9675
Acetyl-Histone H3 (Lys27) Rabbit (IgG) 0.1 µg 1:1000 - - Cell Signaling ref. 4353
Trimethyl-Histone H3 (Lys27) Rabbit (IgG) 4 µg - - 1:1000 Millipore ref. 07-449
Trimethyl-Phsopho-Histone H3 (Lys27Ser28) Rabbit (Serum) 5 µL - - 1:1000 Diagenode ref. CS-091-100 (Lot 1)
JMJD3 Rabbit (IgG) 10 µg  1:250 - - Abcam ref. ab38113
EZH2 Rabbit (IgG) 10 µg - - - Abcam ref. ab3748
HDAC4 Rabbit (IgG) 10 µg - - - Active motif ref. 40969
Phospho-CREB (Ser133) Rabbit (IgG) - 1:1000 - - Cell Signaling ref. 9191
CREB Rabbit (IgG) 10 µg 1:1000 - - Abcam ref. ab31387
CBP Rabbit (IgG) 5 µg - - - Santa Cruz ref. sc-583
CBP Mouse (IgG) - 1:500 - - Abcam ref. ab79270
Phospho-αCaMKII (Thr268) Rabbit (IgG) - 1:2000 - - Abcam ref. ab2724
αCaMKII Rabbit (IgG)  - 1:1000 - - Abcam ref. ab183670
p-38 Rabbit (IgG) 2 µg 1:1000 - - Abcam ref. ab170099
Phospho-p38 (Thr180/Tyr182) Rabbit (IgG) - 1:1000 - - Cell Signaling ref.4511
CDYL Rabbit (IgG) 5 µg 1:500 - - Abcam ref. ab5188
FLAG-M2 Mouse (IgG1) - - 25µL - Sigma ref. F3165
normal rabbit IgG Rabbit (IgG) Santa Cruz ref. sc-2027
normal mouse IgG Mouse (IgG) Santa Cruz ref. sc-2025
assay dependet
assay dependet
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Supp. Table  3: Figure R1 
 
  min Mean N SEM min Mean N SEM
0 1.00 13 0.00 0 1.00 13 0.00
10 0.95 12 0.08 10 1.27 13 0.07
30 1.34 13 0.12 30 2.07 12 0.23
60 1.25 8 0.09 60 1.29 9 0.12
90 1.27 9 0.10 90 1.22 9 0.13
180 1.37 9 0.09 180 1.10 9 0.14
min Mean N SEM min Mean N SEM
0 1.00 13 0.00 0 1.00 14 0.00
10 1.01 12 0.08 10 1.46 14 0.15
30 1.31 13 0.07 30 2.13 14 0.13
60 1.36 9 0.06 60 1.07 9 0.10
90 1.38 8 0.07 90 1.00 9 0.07
180 1.14 9 0.06 180 0.89 9 0.14
95%6confidence6interval6
(*)6p6<61.67ED02
min Mean N SEM Control6/6LTD610
0 1.00 13 0.00
10 0.95 12 0.08
30 1.34 13 0.12
min Mean N SEM Control6/6LTD610
0 1.00 13 0.00
10 1.27 13 0.07
30 2.07 12 0.23
min Mean N SEM Control6/6LTD610
0 1.00 13 0.00
10 1.01 12 0.08
30 1.31 13 0.07
min Mean N SEM Control6/6LTD610
0 1.00 14 0.00
10 1.46 14 0.15
30 2.13 14 0.13
99.9%66confidence6interval6
(**)6p6<663.33ED03 (***)6p6<663.33ED04
A)
Bdnf6 Bdnf6
6Transctipt6I 6Transctipt6II
Bdnf6 Bdnf%
6Transctipt6IV 6Transctipt6VI
B) Bonferroni adjustment 
99%6confidence6interval6
Control6/6LTD630 LTD106/6LTD630
KruskalDWallis6Test
MannDWhitney6U6Test6
Control6/6LTD630 LTD106/6LTD630
KruskalDWallis6Test
MannDWhitney6U6Test6
Bdnf66Transctipt6I 2.31ED02 1.00E+00 1.04ED02 3.50ED02
LTD106/6LTD630
Bdnf66Transctipt6VI 9.22ED05 1.27ED01 3.64ED06 4.68ED03
KruskalDWallis6Test
MannDWhitney6U6Test6
Control6/6LTD630
KruskalDWallis6Test
MannDWhitney6U6Test6
Bdnf66Transctipt6VI 4.08ED06 5.96ED03 1.49ED06 2.82ED03
Control6/6LTD630 LTD106/6LTD630
Bdnf66Transctipt6II 1.95ED07 3.64ED06 4.76ED06 1.10ED03
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Mean N SEM Mean N SEM
0.30 5 0.08 0.045 5 0.018
0.15 5 0.05 0.025 5 0.016
0.36 5 0.07 0.041 5 0.019
0.33 5 0.08 0.008 5 0.003
0.61 4 0.12 0.006 4 0.003
0.02 4 0.01 0.004 4 0.002
Mean N SEM Mean N SEM
Bdnf3Promoter3I 1.78 5 0.27 Bdnf3Promoter3I 0.045 5 0.018
Bdnf3Promoter3II 0.66 5 0.22 Bdnf3Promoter3II 0.025 5 0.016
Bdnf3Promoter3IV 0.86 5 0.21 Bdnf3Promoter3IV 0.041 5 0.019
Bdnf3Promoter3VI 1.16 5 0.38 Bdnf3Promoter3VI 0.008 5 0.003
ßActin 1.80 4 0.10 ßActin 0.006 4 0.003
hoxA1 0.62 4 0.03 hoxA1 0.004 4 0.002
Mean N SEM Mean N SEM
1.69 5 0.63 0.045 5 0.018
2.61 5 0.89 0.025 5 0.016
1.61 5 0.36 0.041 5 0.019
2.53 5 0.81 0.008 5 0.003
0.21 4 0.19 0.006 4 0.003
4.39 4 1.05 0.004 4 0.002
Mean N SEM Mean N SEM
2.05 4 0.30 0.008 4 0.001
2.47 4 0.44 0.013 4 0.003
1.78 4 0.25 0.008 4 0.002
2.01 4 0.27 0.012 4 0.003
0.25 4 0.08 0.014 4 0.005
2.08 4 0.26 0.010 4 0.002
Mean N SEM Mean N SEM
0.41 4 0.11 0.026 4 0.015
0.54 4 0.14 0.031 4 0.024
0.41 4 0.14 0.040 4 0.001
0.40 4 0.12 0.040 4 0.032
0.52 4 0.12 0.038 4 0.028
0.05 4 0.02 0.022 4 0.013
A)
H3K27Ac IgG
B)
Bdnf3Promoter3I
Bdnf3Promoter3II
Bdnf3Promoter3IV
Bdnf3Promoter3VI
ßActin
Bdnf3Promoter3I
Bdnf3Promoter3II
Bdnf3Promoter3IV
Bdnf3Promoter3VI
ßActin
hoxA1
H3K4Me3 IgG
C)
H3K27Me3 IgG
D)
EZH2 IgG
Bdnf3Promoter3I
Bdnf3Promoter3II
Bdnf3Promoter3IV
Bdnf3Promoter3VI
Bdnf3Promoter3I
Bdnf3Promoter3II
Bdnf3Promoter3IV
Bdnf3Promoter3VI
ßActin
hoxA1
ßActin
hoxA1
E)
JMJD3 IgG
Bdnf3Promoter3I
Bdnf3Promoter3II
Bdnf3Promoter3IV
Bdnf3Promoter3VI
ßActin
hoxA1
hoxA1
Bdnf3Promoter3I
Bdnf3Promoter3II
Bdnf3Promoter3IV
Bdnf3Promoter3VI
ßActin
hoxA1
hoxA1
Bdnf3Promoter3I
Bdnf3Promoter3II
Bdnf3Promoter3IV
Bdnf3Promoter3VI
ßActin
hoxA1
Bdnf3Promoter3I
Bdnf3Promoter3II
Bdnf3Promoter3IV
Bdnf3Promoter3VI
ßActin
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Mean N SEM Mann(Whitney.U.Test. Mean N SEM
EZH2 0.91 5 0.13 5.77E(01 EZH2 IgG 0.126 5 0.053
JMJD3 1.23 4 0.26 2.19E(01 JMJD3 IgG 0.083 4 0.012
H3K4Me3 1.02 7 0.13 1.52E(01 H3K4Me3 IgG 0.003 7 0.001
H3K27Ac 0.91 7 0.14 6.33E(01 H3K27Ac IgG 0.030 7 0.010
H3K27Me3 1.00 7 0.14 1.52E(01 H3K27Me3 IgG 0.007 7 0.003
H3K27Me3S28p 1.34 7 0.30 1.52E(01 H3K27Me3S28p IgG 0.165 7 0.058
Mean N SEM Mann(Whitney.U.Test. Mean N SEM
EZH2 0.54 6 0.12 3.35E(03 EZH2 IgG 0.123 6 0.050
JMJD3 1.47 4 0.06 1.19E(02 JMJD3 IgG 0.091 4 0.023
H3K4Me3 1.41 6 0.11 2.09E(03 H3K4Me3 IgG 0.005 6 0.003
H3K27Ac 1.36 6 0.06 1.53E(03 H3K27Ac IgG 0.070 6 0.033
H3K27Me3 1.15 7 0.16 6.33E(01 H3K27Me3 IgG 0.014 7 0.010
H3K27Me3S28p 2.10 6 0.53 1.11E(03 H3K27Me3S28p IgG 0.206 6 0.070
Mean N SEM Mann(Whitney.U.Test. Mean N SEM
EZH2 0.57 6 0.03 2.09E(03 EZH2 IgG 0.091 6 0.032
JMJD3 1.80 4 0.24 1.19E(02 JMJD3 IgG 0.107 4 0.023
H3K4Me3 0.95 7 0.20 1.52E(01 H3K4Me3 IgG 0.005 7 0.002
H3K27Ac 0.86 7 0.07 1.19E(02 H3K27Ac IgG 0.040 7 0.014
H3K27Me3 0.87 6 0.05 6.01E(04 H3K27Me3 IgG 0.008 6 0.004
H3K27Me3S28p 1.11 7 0.26 6.33E(01 H3K27Me3S28p IgG 0.229 7 0.076
Mean N SEM Mann(Whitney.U.Test. Mean N SEM
EZH2 0.54 6 0.12 3.35E(03 EZH2 IgG 0.066 6 0.017
JMJD3 1.55 4 0.10 1.19E(02 JMJD3 IgG 0.083 4 0.011
H3K4Me3 1.38 6 0.03 2.82E(03 H3K4Me3 IgG 0.003 6 0.001
H3K27Ac 1.50 6 0.18 2.09E(03 H3K27Ac IgG 0.036 6 0.010
H3K27Me3 0.59 6 0.04 1.11E(03 H3K27Me3 IgG 0.006 6 0.004
H3K27Me3S28p 1.77 6 0.26 1.11E(03 H3K27Me3S28p IgG 0.254 6 0.054
Mean N SEM Mann(Whitney.U.Test. Mean N SEM
EZH2 1.10 5 0.17 9.47E(02 EZH2 IgG 0.269 5 0.104
JMJD3 1.34 4 0.20 2.19E(01 JMJD3 IgG 0.070 4 0.007
H3K4Me3 1.10 7 0.17 6.33E(01 H3K4me3 IgG 0.006 7 0.002
H3K27Ac 0.96 7 0.08 6.33E(01 H3K27Ac IgG 0.016 7 0.006
H3K27Me3 1.07 7 0.24 6.33E(01 H3K27me3 IgG 0.052 7 0.012
H3K27Me3S28p 1.14 6 0.13 2.77E(01 H3K27me3S28p IgG 0.397 6 0.072
Mean N SEM Mann(Whitney.U.Test. Mean N SEM
EZH2 1.14 5 0.36 5.50E(01 EZH2 IgG 0.071 5 0.018
JMJD3 1.12 4 0.21 2.19E(01 JMJD3 IgG 0.061 4 0.023
H3K4Me3 0.83 6 0.08 1.00E+00 H3K4me3 IgG 0.002 6 0.001
H3K27Ac 0.69 7 0.10 6.33E(01 H3K27Ac IgG 0.131 7 0.050
H3K27Me3 0.87 7 0.17 6.33E(01 H3K27me3 IgG 0.003 7 0.002
H3K27Me3S28p 0.92 7 0.10 6.33E(01 H3K27me3S28p IgG 0.097 7 0.029
hoxA1 hoxA1
Bdnf Bdnf
.Promoter.VI .Promoter.VI
B)
ßActin ßActin
.Promoter.II .Promoter.II
Bdnf Bdnf
.Promoter.IV .Promoter.IV
A)
Bdnf Bdnf
.Promoter.I .Promoter.I
Bdnf Bdnf
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Mean N SEM Mann(Whitney.U.Test. Mean N SEM
EZH2 1.20 5 0.21 5.77E(01 EZH2 IgG 0.101 5 0.023
JMJD3 1.27 4 0.31 2.19E(01 JMJD3 IgG 0.069 4 0.029
H3K4Me3 0.92 6 0.16 2.77E(01 H3K4Me3 IgG 0.007 6 0.003
H3K27Ac 0.61 5 0.17 5.72E(02 H3K27Ac IgG 0.031 5 0.008
H3K27Me3 0.96 5 0.22 5.26E(01 H3K27Me3 IgG 0.005 5 0.002
H3K27Me3S28p 1.13 6 0.21 1.00E+00 H3K27Me3S28p IgG 0.285 6 0.108
Mean N SEM Mann(Whitney.U.Test. Mean N SEM
EZH2 1.06 5 0.14 9.26E(02 EZH2 IgG 0.110 5 0.026
JMJD3 0.95 4 0.13 1.00E+00 JMJD3 IgG 0.068 4 0.025
H3K4Me3 0.67 6 0.14 4.03E(02 H3K4Me3 IgG 0.008 6 0.003
H3K27Ac 0.54 5 0.12 1.53E(03 H3K27Ac IgG 0.031 5 0.008
H3K27Me3 1.01 5 0.20 5.26E(01 H3K27Me3 IgG 0.002 5 0.001
H3K27Me3S28p 0.71 6 0.17 2.77E(01 H3K27Me3S28p IgG 0.175 6 0.123
Mean N SEM Mann(Whitney.U.Test. Mean N SEM
EZH2 1.41 5 0.22 5.50E(01 EZH2 IgG 0.108 5 0.035
JMJD3 1.09 4 0.23 1.00E+00 JMJD3 IgG 0.161 4 0.075
H3K4Me3 0.86 6 0.17 2.77E(01 H3K4Me3 IgG 0.008 6 0.003
H3K27Ac 0.49 5 0.16 1.53E(03 H3K27Ac IgG 0.024 5 0.010
H3K27Me3 0.77 5 0.11 4.52E(02 H3K27Me3 IgG 0.004 5 0.001
H3K27Me3S28p 1.02 5 0.37 1.25E(01 H3K27Me3S28p IgG 0.179 5 0.056
Mean N SEM Mann(Whitney.U.Test. Mean N SEM
EZH2 1.06 5 0.14 9.26E(02 EZH2 IgG 0.119 5 0.026
JMJD3 0.99 4 0.17 1.00E+00 JMJD3 IgG 0.235 4 0.063
H3K4Me3 0.92 6 0.17 1.00E+00 H3K4Me3 IgG 0.006 6 0.003
H3K27Ac 0.54 5 0.10 2.82E(03 H3K27Ac IgG 0.018 5 0.004
H3K27Me3 1.00 6 0.20 5.26E(01 H3K27Me3 IgG 0.003 6 0.002
H3K27Me3S28p 1.06 6 0.21 2.77E(01 H3K27Me3S28p IgG 0.351 6 0.106
Mean N SEM Mann(Whitney.U.Test. Mean N SEM
EZH2 1.45 5 0.30 9.47E(02 EZH2 IgG 0.210 5 0.047
JMJD3 1.27 4 0.08 1.39E(02 JMJD3 IgG 0.115 4 0.035
H3K4Me3 1.10 6 0.13 2.77E(01 H3K4Me3 IgG 0.013 6 0.007
H3K27Ac 0.68 5 0.07 1.53E(03 H3K27Ac IgG 0.014 5 0.004
H3K27Me3 0.86 5 0.15 5.26E(01 H3K27Me3 IgG 0.044 5 0.009
H3K27Me3S28p 1.27 5 0.37 5.26E(01 H3K27Me3S28p IgG 0.310 5 0.120
Mean N SEM Mann(Whitney.U.Test. Mean N SEM
EZH2 1.14 5 0.36 5.50E(01 EZH2 IgG 0.087 5 0.035
JMJD3 1.12 4 0.21 1.00E+00 JMJD3 IgG 0.107 4 0.019
H3K4Me3 0.83 6 0.08 5.72E(02 H3K4Me3 IgG 0.003 6 0.001
H3K27Ac 0.69 5 0.10 1.53E(03 H3K27Ac IgG 0.153 5 0.054
H3K27Me3 0.87 5 0.17 5.26E(01 H3K27Me3 IgG 0.002 5 0.001
H3K27Me3S28p 0.92 6 0.10 2.77E(01 H3K27Me3S28p IgG 0.235 6 0.055
Bdnf Bdnf
A)
Bdnf Bdnf
.Promoter.I .Promoter.I
hoxA1 hoxA1
Bdnf Bdnf
.Promoter.VI .Promoter.VI
B)
ßActin ßActin
.Promoter.II .Promoter.II
Bdnf Bdnf
.Promoter.IV .Promoter.IV
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!SB$203580 Mean N SEM Control/LTD30 Control/Control!+ Control/LTD30+ LTD30/Control+ LTD30/LTD30+ Control+/LTD30+
Control $ 1.00 13 0.00
LTD!30 $ 1.34 13 0.13
Control + 1.11 12 0.08
LTD!30 + 1.32 12 0.12
Control $ 1.00 13 0.00
LTD!30 $ 2.07 12 0.15
Control + 0.71 14 0.08
LTD!30 + 0.89 14 0.11
Control $ 1.00 13 0.00
LTD!30 $ 1.31 13 0.06
Control + 1.19 14 0.08
LTD!30 + 1.53 14 0.14
Control $ 1.00 14 0.00
LTD!30 $ 2.13 14 0.13
Control + 1.14 14 0.09
LTD!30 + 1.04 14 0.16
SB$203580 Mean N SEM Control/LTD10 Control/Control!+ Control/LTD10+ LTD10/Control+ LTD10/LTD10+ Control+/LTD10+ SB$203580 Mean N SEM
Control $ 1.00 7 0.00 Control $ 0.212 7 0.049
LTD!10 $ 1.34 7 0.30 LTD!10 $ 0.165 7 0.058
Control + 0.95 3 0.27 Control + 0.238 3 0.086
LTD!10 + 0.94 3 0.22 LTD!10 + 0.364 3 0.046
Control $ 1.00 6 0.00 Control $ 0.289 6 0.071
LTD!10 $ 2.10 6 0.53 LTD!10 $ 0.206 6 0.070
Control + 0.94 3 0.10 Control + 0.278 3 0.071
LTD!10 + 0.80 3 0.10 LTD!10 + 0.239 3 0.111
Control $ 1.00 7 0.00 Control $ 0.284 7 0.040
LTD!10 $ 1.11 7 0.26 LTD!10 $ 0.229 7 0.076
Control + 1.25 3 0.39 Control + 0.173 3 0.069
LTD!10 + 1.29 3 0.09 LTD!10 + 0.166 3 0.095
Control $ 1.00 6 0.00 Control $ 0.336 6 0.035
LTD!10 $ 1.77 6 0.26 LTD!10 $ 0.254 6 0.054
Control + 1.14 3 0.10 Control + 0.122 3 0.014
LTD!10 + 0.97 3 0.08 LTD!10 + 0.146 3 0.034
SB$203580 Mean N SEM Control/LTD10 Control/Control!+ Control/LTD10+ LTD10/Control+ LTD10/LTD10+ Control+/LTD10+ SB$203580 Mean N SEM
Control $ 1.00 5 0.00 Control $ 0.122 5 0.032
LTD!10 $ 0.91 5 0.13 LTD!10 $ 0.126 5 0.053
Control + 1.12 4 0.15 Control + 0.048 4 0.007
LTD!10 + 1.50 4 0.26 LTD!10 + 0.069 4 0.016
Control $ 1.00 6 0.00 Control $ 0.166 6 0.026
LTD!10 $ 0.54 6 0.12 LTD!10 $ 0.123 6 0.050
Control + 1.09 4 0.06 Control + 0.063 4 0.021
LTD!10 + 1.18 4 0.07 LTD!10 + 0.094 4 0.041
Control $ 1.00 6 0.00 Control $ 0.157 6 0.033
LTD!10 $ 0.57 6 0.03 LTD!10 $ 0.091 6 0.032
Control + 1.05 4 0.12 Control + 0.053 4 0.013
LTD!10 + 1.37 4 0.27 LTD!10 + 0.103 4 0.047
Control $ 1.00 6 0.00 Control $ 0.152 6 0.041
LTD!10 $ 0.54 6 0.12 LTD!10 $ 0.066 6 0.017
Control + 1.09 4 0.06 Control + 0.069 4 0.010
LTD!10 + 1.18 4 0.07 LTD!10 + 0.132 4 0.049
95%!!!!confidence!interval! 99%!!!!confidence!interval! 99,9%!!!confidence!interval!
Bonferroni!adjustment!
8.27E$01
5.13E$01
5.13E$01
2.48E$01
1.44E$01 6.22E$01
Transcript!I
Bdnf 1.01E$05 4.76E$06 8.21E$04 1.00E+00 2.47E$05
Bdnf
6.02E$05
Transcript!II
5.04E$02 1.04E$02
Bdnf 1.42E$03 3.64E$06 1.81E$01 5.95E$05 7.26E$02 6.98E$01
Transcript!IV
Bdnf 6.73E$01 2.49E$05 1.27E$04
Transcript!VI
H3K27Me3S28p
Bdnf 5.06E$01 1.52E$01 3.26E$01 3.26E$01 4.25E$01
Promoter!I
Bdnf 1.93E$03 1.11E$03 3.26E$01 3.24E$03 2.01E$02
2.01E$02
2.01E$02
Promoter!II
Bdnf 6.03E$01 6.33E$01 3.26E$01 3.70E$02 5.69E$01 9.09E$01
Bdnf
Promoter!VI
3.35E$03
EZH2
Bdnf 2.66E$01 5.77E$01 1.80E$01 1.80E$01 4.62E$01
Promoter!VI
IgG
Bdnf
Promoter!I
Bdnf
Promoter!II
Bdnf
Promoter!IV
5.13E$01
Promoter!IV
Bdnf 2.63E$03 1.11E$03 3.24E$03
8.64E$02
1.05E$02 2.48E$01 Bdnf
Promoter!IV
Promoter!I
Bdnf 1.68E$03 3.35E$03 1.87E$01 8.30E$03 1.05E$02 1.05E$02 5.64E$01
Promoter!II
1.05E$02
Bdnf
Promoter!VI
Mann$Whitney!U!Test!
1.05E$02 5.64E$01
Promoter!VI
IgG
Bdnf
Promoter!I
Bdnf
Promoter!II
Promoter!IV
Bdnf 1.68E$03 1.87E$01 8.30E$03 1.05E$02
Bdnf 5.69E$03
2.51E$01
Kruskal$Wallis!Test
Mann$Whitney!U!Test!
Kruskal$Wallis!Test
(***)!p!<!!2.50E$04
95%!!!!confidence!interval! 99%!!!!confidence!interval!
(*)!p!<!1.25E$02 (**)!p!<!!2.50E$03
(*)!p!<!1.25E$02 (**)!p!<!!2.50E$03
7.07E$02
4.25E$01
2.09E$03 1.00E+00 1.00E+00
A)
B)
C) 99,9%!!!confidence!interval!
(***)!p!<!!2.50E$04
Bonferroni!adjustment!
95%!!!!confidence!interval!
(*)!p!<!1.25E$02
99%!!!!confidence!interval! 99,9%!!!confidence!interval!
(**)!p!<!!2.50E$03 (***)!p!<!!2.50E$04
8.08E$02
4.52E$02 1.49E$06 3.49E$02 4.91E$01
Kruskal$Wallis!Test
Mann$Whitney!U!Test!
2.72E$01 3.14E$03 2.59E$01
3.26E$01
Bonferroni!adjustment!
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Mean N SEM Mean N SEM
0.042 3 0.001 MFEs0p380WT 0.020 3 0.006
0.020 3 0.003 MFEs0p380KO 0.023 3 0.001
Mean N SEM Mann8Whitney0U0Test0 Mean N SEM
Bdnf0Promoter0I 0.96 4 0.08 1.00E+00 Bdnf0Promoter0I 0.59 4 0.10
Bdnf0Promoter0II 2.04 4 0.22 1.39E802 Bdnf0Promoter0II 0.79 4 0.20
Bdnf0Promoter0IV 0.93 4 0.13 1.00E+00 Bdnf0Promoter0IV 0.99 4 0.29
Bdnf0Promoter0VI 1.91 4 0.16 1.39E802 Bdnf0Promoter0VI 0.54 4 0.08
Mean N SEM Mann8Whitney0U0Test0 Mean N SEM
ßActin 1.00 4 0.24 1.00E+00 ßActin 1.11 4 0.21
hoxA1 0.92 4 0.11 1.00E+00 hoxA1 0.93 4 0.19p38 IgG
B)
p38 IgG
C)
A)
Cox2 IgGMFEs0p380WTMFEs0p380KO
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GSK$J4 Mean N SEM Control/LTD30 Control/Control8+ Control/LTD30+ LTD30/Control+ LTD30/LTD30+ Control+/LTD30+
Control $ 1.00 13 0.00
LTD830 $ 1.34 13 0.13
Control + 1.15 9 0.09
LTD830 + 1.57 9 0.21
Control $ 1.00 13 0.00
LTD830 $ 2.07 12 0.15
Control + 0.89 8 0.17
LTD830 + 0.77 8 0.12
Control $ 1.00 13 0.00
LTD830 $ 1.31 13 0.06
Control + 1.12 9 0.10
LTD830 + 1.52 9 0.18
Control $ 1.00 14 0.00
LTD830 $ 2.13 14 0.13
Control + 1.04 8 0.22
LTD830 + 1.11 8 0.12
GSK$J4 Mean N SEM Control/LTD10 Control/Control8+ Control/LTD10+ LTD10/Control+ LTD10/LTD10+ Control+/LTD10+ GSK$J4 Mean N SEM
Control $ 1.00 7 0.00 Control $ 0.003 7 0.001
LTD810 $ 1.00 7 0.14 LTD810 $ 0.007 7 0.003
Control + 1.14 3 0.27 Control + 0.009 3 0.005
LTD810 + 1.16 3 0.20 LTD810 + 0.009 3 0.005
Control $ 1.00 7 0.00 Control $ 0.006 7 0.002
LTD810 $ 1.15 7 0.16 LTD810 $ 0.014 7 0.010
Control + 1.21 3 0.27 Control + 0.008 3 0.006
LTD810 + 1.05 3 0.18 LTD810 + 0.008 3 0.006
Control $ 1.00 6 0.00 Control $ 0.007 6 0.002
LTD810 $ 0.87 6 0.05 LTD810 $ 0.008 6 0.004
Control + 1.06 3 0.15 Control + 0.009 3 0.003
LTD810 + 1.18 3 0.14 LTD810 + 0.009 3 0.003
Control $ 1.00 6 0.00 Control $ 0.005 6 0.002
LTD810 $ 0.59 6 0.04 LTD810 $ 0.006 6 0.004
Control + 0.99 3 0.12 Control + 0.007 3 0.003
LTD810 + 1.01 3 0.03 LTD810 + 0.007 3 0.003
GSK$J4 Mean N SEM Control/LTD30 Control/Control8+ Control/LTD30+ LTD30/Control+ LTD30/LTD30+ Control+/LTD30+ GSK$J4 Mean N SEM
Control $ 1.00 4 0.00 Control $ 0.028 4 0.021
LTD810 $ 1.00 4 0.05 LTD810 $ 0.060 4 0.048
Control + 0.93 4 0.09 Control + 0.028 4 0.016
LTD810 + 0.93 4 0.11 LTD810 + 0.032 4 0.019
Control $ 1.00 4 0.00 Control $ 0.018 4 0.009
LTD810 $ 1.09 4 0.07 LTD810 $ 0.050 4 0.043
Control + 1.17 4 0.13 Control + 0.026 4 0.014
LTD810 + 1.08 4 0.11 LTD810 + 0.047 4 0.019
Control $ 1.00 4 0.00 Control $ 0.022 4 0.012
LTD810 $ 0.87 4 0.11 LTD810 $ 0.045 4 0.031
Control + 1.11 4 0.15 Control + 0.032 4 0.018
LTD810 + 0.97 4 0.27 LTD810 + 0.056 4 0.029
Control $ 1.00 4 0.00 Control $ 0.020 4 0.011
LTD810 $ 1.25 4 0.18 LTD810 $ 0.046 4 0.035
Control + 1.24 4 0.23 Control + 0.039 4 0.020
LTD810 + 1.22 4 0.14 LTD810 + 0.079 4 0.041
IgG
Bdnf
Promoter8I
Bdnf
Promoter8II
Bdnf
Promoter8IV
Bdnf
Promoter8VI
1.00E+00 1.00E+00
2.19E$01
2.19E$01
2.19E$01 2.19E$01 1.00E+00
Promoter8VI
7.73E$01 1.00E+00Bdnf 5.38E$01 2.19E$01
Promoter8IV
Bdnf 4.13E$01 2.19E$01 1.00E+00 1.49E$01
Promoter8II
2.19E$01 5.64E$01 7.73E$01 3.86E$01
Promoter8I
5.64E$01 7.73E$01 7.73E$01
7.73E$01 3.86E$01
H3K9Me3
Bdnf 9.84E$01 1.00E+00
Bdnf 4.62E$01 2.19E$01
(**)8p8<882.50E$03 (***)8p8<882.50E$04
Kruskal$Wallis8Test
Mann$Whitney8U8Test8
Promoter8VI Promoter8VI
C) Bonferroni8adjustment8 95%8888confidence8interval8 99%8888confidence8interval8 99,9%888confidence8interval8
(*)8p8<81.25E$02
Bdnf
Promoter8IV Promoter8IV
Bdnf 5.06E$03 1.11E$03 3.26E$01 3.26E$01 2.01E$02 2.01E$02 8.27E$01
Promoter8II Promoter8II
Bdnf 2.11E$02 6.01E$04 2.99E$01 2.99E$01 1.97E$01 7.07E$02 5.13E$01
Promoter8I Promoter8I
Bdnf 9.60E$01 6.33E$01 3.26E$01 3.26E$01 9.09E$01 9.09E$01 5.13E$01
5.69E$01 5.69E$01 8.27E$01
IgG
Bdnf
Bdnf
Bdnf
Kruskal$Wallis8Test
Mann$Whitney8U8Test8
H3K27Me3
Bdnf 6.16E$01 1.52E$01 3.26E$01 3.26E$01
Transcript8VI
B) Bonferroni8adjustment8 95%8888confidence8interval8 99%8888confidence8interval8 99,9%888confidence8interval8
(*)8p8<81.25E$02 (**)8p8<882.50E$03 (***)8p8<882.50E$04
Transcript8IV
Bdnf 3.37E$02 1.49E$06 5.34E$01 2.68E$01 3.62E$03 1.74E$04 3.55E$01
Transcript8II
Bdnf 1.29E$02 3.64E$06 1.67E$01 6.52E$04 6.55E$02 4.43E$01 1.26E$01
Transcript8I
Bdnf 9.55E$05 4.76E$06 5.46E$01 3.12E$02 9.80E$04 3.87E$04 4.18E$01
Bdnf 3.75E$03 1.04E$02 1.87E$03 4.55E$04 2.51E$01 6.16E$01 2.66E$01
A) Bonferroni8adjustment8 95%8888confidence8interval8 99%8888confidence8interval8 99,9%888confidence8interval8
(*)8p8<81.25E$02 (**)8p8<882.50E$03 (***)8p8<882.50E$04
Kruskal$Wallis8Test
Mann$Whitney8U8Test8
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Supp. Table  10: Figure R9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Mean N SEM Mann(Whitney.U.Test.
1.00 5 0.00
0.51 5 0.08
Mean N SEM Mann(Whitney.U.Test.
0.00 4 0.00 2.09E-02
0.12 4 0.06
Lentivirus Mean N SEM Lentivirus Mean N SEM
Bdnf Scr 0.48 3 0.03 Bdnf Scr 0.04 3 0.03
Promoter.I Sh 0.06 3 0.04 Promoter.I Sh 0.06 3 0.02
Bdnf Scr 0.75 3 0.05 Bdnf Scr 0.07 3 0.03
Promoter.II Sh 0.14 3 0.03 Promoter.II Sh 0.09 3 0.01
Bdnf Scr 0.81 3 0.05 Bdnf Scr 0.06 3 0.05
Promoter.IV Sh 0.09 3 0.09 Promoter.IV Sh 0.01 3 0.01
Bdnf Scr 0.85 3 0.19 Bdnf Scr 0.04 3 0.04
Promoter.VI Sh 0.09 3 0.04 Promoter.VI Sh 0.05 3 0.01
Mann(Whitney.U.Test.
Lentivirus Mean N SEM Control/LTD10
Control 1.00 3 0.00
LTD.30 1.41 3 0.09
Control 1.00 3 0.00
LTD.30 1.50 3 0.12
Control 1.00 3 0.00
LTD.30 1.57 3 0.18
Control 1.00 3 0.00
LTD.30 1.04 3 0.08
Control 1.00 3 0.00
LTD.30 1.51 3 0.05
Control 1.00 3 0.00
LTD.30 1.29 3 0.01
Control 1.00 3 0.00
LTD.30 1.35 3 0.02
Control 1.00 3 0.00
LTD.30 0.99 3 0.04
Mann(Whitney.U.Test.
Lentivirus Mean N SEM Control/LTD10 Lentivirus Mean N SEM
Control 1.00 5 0.00 Control 0.03 5 0.01
LTD.10 0.99 5 0.18 LTD.10 0.02 5 0.01
Control 1.00 5 0.00 Control 0.03 5 0.01
LTD.10 0.97 5 0.12 LTD.10 0.01 5 0.00
Control 1.00 5 0.00 Control 0.01 5 0.00
LTD.10 0.89 5 0.12 LTD.10 0.01 5 0.01
Control 1.00 5 0.00 Control 0.03 5 0.02
LTD.10 0.95 5 0.10 LTD.10 0.02 5 0.01
Control 1.00 5 0.00 Control 0.01 5 0.00
LTD.10 0.59 5 0.08 LTD.10 0.01 5 0.01
Control 1.00 5 0.00 Control 0.01 5 0.01
LTD.10 0.87 5 0.10 LTD.10 0.06 5 0.03
Control 1.00 5 0.00 Control 0.04 5 0.03
LTD.10 0.53 5 0.07 LTD.10 0.00 5 0.00
Control 1.00 5 0.00 Control 0.06 5 0.02
LTD.10 0.99 5 0.07 LTD.10 0.03 5 0.01
Bdnf
Sc
Sh
Promoter.I
Sc
Bdnf
IgG
Promoter.VI
4.87E(01
E)
H3K27Me3
Bdnf
Sc 5.77E(01
Promoter.I
Promoter.VI
Sc 5.35E(03
Bdnf
Bdnf
Promoter.IV
Bdnf
3.69E(02
Sh
5.35E(03Sc
Bdnf
Sh
Bdnf
Promoter.IV
Sh 1.89E(01
5.77E(01
Sh
Promoter.II
5.77E(01Sh
Promoter.II
IgG
Sc 5.77E(01
Sh
Sc
Sc
Sh
Bdnf
Promoter.VI
Sh 5.77E(01
D)
C)
Sc
Sh
A)
B)
JMJD3
Jmjd3
JMJD3
Bdnf
Promoter.I
Promoter.II
Sh
Sc
Sh
5.35E-03
Sc
Sc
4.87E(01
Bdnf
3.69E(02
Promoter.IV
3.69E(02
Bdnf
3.69E(02
3.69E(02
3.69E(02
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Supp. Table  11: Figure R10 
 
 
 
 
 
 
 
 
 
 
 
Supp. Table  12: Figure R11 
 
 
 
 
 
Supp. Table  13: Figure R12 
 
 
 
  
AP Mean N SEM AP Mean N SEM
* 0.23 4 0.01 * 0.070 4 0.006
+ 0.08 4 0.02 + 0.049 4 0.022
* 0.26 4 0.03 * 0.042 4 0.008
+ 0.07 4 0.03 + 0.079 4 0.018
* 0.22 4 0.02 * 0.076 4 0.011
+ 0.07 4 0.01 + 0.051 4 0.018
* 0.35 4 0.05 * 0.053 4 0.014
+ 0.06 4 0.03 + 0.069 4 0.019
* 0.14 4 0.01 * 0.067 4 0.007
+ 0.04 4 0.01 + 0.034 4 0.007
* 0.18 4 0.04 * 0.064 4 0.013
+ 0.04 4 0.02 + 0.047 4 0.017
* 0.21 4 0.02 * 0.078 4 0.017
+ 0.06 4 0.02 + 0.050 4 0.021
* 0.28 4 0.01 * 0.071 4 0.006
+ 0.05 4 0.02 + 0.052 4 0.003
AP Mean N SEM Mann*Whitney<U<Test< AP Mean N SEM
!Bdnf! Control 1.00 4 0.00 !Bdnf! Control 0.006 4 0.002
Promoter<I LTD<10 0.90 4 0.09 Promoter<I LTD<10 0.011 4 0.004
!Bdnf! Control 1.00 4 0.00 !Bdnf! Control 0.006 4 0.002
Promoter<II LTD<10 0.83 4 0.17 Promoter<II LTD<10 0.008 4 0.003
!Bdnf! Control 1.00 4 0.00 !Bdnf! Control 0.005 4 0.001
Promoter<IV LTD<10 0.66 4 0.07 Promoter<IV LTD<10 0.014 4 0.007
!Bdnf! Control 1.00 4 0.00 !Bdnf! Control 0.004 4 0.001
Promoter<VI LTD<10 0.50 4 0.08 Promoter<VI LTD<10 0.005 4 0.000
+
+
+
+
H3K27Me3 IgG
2.19E*01
2.19E*01
1.39E*02
1.39E*02
LTD<10
B)
C)
+
+
+
+
Bdnf
Control
Bdnf
H3K27Me3S28p
Bdnf
Control
Promoter<I
LTD<10
Promoter<IV
LTD<10
Bdnf
Control
Promoter<VI
LTD<10
Bdnf
Control
Promoter<II
Control
LTD<10
Bdnf
Promoter<VI
IgG
LTD<10
Control
LTD<10
Promoter<II
Bdnf
Promoter<IV
Control
LTD<10
Control
Bdnf
Promoter<I
JMJD3%(pmols) Mean N SEM
0 0.00 4 0.00
3.5 23.44 4 2.39
7 32.28 4 0.95 Mann;Whitney%U%Test%
14 45.31 4 4.76
14 39.44 4 6.24
C)
%%of%demethylated%H3K27Me3S28p%peptide
1.00E+00
%%of%demethylated%H3K27Me3%peptide
99%##confidence#interval#
(**)#p#<##3.33E803
Mean N SEM Control#/#LTD#10 Control#/#LTD#30 LTD10#/#LTD#30
CNT 1.00 4 0.00
LTD#10 1.88 4 0.28
LTD#30 1.35 4 0.09
KN93 Mean N SEM Control/LTD10 Control/Control#+ Control/LTD10+ LTD10/Control+ LTD10/LTD10+ Control+/LTD10+
CNT 8 1.00 7 0.00
LTD10 8 1.79 7 0.16
CNT + 1.09 7 0.14
LTD10 + 1.29 7 0.17
Cheleritryne Mean N SEM Control/LTD10 Control/Control#+ Control/LTD10+ LTD10/Control+ LTD10/LTD10+ Control+/LTD10+
CNT 8 1.00 7 0.00
LTD10 8 1.79 7 0.16
CNT + 1.08 7 0.13
LTD10 + 1.05 7 0.16
H89 Mean N SEM Control/LTD10 Control/Control#+ Control/LTD10+ LTD10/Control+ LTD10/LTD10+ Control+/LTD10+
CNT 8 1.00 7 0.00
LTD10 8 1.79 7 0.16
CNT + 1.02 7 0.17
LTD10 + 0.93 7 0.17
Kruskal8Wallis#Test
Mann8Whitney#U#Test#
pS1338CREB 3.31E803 8.29E804 6.33E801 6.33E801 8.81E803 2.68E803 7.49E801
A)
Kruskal8Wallis#Test Mann8Whitney#U#Test#
Bonferroni#adjustment#
95%####confidence#interval# 99%####confidence#interval#
(*)#p#<#1.25E802 (**)#p#<##2.50E803
99%####confidence#interval#
(*)#p#<#1.25E802 (**)#p#<##2.50E803
D) Bonferroni#adjustment#
95%####confidence#interval# 99%####confidence#interval#
(*)#p#<#1.25E802 (**)#p#<##2.50E803
pS1338CREB 1.06E802
99,9%###confidence#interval#
(***)#p#<##2.50E804
8.48E801
99,9%###confidence#interval#
(***)#p#<##2.50E804
Kruskal8Wallis#Test
Mann8Whitney#U#Test#
1.52E801 1.81E802 2.53E802 4.06E8017.32E803 8.29E804 6.33E801
Bonferroni#adjustment#
95%####confidence#interval#
(***)#p#<##2.50E804
8.29E804 6.33E801 6.33E801 2.68E803 8.81E803
95%####confidence#intervalBonferroni#adjustment# (*)#p#<#1.67E802
99.9%##confidence#interval#
(***)#p#<##3.33E804
Kruskal8Wallis#Test
Mann8Whitney#U#Test#
pS1338CREB 3.41E803
8.33E802
B)
99,9%###confidence#interval#
1.39E802 1.39E802
pS1338CREB
C)
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95%$$confidence$interval$ 99%$$confidence$interval$ 99.9%$$confidence$interval$
(*)$p$<$1.67E;02 (**)$p$<$$3.33E;03 (***)$p$<$$3.33E;04
Mean N SEM Control$/$LTD$10 Control$/$LTD$30 LTD10$/$LTD$30
CNT 1.00 6 0.00
LTD$10 1.33 6 0.11
LTD$30 0.60 6 0.06
95%$$confidence$interval$ 99%$$confidence$interval$ 99.9%$$confidence$interval$
(*)$p$<$1.67E;02 (**)$p$<$$3.33E;03 (***)$p$<$$3.33E;04
Mean N SEM Control$/$LTD$10 Control$/$LTD$30 LTD10$/$LTD$30
CNT 1.00 6 0.00
LTD$10 1.06 6 0.17
LTD$30 0.88 6 0.20
95%$$confidence$interval$ 99%$$confidence$interval$ 99.9%$$confidence$interval$
(*)$p$<$1.67E;02 (**)$p$<$$3.33E;03 (***)$p$<$$3.33E;04
Mean N SEM Control$/$LTD$10 Control$/$LTD$30 LTD10$/$LTD$30
CNT 1.00 6 0.00
LTD$10 1.15 6 0.17
LTD$30 0.74 6 0.24
95%$$confidence$interval$ 99%$$confidence$interval$ 99.9%$$confidence$interval$
(*)$p$<$1.67E;02 (**)$p$<$$3.33E;03 (***)$p$<$$3.33E;04
Mean N SEM Control$/$LTD$10 Control$/$LTD$30 LTD10$/$LTD$30
CNT 1.00 6 0.00
LTD$10 0.82 6 0.07
LTD$30 0.87 6 0.16
D) Bonferroni$adjustment$
Kruskal;Wallis$Test Mann;Whitney$U$Test$
H3K18Ac 1.88E;01 1.39E;02 1.00E+00 5.64E;01
C) Bonferroni$adjustment$
Kruskal;Wallis$Test Mann;Whitney$U$Test$
H3K14Ac 1.63E;01 5.77E;01 9.47E;02 1.17E;01
B) Bonferroni$adjustment$
Kruskal;Wallis$Test Mann;Whitney$U$Test$
H3K9Ac 7.25E;01 5.77E;01 5.77E;01 4.65E;01
A) Bonferroni$adjustment$
Kruskal;Wallis$Test Mann;Whitney$U$Test$
H3K27Ac 5.89E;04 2.82E;03 2.09E;03 6.17E;03
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CCIIh Mean N SEM Control/LTD30 Control/Control5+ Control/LTD30+ LTD30/Control+ LTD30/LTD30+ Control+/LTD30+
Control 7 1.00 13 0.00
LTD530 7 1.34 13 0.13
Control + 1.13 8 0.10
LTD530 + 1.69 8 0.13
Control 7 1.00 13 0.00
LTD530 7 2.07 12 0.15
Control + 0.92 8 0.07
LTD530 + 1.01 8 0.20
Control 7 1.00 13 0.00
LTD530 7 1.31 13 0.06
Control + 1.18 8 0.08
LTD530 + 1.57 8 0.08
Control 7 1.00 14 0.00
LTD530 7 2.13 14 0.13
Control + 1.07 7 0.11
LTD530 + 1.49 7 0.04
CCIIh Mean N SEM Control/LTD10 Control/Control5+ Control/LTD10+ LTD10/Control+ LTD10/LTD10+ Control+/LTD10+ CCIIh Mean N SEM
Control 7 1.00 7 0.00 Control 7 0.031 7 0.006
LTD510 7 0.91 7 0.14 LTD510 7 0.030 7 0.010
Control + 0.89 5 0.20 Control + 0.091 5 0.012
LTD510 + 0.86 5 0.21 LTD510 + 0.082 5 0.036
Control 7 1.00 6 0.00 Control 7 0.065 6 0.015
LTD510 7 1.36 6 0.06 LTD510 7 0.070 6 0.033
Control + 0.88 5 0.14 Control + 0.072 5 0.016
LTD510 + 0.70 5 0.13 LTD510 + 0.137 5 0.047
Control 7 1.00 7 0.00 Control 7 0.050 7 0.011
LTD510 7 0.86 7 0.07 LTD510 7 0.040 7 0.014
Control + 0.98 5 0.35 Control + 0.106 5 0.024
LTD510 + 0.98 5 0.24 LTD510 + 0.068 5 0.033
Control 7 1.00 6 0.00 Control 7 0.027 6 0.005
LTD510 7 1.50 6 0.18 LTD510 7 0.036 6 0.010
Control + 0.72 5 0.13 Control + 0.056 5 0.015
LTD510 + 0.79 5 0.09 LTD510 + 0.145 5 0.078
CCIIh Mean N SEM Control/LTD10 Control/Control5+ Control/LTD10+ LTD10/Control+ LTD10/LTD10+ Control+/LTD10+ CCIIh Mean N SEM
Control 7 1.00 5 0.00 Control 7 0.346 5 0.020
LTD510 7 2.50 5 0.44 LTD510 7 0.302 5 0.015
Control + 1.19 5 0.09 Control + 0.300 5 0.122
LTD510 + 2.12 5 0.29 LTD510 + 0.401 5 0.071
Control 7 1.00 5 0.00 Control 7 0.506 5 0.113
LTD510 7 2.23 5 0.40 LTD510 7 0.500 5 0.057
Control + 0.84 5 0.11 Control + 0.448 5 0.106
LTD510 + 2.45 5 0.10 LTD510 + 0.668 5 0.089
Control 7 1.00 5 0.00 Control 7 0.545 5 0.085
LTD510 7 2.74 5 0.84 LTD510 7 0.479 5 0.133
Control + 1.04 5 0.12 Control + 0.430 5 0.067
LTD510 + 2.94 5 0.83 LTD510 + 0.506 5 0.067
Control 7 1.00 5 0.00 Control 7 0.593 5 0.115
LTD510 7 2.42 5 0.30 LTD510 7 0.646 5 0.073
Control + 0.98 5 0.10 Control + 0.430 5 0.150
LTD510 + 2.93 5 0.80 LTD510 + 0.654 5 0.041
B)
(**)5p5<552.50E703(*)5p5<51.25E702
99,9%555confidence5interval599%5555confidence5interval595%5555confidence5interval5
Bonferroni5adjustment5
Promoter5VI Promoter5VI
2.53E702 9.17E701 2.53E702 Bdnf
Promoter5IV Promoter5IV
Bdnf 4.59E703 5.35E703 3.93E701 5.35E703
2.53E702 9.17E701 5.26E702 Bdnf
Promoter5II Promoter5II
Bdnf 6.34E703 5.35E703 3.93E701 5.35E703
2.53E702 1.75E701 2.53E702 Bdnf
Promoter5I Promoter5I
Bdnf 2.22E703 5.35E703 1.04E702 5.35E703
IgG
Bdnf
CREB
Bdnf 3.42E703 5.35E703 1.04E702 5.35E703 2.53E702 6.02E701 5.26E702
(*)5p5<51.25E702 (**)5p5<552.50E703 (***)5p5<552.50E704
Kruskal7Wallis5Test
Mann7Whitney5U5Test5
Promoter5VI Promoter5VI
C) Bonferroni5adjustment5 95%5555confidence5interval5 99%5555confidence5interval5 99,9%555confidence5interval5
7.54E701 Bdnf
Promoter5IV Promoter5IV
Bdnf 8.90E704 2.09E703 7.32E702 2.82E703 6.17E703 6.17E703
Promoter5II Promoter5II
Bdnf 3.99E701 1.19E702 5.26E701 5.26E701 9.35E701 6.85E701
Promoter5I Promoter5I
Bdnf 3.83E703 1.53E703 5.26E701 5.72E702 9.02E703 9.02E703
5.26E701 8.08E701 9.35E701 9.17E701
IgG
Bdnf
2.51E701 Bdnf
9.17E701 Bdnf
(***)5p5<552.50E704
Kruskal7Wallis5Test
Mann7Whitney5U5Test5
H3K27Ac
Bdnf 9.92E701 6.33E701 5.26E701
Transcript5VI
6.64E703
Transcript5IV
Bdnf 1.87E703 1.49E706 5.34E701 1.95E705 2.57E704 1.30E703
9.82E703
Transcript5II
Bdnf 8.58E705 3.64E706 3.39E705 1.64E705 1.14E701 5.97E702
8.17E701
Transcript5I
Bdnf 4.08E704 4.76E706 5.46E701 1.00E+00 3.86E704 2.62E703
Bdnf 4.64E704 1.04E702 5.34E701 9.25E706 1.91E701 8.22E702 7.77E703
(*)5p5<51.25E702 (**)5p5<552.50E703 (***)5p5<552.50E704
Kruskal7Wallis5Test
Mann7Whitney5U5Test5
A) Bonferroni5adjustment5 95%5555confidence5interval5 99%5555confidence5interval5 99,9%555confidence5interval5
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CCIIh Mean N SEM Control/LTD10 Control/Control5+ Control/LTD10+ LTD10/Control+ LTD10/LTD10+ Control+/LTD10+ CCIIh Mean N SEM
Control 7 1.00 5 0.00 Control 7 0.105 5 0.026
LTD510 7 1.77 5 0.10 LTD510 7 0.125 5 0.045
Control + 1.16 5 0.16 Control + 0.037 5 0.017
LTD510 + 0.77 5 0.14 LTD510 + 0.207 5 0.059
Control 7 1.00 5 0.00 Control 7 0.116 5 0.034
LTD510 7 1.87 5 0.27 LTD510 7 0.118 5 0.037
Control + 0.92 5 0.19 Control + 0.074 5 0.057
LTD510 + 0.78 5 0.12 LTD510 + 0.160 5 0.053
Control 7 1.00 5 0.00 Control 7 0.181 5 0.061
LTD510 7 2.07 5 0.17 LTD510 7 0.073 5 0.003
Control + 0.81 5 0.16 Control + 0.058 5 0.022
LTD510 + 1.12 5 0.15 LTD510 + 0.180 5 0.121
Control 7 1.00 5 0.00 Control 7 0.122 5 0.047
LTD510 7 2.81 5 0.28 LTD510 7 0.127 5 0.049
Control + 0.98 5 0.07 Control + 0.047 5 0.019
LTD510 + 1.08 5 0.16 LTD510 + 0.133 5 0.070
CCIIh Mean N SEM Control/LTD10 Control/Control5+ Control/LTD10+ LTD10/Control+ LTD10/LTD10+ Control+/LTD10+ CCIIh Mean N SEM
Control 7 1.00 4 0.00 Control 7 0.084 4 0.013
LTD510 7 1.23 4 0.26 LTD510 7 0.083 4 0.012
Control + 1.11 3 0.38 Control + 0.069 3 0.029
LTD510 + 1.00 3 0.09 LTD510 + 0.056 3 0.028
Control 7 1.00 4 0.00 Control 7 0.073 4 0.011
LTD510 7 1.47 4 0.06 LTD510 7 0.091 4 0.023
Control + 0.75 3 0.09 Control + 0.019 3 0.015
LTD510 + 0.78 3 0.11 LTD510 + 0.139 3 0.084
Control 7 1.00 4 0.00 Control 7 0.138 4 0.039
LTD510 7 1.80 4 0.24 LTD510 7 0.107 4 0.023
Control + 1.02 3 0.35 Control + 0.224 3 0.109
LTD510 + 0.59 3 0.17 LTD510 + 0.082 3 0.053
Control 7 1.00 4 0.00 Control 7 0.102 4 0.027
LTD510 7 1.55 4 0.10 LTD510 7 0.083 4 0.011
Control + 0.76 3 0.20 Control + 0.089 3 0.027
LTD510 + 0.84 4 0.14 LTD510 + 0.053 4 0.025
CCIIh Mean N SEM Control/LTD10 Control/Control5+ Control/LTD10+ LTD10/Control+ LTD10/LTD10+ Control+/LTD10+ CCIIh Mean N SEM
Control 7 1.00 7 0.00 Control 7 0.003 7 0.001
LTD510 7 1.00 7 0.14 LTD510 7 0.007 7 0.003
Control + 1.01 3 0.07 Control + 0.006 3 0.001
LTD510 + 1.23 3 0.31 LTD510 + 0.006 3 0.001
Control 7 1.00 7 0.00 Control 7 0.006 7 0.002
LTD510 7 1.15 7 0.16 LTD510 7 0.014 7 0.010
Control + 1.18 3 0.17 Control + 0.005 3 0.002
LTD510 + 1.51 3 0.28 LTD510 + 0.005 3 0.002
Control 7 1.00 6 0.00 Control 7 0.007 6 0.002
LTD510 7 0.87 6 0.05 LTD510 7 0.008 6 0.004
Control + 1.44 3 0.32 Control + 0.007 3 0.001
LTD510 + 1.24 3 0.33 LTD510 + 0.007 3 0.001
Control 7 1.00 6 0.00 Control 7 0.005 6 0.002
LTD510 7 0.59 6 0.04 LTD510 7 0.006 6 0.004
Control + 0.94 3 0.03 Control + 0.006 3 0.001
LTD510 + 1.35 3 0.18 LTD510 + 0.006 3 0.001
Promoter5VI Promoter5VI
2.01E702 1.27E701 BdnfBdnf 5.04E703 1.11E703 3.57E701 3.57E701 2.01E702
Promoter5IV Promoter5IV
3.02E701 5.13E701 BdnfBdnf 5.14E703 6.01E704 1.84E703 2.99E701 2.01E702
Promoter5II Promoter5II
2.10E701 5.13E701 BdnfBdnf 2.33E701 6.33E701 3.26E701 3.24E703 5.69E701
Promoter5I Promoter5I
5.13E701
IgG
Bdnf
H3K27Me3
Bdnf 5.32E701 1.52E701 3.26E701 3.26E701 2.10E701 7.32E701
F) Bonferroni5adjustment5 95%5555confidence5interval5 99%5555confidence5interval5 99,9%555confidence5interval5
(*)5p5<51.25E702 (**)5p5<552.50E703 (***)5p5<552.50E704
Kruskal7Wallis5Test
Mann7Whitney5U5Test5
Promoter5VI Promoter5VI
2.09E702 7.24E701 BdnfBdnf 2.77E702 1.19E702 4.35E701 2.19E701 3.39E702
Promoter5IV Promoter5IV
3.39E702 2.75E701 BdnfBdnf 2.22E702 1.19E702 4.35E701 1.93E702 7.71E702
Promoter5II Promoter5II
3.39E702 8.27E701 BdnfBdnf 8.50E703 1.19E702 1.93E702 1.93E702 3.39E702
Promoter5I Promoter5I
5.13E701
IgG
Bdnf
JMJD3
Bdnf 8.29E701 2.19E701 4.35E701 4.35E701 1.00E+00 4.80E701
E) Bonferroni5adjustment5 95%5555confidence5interval5 99%5555confidence5interval5 99,9%555confidence5interval5
(*)5p5<51.25E702 (**)5p5<552.50E703 (***)5p5<552.50E704
Kruskal7Wallis5Test
Mann7Whitney5U5Test5
Promoter5VI Promoter5VI
9.02E703 6.55E701 BdnfBdnf 1.29E702 5.35E703 3.93E701 5.77E701 2.53E702
Promoter5IV Promoter5IV
9.02E703 1.01E701 BdnfBdnf 8.48E703 5.35E703 3.93E701 5.77E701 2.53E702
Promoter5II Promoter5II
9.02E703 4.56E701 BdnfBdnf 1.03E702 5.35E703 3.93E701 9.47E702 5.26E702
Promoter5I Promoter5I
1.80E701
IgG
Bdnf
CBP
Bdnf 8.04E703 5.35E703 3.93E701 9.47E702 5.26E702 9.02E703
D) Bonferroni5adjustment5 95%5555confidence5interval5 99%5555confidence5interval5 99,9%555confidence5interval5
(*)5p5<51.25E702 (**)5p5<552.50E703 (***)5p5<552.50E704
Kruskal7Wallis5Test
Mann7Whitney5U5Test5
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Supp. Table  16: Figure R15 
 
 
 
Supp. Table  17: Figure R17 
 
 
 
 
 
 
  
Mean N SEM Mann(Whitney.U.Test.
Control 1.00 6 0.00
LTD.10 1.10 6 0.11
3.05E(01pS276(p65
Bonferroni adjustment 95%$confidence$interval$ 99%$confidence$interval$ 99.9%$$confidence$interval$
(*)$p$<$1.67E;02 (**)$p$<$$3.33E;03 (***)$p$<$$3.33E;04
Mean N SEM Control$/$LTD$10 Control$/$LTD$30 LTD10$/$LTD$30
Control 1.00 8 0.00
LTD$10 0.98 6 0.08
LTD$30 1.24 8 0.09
Mean N SEM Control$/$LTD$10 Control$/$LTD$30 LTD10$/$LTD$30
Control 1.00 8 0.00
LTD$10 1.30 6 0.11
LTD$30 1.52 8 0.10
Mean N SEM Control$/$LTD$10 Control$/$LTD$30 LTD10$/$LTD$30
Control 1.00 8 0.00
LTD$10 1.00 6 0.12
LTD$30 1.25 7 0.06
Mean N SEM Control$/$LTD$10 Control$/$LTD$30 LTD10$/$LTD$30
Control 1.00 8 0.00
LTD$10 1.28 5 0.09
LTD$30 1.49 8 0.10
Bdnf$$Transctipt$VI
Bdnf$$Transctipt$VI
Kruskal;Wallis$Test
1.09E;04 3.31E;04 2.55E;04 9.90E;02
6.73E;03 1.67E;02 7.10E;03
Mann;Whitney$U$Test$
3.89E;02Bdnf$$Transctipt$I
Bdnf$$Transctipt$II
1.69E;04 4.72E;04 3.31E;04 1.07E;01
Kruskal;Wallis$Test
Mann;Whitney$U$Test$
Kruskal;Wallis$Test
Mann;Whitney$U$Test$
1.05E;02 1.00E+00 4.40E;04 1.99E;01
Kruskal;Wallis$Test
Mann;Whitney$U$Test$
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Supp. Table  18: Figure R18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Mean N SEM Mean N SEM
2.62 4 0.63 Bdnf.Promoter.I 0.027 4 0.010
2.08 4 0.21 Bdnf.Promoter.II 0.042 4 0.018
2.09 4 0.48 Bdnf.Promoter.IV 0.028 4 0.013
2.67 4 0.11 Bdnf.Promoter.VI 0.044 4 0.008
0.37 4 0.12 ßActin 0.029 4 0.008
6.43 4 1.15 hoxA1 0.021 4 0.007
Mean N SEM Mean N SEM
Bdnf.Promoter.I 2.73 6 0.49 Bdnf.Promoter.I 0.034 6 0.012
Bdnf.Promoter.II 2.90 6 0.53 Bdnf.Promoter.II 0.029 6 0.008
Bdnf.Promoter.IV 2.64 6 0.46 Bdnf.Promoter.IV 0.022 6 0.012
Bdnf.Promoter.VI 3.50 6 0.65 Bdnf.Promoter.VI 0.034 6 0.009
ßActin 1.25 6 0.23 ßActin 0.025 6 0.007
hoxA1 5.46 6 0.53 hoxA1 0.027 6 0.009
Mean N SEM Mean N SEM
0.47 5 0.07 Bdnf.Promoter.I 0.053 5 0.033
0.45 5 0.06 Bdnf.Promoter.II 0.040 5 0.014
0.52 5 0.07 Bdnf.Promoter.IV 0.079 5 0.034
0.59 5 0.12 Bdnf.Promoter.VI 0.044 5 0.019
0.40 5 0.09 ßActin 0.066 5 0.016
0.08 5 0.02 hoxA1 0.070 5 0.029
Mean N SEM Mean N SEM
5.36 4 0.76 Bdnf.Promoter.I 0.027 4 0.010
1.50 4 0.09 Bdnf.Promoter.II 0.042 4 0.018
1.21 4 0.17 Bdnf.Promoter.IV 0.028 4 0.013
5.74 4 0.65 Bdnf.Promoter.VI 0.044 4 0.008
6.25 4 0.46 ßActin 0.029 4 0.008
2.29 4 0.22 hoxA1 0.021 4 0.007
Mean N SEM Mean N SEM
0.40 4 0.05 Bdnf.Promoter.I 0.027 4 0.010
0.11 4 0.03 Bdnf.Promoter.II 0.042 4 0.018
0.73 4 0.14 Bdnf.Promoter.IV 0.028 4 0.013
0.49 4 0.06 Bdnf.Promoter.VI 0.044 4 0.008
1.15 4 0.16 ßActin 0.029 4 0.008
0.08 4 0.03 hoxA1 0.021 4 0.007hoxA1
Bdnf.Promoter.IV
Bdnf.Promoter.VI
ßActin
ßActin
hoxA1
E)
H3K27Ac
Bdnf.Promoter.I
IgG
Bdnf.Promoter.II
H3K4Me3
Bdnf.Promoter.I
IgG
Bdnf.Promoter.II
Bdnf.Promoter.IV
Bdnf.Promoter.VI
ßActin
hoxA1
D)
C)
JMJD3
Bdnf.Promoter.I
IgG
Bdnf.Promoter.II
Bdnf.Promoter.IV
Bdnf.Promoter.VI
B)
EZH2 IgG
Bdnf.Promoter.VI
ßActin
hoxA1
A)
H3K27Me3
Bdnf.Promoter.I
IgG
Bdnf.Promoter.II
Bdnf.Promoter.IV
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Supp. Table  19: Figure R19 
 
 
 
 
 
 
 
 
 
Supp. Table  20: Figure R20 
 
 
 
  
Mean N SEM Mann(Whitney.U.Test. Mean N SEM
EZH2 0.79 6 0.05 2.09E(03 EZH2 IgG 0.012 6 0.0048
JMJD3 2.19 6 0.32 2.09E(03 JMJD3 IgG 0.072 6 0.0218
H3K4Me3 2.19 6 0.32 1.69E(02 H3K4Me3 IgG 0.061 6 0.0244
H3K27Ac 1.24 7 0.31 1.00E+00 H3K27Ac IgG 0.019 7 0.0047
H3K27Me3 0.97 6 0.19 1.52E(01 H3K27Me3 IgG 0.001 6 0.0005
H3K27Me3S28p 1.46 7 0.13 7.10E(03 H3K27Me3S28p IgG 0.075 7 0.0202
Mean N SEM Mann(Whitney.U.Test. Mean N SEM
EZH2 0.81 6 0.04 2.09E(03 EZH2 IgG 0.029 6 0.0170
JMJD3 2.42 6 0.41 2.09E(03 JMJD3 IgG 0.061 6 0.0244
H3K4Me3 1.32 6 0.10 2.09E(03 H3K4Me3 IgG 0.001 6 0.0004
H3K27Ac 1.60 6 0.29 4.03E(02 H3K27Ac IgG 0.068 6 0.0345
H3K27Me3 0.80 7 0.11 1.69E(02 H3K27Me3 IgG 0.001 7 0.0004
H3K27Me3S28p 1.59 7 0.33 1.69E(02 H3K27Me3S28p IgG 0.064 7 0.0385
Mean N SEM Mann(Whitney.U.Test. Mean N SEM
EZH2 0.74 6 0.06 2.09E(03 EZH2 IgG 0.012 6 0.0041
JMJD3 2.14 6 0.30 2.09E(03 JMJD3 IgG 0.158 6 0.0644
H3K4Me3 1.32 6 0.10 2.09E(03 H3K4Me3 IgG 0.001 6 0.0004
H3K27Ac 1.05 6 0.25 3.05E(01 H3K27Ac IgG 0.029 6 0.0188
H3K27Me3 0.70 6 0.10 2.97E(02 H3K27Me3 IgG 0.001 6 0.0005
H3K27Me3S28p 1.34 6 0.15 4.03E(02 H3K27Me3S28p IgG 0.070 6 0.0393
Mean N SEM Mann(Whitney.U.Test. Mean N SEM
EZH2 0.75 6 0.05 2.09E(03 EZH2 IgG 0.018 6 0.0099
JMJD3 2.42 6 0.49 2.09E(03 JMJD3 IgG 0.057 6 0.0249
H3K4Me3 1.36 6 0.08 2.09E(03 H3K4Me3 IgG 0.000 6 0.0002
H3K27Ac 1.54 7 0.24 1.69E(02 H3K27Ac IgG 0.013 7 0.0066
H3K27Me3 0.68 7 0.09 1.69E(02 H3K27Me3 IgG 0.001 7 0.0003
H3K27Me3S28p 1.34 7 0.11 1.69E(02 H3K27Me3S28p IgG 0.034 7 0.0185
Mean N SEM Mann(Whitney.U.Test. Mean N SEM
EZH2 0.95 6 0.11 3.05E(01 EZH2 IgG 0.018 6 0.0089
JMJD3 1.73 6 0.21 2.82E(03 JMJD3 IgG 0.109 6 0.0639
H3K4Me3 0.91 6 0.22 6.33E(01 H3K4Me3 IgG 0.091 6 0.0330
H3K27Ac 1.20 7 0.39 7.27E(02 H3K27Ac IgG 0.001 7 0.0004
H3K27Me3 0.88 7 0.19 6.33E(01 H3K27Me3 IgG 0.145 7 0.1397
H3K27Me3S28p 1.33 7 0.33 6.33E(01 H3K27Me3S28p IgG 0.401 7 0.2598
Mean N SEM Mann(Whitney.U.Test. Mean N SEM
EZH2 0.79 6 0.13 9.47E(02 EZH2 IgG 0.028 6 0.0170
JMJD3 1.32 6 0.17 9.47E(02 JMJD3 IgG 0.091 6 0.0330
H3K4Me3 0.96 6 0.21 6.33E(01 H3K4Me3 IgG 0.001 6 0.0005
H3K27Ac 1.27 7 0.35 6.33E(01 H3K27Ac IgG 0.099 7 0.0237
H3K27Me3 0.92 7 0.10 1.52E(01 H3K27Me3 IgG 0.002 7 0.0008
H3K27Me3S28p 1.09 7 0.06 2.77E(01 H3K27Me3S28p IgG 0.137 7 0.1210
.Promoter.I .Promoter.I
Bdnf Bdnf
hoxA1 hoxA1
Bdnf Bdnf
.Promoter.VI .Promoter.VI
B)
ßActin ßActin
.Promoter.II .Promoter.II
Bdnf Bdnf
.Promoter.IV .Promoter.IV
A)
Bdnf Bdnf
Mean N Error Shapiro-Wilk Levene Student's8t-Test
Adult 1.00 7 0.129 5.10E-02
Old 0.66 7 0.063 8.41E-01
Shapiro-Wilk Levene Mann-Whitney
Adult 1.00 7 0.222 3.75E-02
Old 0.35 7 0.024 3.25E-01
Bdnf8Transcript8II 4.41E-01 1.30E-02
Bdnf8Transcript8VI 2.67E-02 1.72E-03
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Supp. Table  21: Figure R21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supp. Table  22: Figure R22 
 
 
 
 
 
 
  
Mean N Error Shapiro-Wilk Levene Student's8t-Test
Adult 1.77 7 0.126 7.12E-01
Old 3.13 7 0.353 1.20E-01
Adult 1.81 7 0.206 2.35E-01
Old 2.87 7 0.222 9.64E-01
Mean N Error Shapiro-Wilk Levene Student's8t-Test
Adult 0.03 3 0.010 8.61E-01
Old 0.13 3 0.020 9.43E-01
Adult 0.03 3 0.006 1.06E-01
Old 0.12 3 0.035 2.92E-01
Mean N Error Shapiro-Wilk Levene Student's8t-Test
Adult 0.23 6 0.024 1.55E-01
Old 0.15 6 0.011 4.29E-01
Adult 0.68 6 0.092 1.86E-01
Old 0.38 6 0.040 7.20E-01
Mean N Error Shapiro-Wilk Levene Student's8t-Test
Adult 0.53 7 0.162 4.26E-01
Old 0.16 7 0.012 8.49E-01
Adult 0.76 6 0.251 3.92E-01
Old 0.27 6 0.030 8.19E-01
Mean N Error Shapiro-Wilk Levene Student's8t-Test
Adult 0.07 6 0.016 9.87E-01
Old 0.29 6 0.017 9.53E-01
Adult 0.11 6 0.029 5.91E-01
Old 0.35 6 0.046 3.45E-01
E)
HDAC4
Bdnf8Promoter8II 8.54E-01 3.27E-06
Bdnf8Promoter8VI 9.97E-02 1.20E-03
D)
CBP
Bdnf8Promoter8II 7.37E-04 2.15E-02
Bdnf8Promoter8VI 3.22E-04 2.96E-02
C)
H3K27Ac
Bdnf8Promoter8II 7.23E-02 9.65E-03
Bdnf8Promoter8VI 9.27E-03 1.42E-02
B)
H3K27Me3S28p
Bdnf8Promoter8II 9.20E-02 1.14E-02
Bdnf8Promoter8VI 1.18E-01 1.63E-02
A)
H3K27Me3
Bdnf8Promoter8II 5.70E-03 7.43E-03
Bdnf8Promoter8VI 9.57E-01 4.51E-03
Mean N Error Shapiro-Wilk Levene One4way4ANOVA
CNT 1.00 7 0.00 - CNT4/4LTD410 CNT4/4LTD430 LTD4104/4LTD30
LTD410 1.23 7 0.07 5.93E-01
LTD430 1.36 7 0.08 7.57E-01
Shapiro-Wilk Levene Kruskal-Wallis
CNT 1.00 9 0.00 - CNT4/4LTD410 CNT4/4LTD430 LTD4104/4LTD30
LTD410 1.06 9 0.09 2.89E-02
LTD430 1.03 6 0.08 7.48E-01
Shapiro-Wilk Levene One4way4ANOVA
CNT 1.00 7 0.00 - CNT4/4LTD410 CNT4/4LTD430 LTD4104/4LTD30
LTD410 1.41 7 0.10 2.23E-01
LTD430 1.40 7 0.11 9.43E-01
Shapiro-Wilk Levene One4way4ANOVA
CNT 1.00 9 0.00 - CNT4/4LTD410 CNT4/4LTD430 LTD4104/4LTD30
LTD410 1.03 9 0.12 2.82E-01
LTD430 1.07 6 0.18 3.91E-01
4.02E-03 9.18E-01 9.59E-01 9.26E-01 9.87E-01
Games-Howell
Bdnf4Transcript4VI
Adult 1.28E-02 4.15E-03 1.43E-02 2.47E-02 9.94E-01
Games-Howell
Old
Mann-Whitney
Old 5.39E-03 4.14E-01 2.23E-01 2.53E-01 8.14E-01
Games-Howell
Bdnf4Transcript4II
Adult 1.55E-02 3.80E-03 3.29E-02 1.48E-02 6.65E-01
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upp. Table  23: Figure R
23 
           
     
 
Mean N Error Shapiro-Wilk Levene Test
CNT 1.00 8 0.00 - Mann-Whitney
LTD=10 1.48 8 0.11 1.90E-02 5.83E-04
CNT 1.00 8 0.00 - One=Sample=t-Test
LTD=10 0.99 8 0.10 2.60E-01 9.43E-01
Mean N Error Shapiro-Wilk Levene Test
CNT 1.00 9 0.00 - Mann-Whitney
LTD=10 1.27 9 0.06 2.94E-02 1.08E-05
CNT 1.00 9 0.00 - One=Sample=t-Test
LTD=10 0.87 9 0.08 6.86E-01 1.62E-01
Mean N Error Shapiro-Wilk Levene Test Mean N Error
CNT 1.00 5 0.00 - One=Sample==t-Test CNT 0.029 5 0.010
LTD=10 1.50 5 0.14 2.37E-01 2.34E-02 LTD=10 0.022 5 0.009
CNT 1.00 4 0.00 - One=Sample==t-Test CNT 0.085 4 0.020
LTD=10 0.85 4 0.06 1.79E-01 8.12E-02 LTD=10 0.060 4 0.037
CNT 1.00 5 0.00 - Mann-Whitney CNT 0.057 5 0.038
LTD=10 1.53 5 0.15 2.08E-02 5.35E-03 LTD=10 0.083 5 0.072
CNT 1.00 4 0.00 - One=Sample==t-Test CNT 0.043 4 0.014
LTD=10 1.09 4 0.07 3.25E-01 2.96E-01 LTD=10 0.066 4 0.022
Mean N Error Shapiro-Wilk Levene One=Sample==t-Test Mean N Error
CNT 1.00 5 0.00 - CNT 0.150 5 0.043
LTD=10 1.53 5 0.19 5.84E-01 LTD=10 0.125 5 0.040
CNT 1.00 7 0.00 - CNT 0.109 7 0.035
LTD=10 1.06 7 0.09 5.69E-01 LTD=10 0.261 7 0.120
CNT 1.00 5 0.00 - CNT 0.064 5 0.023
LTD=10 1.50 5 0.14 3.17E-01 LTD=10 0.042 5 0.017
CNT 1.00 7 0.00 - CNT 0.048 7 0.022
LTD=10 1.01 7 0.13 5.95E-01 LTD=10 0.056 7 0.020
Mean N Error Shapiro-Wilk Levene Test Mean N Error
CNT 1.00 4 0.00 - One=Sample==t-Test CNT 0.248 4 0.128
LTD=10 0.60 4 0.06 1.66E-01 1.91E-02 LTD=10 0.233 4 0.115
CNT 1.00 5 0.00 - One=Sample="t-Test CNT 0.097 5 0.038
LTD=10 1.01 5 0.04 6.33E-01 7.69E-01 LTD=10 0.092 5 0.051
CNT 1.00 4 0.00 - Mann-Whitney CNT 0.138 4 0.131
LTD=10 0.49 4 0.10 4.66E-03 2.77E-02 LTD=10 0.075 4 0.058
CNT 1.00 5 0.00 - One=Sample==t-Test CNT 0.080 5 0.026
LTD=10 1.00 5 0.06 3.55E-01 9.62E-01 LTD=10 0.073 5 0.025Old 1.07E-02 Old
Bdnf=Promoter=II
Adult
Old 2.52E-02 Old
Bdnf=Promoter=VI
Adult 2.90E-03
Bdnf=Promoter=VI
Adult
Old 1.11E-03 9.34E-01 Old
E)
HDAC4
Bdnf=Promoter=II
Adult 1.06E-01
IgG
Old 9.28E-03 5.23E-01 Old
Bdnf=Promoter=VI
Adult 8.93E-04 5.91E-03
Bdnf=Promoter=VI
Adult
Old
D)
H3K27Ac
Bdnf=Promoter=II
Adult 9.74E-03 3.53E-02
IgG
Bdnf=Promoter=II
Adult
Bdnf=Promoter=II
Adult
Old 3.96E-02 Old
Bdnf=Promoter=VI
Adult 1.46E-01
Bdnf=Promoter=VI
Adult
C)
CBP
Bdnf=Promoter=II
Adult 1.46E-01
IgG
Old 6.65E-03
B)
αCaMKII
Adult 8.91E-04
Old 1.10E-04
A)
CREB
Adulr 3.82E-03
Old 2.41E-04
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Supp. Table  24: Figure R24 
 
 
 
 
 
 
 
 
  
Mean N Error Shapiro-Wilk Levene Student's8t-Test
Adult 0.10 7 0.01 7.98E-01
Old 0.08 9 0.00 2.24E-01
Mean N Error Shapiro-Wilk Levene Student's8t-Test
- 0.09 7 0.00 5.81E-01
8+8MßCD-Ch 0.13 7 0.01 2.77E-01
Mean N Error Shapiro-Wilk Levene Kruskal-Wallis
CNT 1.00 9 0.00 - CNT8/8LTD810 CNT8/8LTD830 LTD8108/8LTD30
LTD810 1.06 9 0.09 2.89E-02
LTD830 1.03 6 0.08 7.48E-01
Shapiro-Wilk Levene One8way8ANOVA
CNT 0.95 7 0.12 - CNT8/8LTD810 CNT8/8LTD830 LTD8108/8LTD30
LTD810 1.30 7 0.08 9.69E-01
LTD830 1.74 6 0.14 3.00E-01
Shapiro-Wilk Levene One8way8ANOVA
CNT 1.00 9 0.00 - CNT8/8LTD810 CNT8/8LTD830 LTD8108/8LTD30
LTD810 1.03 9 0.12 2.82E-01
LTD830 1.07 6 0.18 3.91E-01
Shapiro-Wilk Levene One8way8ANOVA
CNT 1.04 7 0.07 - CNT8/8LTD810 CNT8/8LTD830 LTD8108/8LTD30
LTD810 1.41 7 0.08 1.65E-01
LTD830 1.59 6 0.11 4.02E-01
1.74E-04 9.22E-05 5.00E-03 7.00E-03 3.93E-01
Games-Howell
Bdnf8Transcript8VI
8-8 4.02E-03 9.18E-01 9.59E-01 9.26E-01 9.87E-01
Games-Howell
8+8MßCD-Ch
8.14E-01
Games-Howell
8+8MßCD-Ch 4.21E-03 6.42E-03 2.27E-02 3.60E-02 4.87E-01
C)
Mann-Whitney
Bdnf8Transcript8II
8-8 5.39E-03 4.14E-01 2.23E-01 2.53E-01
B)
Cholesterol8Quantification 8.90E-02 3.46E-04
A)
Cholesterol8Quantification 7.60E-02 2.50E-02
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Mean N Error Shapiro-Wilk Levene One4Sample4t-Test
CNT 1.00 9 0.00 -
LTD410 1.43 9 0.19 5.65E-01
Mean N Error Shapiro-Wilk Levene One4Sample4t-Test
CNT 1.00 9 0.00 -
LTD410 1.55 9 0.16 1.20E-01
Mean N Error Shapiro-Wilk Levene One4Sample44t-Test Mean N Error
CNT 1.00 7 0.00 - CNT 0.11 7 0.04
LTD410 1.06 7 0.09 5.69E-01 LTD410 0.26 7 0.12
CNT 1.00 6 0.00 - CNT 0.23 6 0.08
LTD410 1.66 6 0.23 1.49E-01 LTD410 0.29 6 0.07
CNT 1.00 8 0.00 - CNT 0.05 8 0.02
LTD410 1.01 8 0.13 5.95E-01 LTD410 0.06 8 0.02
CNT 1.00 8 0.00 - CNT 0.18 8 0.10
LTD410 1.81 8 0.24 8.25E-01 LTD410 0.12 8 0.07
Mean N Error Shapiro-Wilk Levene One4Sample44t-Test Mean N Error
CNT 1.00 4 0.00 - CNT 0.08 4 0.02
LTD410 0.85 4 0.06 1.79E-01 LTD410 0.06 4 0.04
CNT 1.00 4 0.00 - CNT 0.04 4 0.03
LTD410 1.57 4 0.17 7.10E-01 LTD410 0.21 4 0.07
CNT 1.00 4 0.00 - CNT 0.04 4 0.01
LTD410 1.09 4 0.07 3.25E-01 LTD410 0.07 4 0.02
CNT 1.00 4 0.00 - CNT 0.13 4 0.10
LTD410 1.96 4 0.19 9.28E-01 LTD410 0.06 4 0.02
Mean N Error Shapiro-Wilk Levene One4Sample44t-Test Mean N Error
CNT 1.00 5 0.00 - CNT 0.10 5 0.04
LTD410 1.01 5 0.04 6.33E-01 LTD410 0.09 5 0.05
CNT 1.00 5 0.00 - CNT 0.07 5 0.03
LTD410 0.56 5 0.08 1.43E-01 LTD410 0.11 5 0.03
CNT 1.00 5 0.00 - CNT 0.08 5 0.03
LTD410 1.00 5 0.06 3.55E-01 LTD410 0.07 5 0.03
CNT 1.00 5 0.00 - CNT 0.09 5 0.06
LTD410 0.55 5 0.05 2.31E-01 LTD410 0.06 5 0.02
Bdnf4Promoter4VI
-
4+4MßCD-Ch 1.86E-02 1.07E-03 4+4MßCD-Ch
Bdnf4Promoter4II
-
4+4MßCD-Ch 1.42E-02 5.92E-03 4+4MßCD-Ch
HDAC4
Bdnf4Promoter4II
- 2.52E-02 7.69E-01
IgG
Bdnf4Promoter4VI
- 1.07E-02 9.62E-01
-
4+4MßCD-Ch 6.75E-02 1.49E-02 4+4MßCD-Ch
E)
-
4+4MßCD-Ch 3.85E-02 4.56E-02 4+4MßCD-Ch
Bdnf4Promoter4VI
- 6.65E-03 2.96E-01
Bdnf4Promoter4VI
D)
CBP
Bdnf4Promoter4II
- 3.96E-02 8.12E-02
IgG
Bdnf4Promoter4II
Bdnf4Promoter4VI
-
4+4MßCD-Ch 4.03E-03 1.20E-02 4+4MßCD-Ch
IgG
Bdnf4Promoter4II
-
4+4MßCD-Ch 7.83E-04 3.60E-02 4+4MßCD-Ch
- 1.11E-03 9.34E-01
C)
H3K27Ac
Bdnf4Promoter4II
- 9.28E-03 5.20E-01
Bdnf4Promoter4VI
B)
CREB 4+4MßCD-Ch 5.80E-04 9.70E-03
A)
αCaMKII 4+4MßCD-Ch 3.92E-04 4.56E-02
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Supp. Table  26: Figure R26 
 
 
 
 
 
  
Mean N Error Shapiro-Wilk Levene Student's8t-Test
- 0.10 5 0.00 2.62E-01
8+8COase 0.08 5 0.00 4.54E-01
Mean N Error Shapiro-Wilk Levene One8way8ANOVA
CNT 1.00 8 0.00 - CNT8/8LTD810 CNT8/8LTD830 LTD8108/8LTD30
LTD810 1.23 8 0.07 5.93E-01
LTD830 1.36 8 0.08 7.57E-01
Shapiro-Wilk Levene One8way8ANOVA
CNT 1.00 8 0.00 - CNT8/8LTD810 CNT8/8LTD830 LTD8108/8LTD30
LTD810 0.91 8 0.07 5.40E-01
LTD830 0.99 8 0.08 1.80E-01
Shapiro-Wilk Levene One8way8ANOVA
CNT 1.00 8 0.00 - CNT8/8LTD810 CNT8/8LTD830 LTD8108/8LTD30
LTD810 1.41 8 0.10 2.23E-01
LTD830 1.40 8 0.11 9.43E-01
Shapiro-Wilk Levene One8way8ANOVA
CNT 1.00 8 0.00 - CNT8/8LTD810 CNT8/8LTD830 LTD8108/8LTD30
LTD810 0.99 8 0.09 9.00E-01
LTD830 0.95 8 0.13 1.34E-01
8+8COase 5.06E-05 2.79E-01 3.90E-01 3.01E-01 8.63E-01
Games-Howell
Bdnf8Transcript8VI
8-8 1.28E-02 4.15E-03 1.43E-02 2.47E-02 9.94E-01
Games-Howell
8+8COase 2.99E-02 8.08E-01 9.90E-01 8.54E-01 8.72E-01
B)
Games-Howell
Bdnf8Transcript8II
8-8 1.55E-02 3.80E-03 3.29E-02 1.48E-02 6.65E-01
Games-Howell
A)
Cholesterol8Quantification 8.50E-02 2.50E-05
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S
upp. Table  27: Figure R
27 
                          
Mean N Error Shapiro-Wilk Levene One4Sample4t-Test
CNT 1.00 8 0.00 -
LTD410 0.91 8 0.07 5.98E-01
Mean N Error Shapiro-Wilk Levene One4Sample4t-Test
CNT 1.00 8 0.00 -
LTD410 0.97 8 0.15 5.50E-01
Mean N Error Shapiro-Wilk Levene Test Mean N Error
CNT 1.00 5 0.00 - One4Sample4t-Test CNT 0.03 5 0.01
LTD410 1.50 5 0.14 2.37E-01 2.34E-02 LTD410 0.02 5 0.01
CNT 1.00 5 0.00 - One4Sample4t-Test CNT 0.01 5 0.01
LTD410 0.91 5 0.16 4.24E-01 6.10E-01 LTD410 0.03 5 0.02
CNT 1.00 5 0.00 - Mann-Whitney CNT 0.06 5 0.04
LTD410 1.53 5 0.15 2.08E-02 5.35E-03 LTD410 0.08 5 0.07
CNT 1.00 5 0.00 - One4Sample4t-Test CNT 0.05 5 0.02
LTD410 0.91 5 0.09 8.55E-01 3.40E-01 LTD410 0.01 5 0.00
Mean N Error Shapiro-Wilk Levene One4Sample4T.Test Mean N Error
CNT 1.00 5 0.00 - CNT 0.15 5 0.04
LTD410 1.53 5 0.19 5.84E-01 LTD410 0.12 5 0.04
CNT 1.00 7 0.00 - CNT 0.15 7 0.05
LTD410 0.95 7 0.16 3.37E-01 LTD410 0.09 7 0.03
CNT 1.00 5 0.00 - CNT 0.06 5 0.02
LTD410 1.50 5 0.14 3.17E-01 LTD410 0.04 5 0.02
CNT 1.00 7 0.00 - CNT 0.06 7 0.01
LTD410 0.95 7 0.16 4.97E-01 LTD410 0.06 7 0.03
Mean N Error Shapiro-Wilk Levene Test Mean N Error
CNT 1.00 3 0.00 - One4Sample4t-Test CNT 0.25 3 0.13
LTD410 0.60 3 0.06 1.66E-01 1.91E-02 LTD410 0.23 3 0.11
CNT 1.00 3 0.00 - One4Sample4t-Test CNT 0.10 3 0.08
LTD410 1.13 3 0.11 4.99E-01 3.34E-01 LTD410 0.15 3 0.09
CNT 1.00 4 0.00 - Mann-Whitney CNT 0.14 4 0.13
LTD410 0.49 4 0.10 4.66E-03 2.77E-02 LTD410 0.08 4 0.06
CNT 1.00 4 0.00 - One4Sample4t-Test CNT 0.42 4 0.41
LTD410 0.78 4 0.17 7.29E-02 3.36E-01 LTD410 0.08 4 0.08
Bdnf4Promoter4VI
- 2.90E-03
Bdnf4Promoter4VI
-
4+4COase 1.65E-02 4+4COase
Bdnf4Promoter4II
-
4+4COase 3.55E-02 4+4COase
4+4COase 3.81E-04 7.22E-01 4+4COase
E)
HDAC4
Bdnf4Promoter4II
- 1.06E-01
IgG
4+4COase 1.46E-04 7.55E-01 4+4COase
Bdnf4Promoter4VI
- 8.93E-04 5.91E-03
Bdnf4Promoter4VI
-
4+4COase
D)
H3K27Ac
Bdnf4Promoter4II
- 9.74E-03 3.53E-02
IgG
Bdnf4Promoter4II
-
Bdnf4Promoter4II
-
4+4COase 1.57E-03 4+4COase
- 4.02E-02
Bdnf4Promoter4VI
-
C)
CBP
Bdnf4Promoter4II
- 5.48E-02
IgG
Bdnf4Promoter4VI
4+4COase 1.90E-02
B)
CREB 4+4Coase 2.24E-03 8.36E-01
A)
αCaMKII 4+4Coase 8.09E-05 2.15E-01
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Supp. Table  28: Figure R28 
 
 
 
 
Supp. Table  29: Figure R29 
 
 
 
 
 
 
 
 
 
 
  
Mean N Error Shapiro-Wilk Levene Student's8t-Test
Veh 0.10 7 0.01 6.15E-01
Vori 0.15 8 0.01 3.76E-01Cholesterol8Quantification 2.68E-01 1.29E-03
Mean N Error Shapiro-Wilk Levene One4way4ANOVA
CNT 1.00 10 0.00 - CNT4/4LTD410 CNT4/4LTD430 LTD4104/4LTD30
LTD410 0.89 10 0.12 8.57E-01
LTD430 0.89 10 0.12 8.58E-01
Shapiro-Wilk Levene One4way4ANOVA
CNT 1.00 10 0.00 - CNT4/4LTD410 CNT4/4LTD430 LTD4104/4LTD30
LTD410 1.35 10 0.14 2.28E-01
LTD430 1.68 10 0.20 3.36E-01
Shapiro-Wilk Levene One4way4ANOVA
CNT 1.00 10 0.00 - CNT4/4LTD410 CNT4/4LTD430 LTD4104/4LTD30
LTD410 0.97 10 0.08 8.12E-01
LTD430 0.97 10 0.09 5.08E-02
Shapiro-Wilk Levene One4way4ANOVA
CNT 1.00 10 0.00 - CNT4/4LTD410 CNT4/4LTD430 LTD4104/4LTD30
LTD410 1.49 10 0.12 5.69E-01
LTD430 1.64 10 0.21 9.91E-01
Mean N Error Shapiro-Wilk Levene One4Sample4t-Test
CNT 1.00 5 0.00 -
LTD410 0.91 5 0.20 4.42E-01
CNT 1.00 5 0.00 -
LTD410 2.35 5 0.49 1.94E-01
CNT 1.00 6 0.00 -
LTD410 0.89 6 0.07 5.83E-01
CNT 1.00 6 0.00 -
LTD410 1.64 6 0.20 8.90E-02
Mean N Error
CNT 0.057 5 0.007
LTD410 0.060 5 0.044
CNT 0.186 5 0.073
LTD410 0.097 5 0.047
CNT 0.026 6 0.006
LTD410 0.029 6 0.015
CNT 0.080 6 0.017
LTD410 0.036 6 0.015
Bdnf4Promoter4VI
-
Vori 3.51E-02 0.026
4+4MßCD-Ch
Bdnf4Promoter4II
-
Vori 2.54E-04 0.046
4+4MßCD-Ch
H3K27Ac
Bdnf4Promoter4II
Veh 1.72E-03 0.676
IgG
Bdnf4Promoter4VI
Veh 2.24E-03 0.194
4.26E-05 8.84E-03 7.39E-03 3.46E-02 8.13E-01
B)
Games-Howell
Bdnf4Transcript4VI
Veh 3.15E-04 9.54E-01 9.48E-01 9.51E-01 1.00E+00
Games-Howell
Vori
6.66E-01 1.00E+00
Games-Howell
Vori 1.09E-04 6.53E-04 6.54E-03 1.09E-02 3.60E-01
A)
Games-Howell
Bdnf4Transcript4II
Veh 5.74E-04 6.66E-01 6.32E-01
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Supp. Table  30: Figure R30 
 
 
 
 
 
 
 
 
 
Supp. Table  31: Figure R31 
 
 
 
 
 
 
 
 
 
 
 
 
  
Mean N Error Shapiro-Wilk Levene Student's8t-Test
Veh 0.60 13 0.04 3.37E-01
Vori 0.72 11 0.04 4.92E-01
Mean N Error Shapiro-Wilk Levene
Veh 66.73 13 6.29 1.57E-01
Vori 68.58 11 5.36 4.16E-01
Veh 62.46 13 6.99 1.90E-02 Veh
Vori 56.55 11 5.22 7.97E-01
Veh 55.15 13 5.69 9.94E-01
Vori 52.13 11 5.90 2.70E-02 Vori
Veh 51.40 13 5.11 3.51E-01
Vori 45.00 11 6.42 5.86E-01
Mean N Error Shapiro-Wilk Levene Student's8t-Test
Veh 27.13 13 3.00 6.51E-01
Vori 39.53 11 4.91 8.68E-01
Mean N Error Shapiro-Wilk Levene Student's8t-Test
Veh 24.35 13 4.87 5.16E-02
Vori 48.28 12 7.37 8.75E-01
Mean N Error Shapiro-Wilk Levene Mann-Whitney
Veh 2.18 13 0.79 2.45E-03
Vori 3.88 12 0.93 2.97E-01
Mean N Error Shapiro-Wilk Levene Student's8t-Test
Veh 12.41 13 2.26 2.00E-01
Vori 17.22 12 4.01 1.34E-01
E)
Auditory-cued8fear8conditioning8test
pre-tone
4.13E-01 1.64E-01
post-tone 8.59E-02 2.97E-01
C)
Spatial8memory8test 1.16E-01 3.46E-02
D)
Contextual8fear8conditioning8test 2.42E-01 1.14E-02
Day82 5.70E-02
1.50E-01
4.20E-02
Day83 9.60E-01
Day84
Friedman8Tests
Spatial8learneing
Day81 2.68E-01 Treatments Interaction
6.50E-01 4.00E-03
A)
Object8location8memory8test 2.90E-02 4.40E-02
B)
Mean N Error Shapiro-Wilk Levene One4way4ANOVA
CNT 1.00 7 0.00 - CNT4/4LTD410 CNT4/4LTD430 LTD4104/4LTD30
LTD410 1.42 7 0.12 3.56E-01
LTD430 1.25 6 0.02 5.27E-01
Shapiro-Wilk Levene One4way4ANOVA
CNT 1.00 7 0.00 - CNT4/4LTD410 CNT4/4LTD430 LTD4104/4LTD30
LTD410 1.17 7 0.10 1.63E-01
LTD430 0.92 6 0.12 2.91E-01
Shapiro-Wilk Levene One4way4ANOVA
CNT 1.00 10 0.00 - CNT4/4LTD410 CNT4/4LTD430 LTD4104/4LTD30
LTD410 1.01 10 0.10 3.38E-01
LTD430 1.03 10 0.13 2.80E-01
Shapiro-Wilk Levene One4way4ANOVA
CNT 1.00 10 0.00 - CNT4/4LTD410 CNT4/4LTD430 LTD4104/4LTD30
LTD410 1.58 10 0.27 2.80E-01
LTD430 1.73 10 0.29 1.40E-01
Mean N Error Shapiro-Wilk Levene One4way4ANOVA
CNT 1.00 7 0.00 - CNT4/4LTD410 CNT4/4LTD430 LTD4104/4LTD30
LTD410 1.33 7 0.06 5.51E-01
LTD430 1.32 6 0.04 4.93E-01
Shapiro-Wilk Levene One4way4ANOVA
CNT 1.00 7 0.00 - CNT4/4LTD410 CNT4/4LTD430 LTD4104/4LTD30
LTD410 1.11 7 0.08 9.93E-01
LTD430 0.97 6 0.06 9.99E-01
Shapiro-Wilk Levene One4way4ANOVA
CNT 1.00 7 0.00 - CNT4/4LTD410 CNT4/4LTD430 LTD4104/4LTD30
LTD410 0.90 7 0.06 3.13E-01
LTD430 0.88 7 0.07 2.35E-01
Shapiro-Wilk Levene One4way4ANOVA
CNT 1.00 8 0.00 - CNT4/4LTD410 CNT4/4LTD430 LTD4104/4LTD30
LTD410 1.21 8 0.08 4.37E-01
LTD430 1.32 8 0.14 6.38E-01
Games-Howell
Old4+4Vori 1.37E-02 1.58E-04 3.14E-02 5.30E-03 1.18E-01
Games-Howell
Old4+4Veh 5.20E-02 2.80E-01 2.55E-01 3.29E-01 9.81E-01
Old 1.36E-03 1.79E-01 4.85E-01 6.01E-01 2.96E-01
B)
Games-Howell
Ppp1cc
Adult 2.84E-04 2.21E-05 2.72E-03 1.57E-03 9.69E-01
Games-Howell
Games-Howell
Old4+4Vori 1.48E-03 2.12E-02 4.69E-02 4.27E-02 9.35E-01
Games-Howell
Old4+4Veh 3.19E-03 9.78E-01 9.68E-01 9.86E-01 9.99E-01
Games-Howell
Old 3.16E-04 3.95E-01 5.26E-01 9.22E-01 5.36E-01
A)
Games-Howell
Arc
Adult 3.17E-07 7.21E-06 3.28E-04 6.84E-04 7.63E-01
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Supp. Table  31: Figure D2 
 
 
 
 
 
 
 
 
 
 
Mean SEM Mean N SEM
0.05 0.005 Bdnf+Promoter+I 0.030 4 0.008
0.10 0.005 Bdnf+Promoter+II 0.013 4 0.003
0.03 0.006 Bdnf+Promoter+IV 0.019 4 0.003
0.03 0.005 Bdnf+Promoter+VI 0.017 4 0.005
Mean N
CNT 1.00 4
LTD+10 0.46 4
LTD+30 0.48 4
Mean N
CNT 0.14 4
LTD+10 0.23 4
LTD+30 0.20 4
Mean N SEM
CNT 1.00 5 0.00
LTD+10 0.73 5 0.09
LTD+30 0.50 5 0.09
KruskalDWallis+Test MannDWhitney+U+Test+Control+/+LTD+10 Control+/+LTD+30 LTD10+/+LTD+30
CDYL 3.66ED03 5.35ED03 5.35ED03 7.58ED02
C) Bonferroni+adjustment+
95%++confidence+interval+ 99%++confidence+interval+ 99.9%+++confidence+interval+
(*)+p+<+1.67ED02 (**)+p+<++3.33ED03 (***)+p+<++3.33ED04
SEM
IgG Bdnf+Promoter+II
0.03
0.07
0.08
LTD10+/+LTD+30
CDYL Bdnf+Promoter+II
0.00
2.18ED02 1.39ED02 1.39ED02 1.00E+000.12
0.01
99%++confidence+interval+ 99.9%+++confidence+interval+
(*)+p+<+1.67ED02 (**)+p+<++3.33ED03 (***)+p+<++3.33ED04
KruskalDWallis+Test MannDWhitney+U+Test+SEM Control+/+LTD+10 Control+/+LTD+30
4
Bdnf+Promoter+VI 4
B) Bonferroni+adjustment+
95%++confidence+interval+
A)
N
CDYL
Bdnf+Promoter+I 4
IgGBdnf+Promoter+II 4Bdnf+Promoter+IV
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